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Abstract 
Sugar oligomers which are linked to proteins and lipids play important roles in a 
large number of biological processes. These sugars are referred to as glycans. In 
the immune system, almost all key proteins are glycosylated. Glycans regulate the 
migration, recognition, activation, and apoptosis of immune cells, as well as the 
activities of antibodies. Owing to glycan complexity, the study of glycosylation is 
challenging. Mass spectrometry (MS) is a state-of-the-art technology which is 
ideally suited to investigating glycosylation, because of its ultra-high sensitivity and 
resolution, as well as its ability to analyze individual molecules in a complex, 
heterogeneous mixture. 
 
In this thesis, mass spectrometry was used to investigate the abnormal 
glycosylation of two newly discovered immune disorders: a hyper IgE syndrome 
and a congenital disorder of glycosylation (CDG). In the hyper IgE syndrome, a total 
set of glycans on leukocytes was analysed (glycomic studies). A reduction in tri- and 
tetra-antennary glycans was observed in the patients. In addition, substantially 
increased levels of hybrid glycans were detected in a patient with more severe 
symptoms, and decreased fucosylation was found on their neutrophils. Site specific 
glycosylation analysis (glycoproteomic studies) was done on IgE, and 6 of 7 
potential N-glycosylation sites on this antibody were mapped, which did not show 
significant glycosylation changes. In the CDG, tri-glucosylated high mannose 
glycans were observed, which helped the identification of an ER glucosidase I 
defect. Mass spectrometry was also used to investigate engineered antibodies 
which are designed to treat immune disorders. A dramatic increase in sialylation 
was observd in an IgG1 after introducing point mutations in the Fc region, and a 
considerable amount of high mannose glycans were detected in an IgG1 hexamer. 
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1 Introduction 
1.1 Glycans 
Sugars are not merely a source of energy; they are widely found on proteins and 
lipids and play important roles in a large number of biological processes. For 
example, the antigenic determinants of the ABO blood group system are sugars 
(Bhende, Deshpande et al. 1952), the receptor of the influenza virus is a sugar 
known as sialic acid (Gottschalk 1952), and the binding of human sperm to zona 
pellucida of the oocyte is mediated by a sugar epitope called Sialyl Lewis X (Pang, 
Chiu et al. 2011). Incorrect synthesis of sugars will cause a large number of 
diseases. In 2013, a new sugar related disorder was reported every 17 days 
(Freeze, Chong et al. 2014). Glycobiology is the study of the structures and 
biological functions of sugars attached to proteins and lipids. These sugars are 
commonly referred to as glycans.  
 
The basic constituents of glycans are monosaccharides. Hexoses are common 
monosaccharides which contain six carbons numbered carbon 1 (C1) to carbon 6 
(C6) from the aldehyde group (Figure 1.1). Four of the six carbons (C2 to C5) are 
chiral centres. Each carbon at a chiral center can have two configurations, so there 
are sixteen (24) possible hexoses, half of which are L-hexoses and half are 
D-hexoses. D- or L- refers to the configuration of the C5. A change of configuration 
at a single chiral carbon is called epimerization. The epimerization at C4 of 
D-Glucose results in D-Galactose (Figure 1.1), so the two monosaccharides are 
called epimers. Changes of configurations at all chiral carbons of a hexose result in 
a mirror image of this hexose. The pair of mirror images are referred to as 
enantiomers. For example, the change of each chiral carbon of D-Glucose results in 
its enantiomer L-Glucose. Linear hexoses can form ring structures through the 
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reaction of the aldehyde group at C1 and the hydroxyl group at C5 (Figure 1.1). 
During ring formation, C1 becomes a chiral carbon called the anomeric carbon, 
which can form two configurations known as α and β anomers. Other 
monosaccharides can be derived from hexoses. For example, the removal of 
oxygen produces deoxyhexoses, while replacement of hydroxyl groups by 
acetylated amino groups yields N-acetylhexosamines. The latter can be further 
modified via reaction with phosphoenolpyruvate to ultimately yield a large family of 
sugars called sialic acids. Although chemically there are a large number of 
monosaccharides, eight common monosaccharides are found in mammals (Table 
1.1).  
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Figure 1.1 An example of two common hexoses: D-Glucose and D-Galactose 
Linear structures are shown in the form of the Fischer projection. Cyclic structures 
are shown as both stereochemical and Haworth representations. Epimerization at 
C4 (within green rectangles) of D-Glucose yields D-Galactose. Ring formation 
produces α or β anomers (within blue rectangles). 
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Table 1.1 Eight common monosaccharides in mammalian glycans 
Name D-Glucose D-Mannose D-Galactose L-Fucose
Abbreviation Glc Man Gal Fuc
Structure
Symbol
Name D-N-acetylglucosamine D-N-acetylgalactosamine N-acetylneuraminic acid N-glycolylneuraminic acid
Abbreviation GlcNAc GalNAc NeuAc NeuGc
Structure
Symbol
 
The name, abbreviation, structure and symbol of each monosaccharide are shown. 
The symbol is assigned to each monosaccharide according to the rules adopted by 
the textbook Essentials of Glycobiology (Varki 1999) and by the Consortium for 
Functional Glycomics (CFG, link: http://www.functionalglycomics.org). Glc, Man and 
Gal are hexoses, Fuc is a 6-deoxyhexose, GlcNAc and GalNAc are 
N-acetylhexosamines, and NeuAc and NeuGc are sialic acid.  
 
Monosaccharides can be linked by glycosidic bonds to form polysaccharides. 
Figure 1.2 shows the linking of a Gal to a Glc through the reaction of the anomeric 
carbon of Gal and the hydroxyl group at C4 of Glc. The product is lactose. As the 
oxygen attached to the C1 of Gal is in the β configuration, the glycosidic bond is 
called β1-4 linkage. The Glc residue in the lactose retains its hemiacetal group, 
which is able to reduce inorganic ions like Cu2+, so it is called the reducing end of 
lactose. By contrast, the Gal residue loses its hemiacetal group during glycosidic 
bond formation and is called the non-reducing end of lactose. Each glycan has a 
reducing end and one or more non-reducing ends. Like the lactose structure shown 
in Figure 1.2, the sequences of glycans are usually displayed from the non-reducing 
ends to the reducing end. A convenient way to display lactose is to use a symbolic 
representation (Figure 1.2). In many cases, an even more simplified symbolic 
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representation is used, which shows the sequence of a glycan but does not display 
linkage information.   
 
Formation of glycosidic bonds is energetically unfavourable and requires free 
energy. In biological systems, monosaccharides are converted to sugar nucleotides 
(Table 1.2), or, less commonly, dolichol-phosphate-sugars, which store the energy 
for the formation of glycosidic bonds. In addition, a group of enzymes known as 
glycosyltransferases are responsible for catalyzing the formation of glycosidic 
bonds. In the biological synthesis of lactose, for example, Gal has to be converted 
into UDP-Gal at first. Then a glycotransferase known as β1-4-galactosyltransferase 
catalyzes the formation of the β1-4 linkage between Gal and Glc, using the energy 
provided by UDP-Gal. In this reaction, the UDP-Gal is called the nucleotide sugar 
donor, while the Glc is called the acceptor. A glycosyltransferase is often specific to 
its sugar donor and acceptor, so it catalyzes the formation of a specific linkage. For 
example, ST6Gal I is a glycosyltransferase that catalyze the linking of sialic acid to 
Gal in α2-6 linkage, while ST3Gal I synthesises an α2-3 linkage between a sialic 
acid and Gal. However, there are exceptions. For example, the glycosyltransferase 
FucT-III is able to incorporate Fuc into the Galβ1-4GlcNAc moiety in either α1-3 or 
α1-4 linkage.  
 
Besides glycotransferases which elongate a glycan, an opposite group of enzymes 
are able to cleave glycosidic bonds to trim a glycan. They are called glycosidases. 
Like glycosyltransferases, glycosidases are specific. For example, endoplasmic 
reticulum (ER) glucosidase I cleaves α1-2 linked Glc, whereas ER glucosidase II 
cleaves α1-3 linked Glc. Again, there are exceptions. For example, sialidases are a 
group of glycosidases which are able to release terminal sialic acid residues from 
glycans. However, some sialidases only hydrolyze α2-3 linked sialic acid while 
others can hydrolyze α2-3 and α2-6 linked sialic acid. Another common example is 
22 
 
jack bean α-mannosidase, which is able to cleave α1-2, 1-3 and 1-6 linked Man.  
 
 
 
Figure 1.2 Formation of a β1-4 linkage between Gal and Glc 
Formation of the β1-4 linkage between Gal and Glc are through the reaction of the 
anomeric carbon of Gal and the hydroxyl group on the C4 of Glc respectively. The 
reaction is displayed in Hawoth representation. The product is a lactose, the 
reducing end and the non-reducing end of which are indicated. Lactose is also 
displayed in symbolic representation and simplified symbolic representation. The 
latter does not contain linkage information.  
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Table 1.2 Sugar nucleotides of eight common monosaccharides 
 
1.2 Protein glycosylation 
Protein glycosylation is the process of attaching glycans to proteins, which is the 
most complicated post translational modification. There are two major types of 
protein glycosylation, N-linked glycosylation (or N-glycosylation) and O-linked 
glycosylation (or O-glycosylation).    
1.2.1 N-glycosylation 
N-glycosylation is the attaching of glycans to a target glycoprotein in a 
β-N-glycosidic bond to the amide nitrogen of Asn residue. N-glycosylation sites on 
proteins have a consensus sequence of Asn-Xaa-Ser/Thr, where the Xaa cannot be 
proline. Figure 1.3 shows an overview pathway of N-glycosylation in mammals. It 
occurs in the ER and the Golgi complex. A precursor glycan is synthesized on a 
lipid dolichol and then is en bloc transferred to a target protein. After that, the 
precursor is trimmed and re-extended in a series of steps occurring along the 
ER-Golgi network. Finally, the protein with mature glycans is transported to the 
plasma membrane or secreted outside the cell.  
 
24 
 
 
Figure 1.3 An overview of the mammalian N-glycosylation pathway 
A: synthesis of precursor glycan on lipid dolichol. B: Transfer of the precursor to 
protein. C: Initial trimming. D: Further trimming until five Man residues left. E: 
Incorporate the first GlcNAc. F: Remove another two terminal Man. G: Incorporate 
another GlcNAc. H: Incorporate Gal to GlcNAc to form LacNAc units. I: 
Modifications of LacNAc units. The mature glycoprotein is transported to the plasma 
membrane or is secreted.  
1.2.1.1 Transfer and early processing of N-glycans in the ER 
The N-glycan precursor of most eukaryotes is a 14-sugar glycan which consists of 
three Glc, nine Man and two GlcNAc residues (GlcNAc2Man9Glc3). It is synthesized 
in two phases on the ER membrane (Figure 1.4) (Burda and Aebi 1999). The first 
phase occurs on the cytoplasmic side and uses sugar nucleotides as donors. Two 
GlcNAc residues are linked to a dolichol through a pyrophosphate. Then five Man 
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residues are added to the GlcNAc2. After the sugar GlcNAc2Man5 is flipped to the 
ER luminal side, the second phase of synthesis starts, and dolichol-phosphate 
sugars serve as sugar donors, which are synthesized on the cytoplasmic side using 
sugar nucleotides as substrate and then are flipped to the ER lumen. Another four 
Man residues are incorporated, followed by the addition of three Glc residues, 
resulting in a lipid linked N-glycan precursor GlcNAc2Man9Glc3, which is en bloc 
transferred to N-glycosylation sites of a target protein.     
 
 
Figure 1.4 Synthesis of N-glycan precursor and its transfer to a protein 
On the cytoplasmic side, GlcNAc2Man5 is synthesized on a dolichol through a 
pyrophosphate linkage and is flipped to the ER lumen. Dolichol-phosphate-Man 
(dolichol-P-Man) and dolichol-P-Glc are synthesized on dolichol-P and are also 
flipped in the ER lumen. The sugar donors are sugar nucleotides. In the ER lumen, 
another four Man and three Glc residues are incorporated using dolichol-phosphate 
sugars as donor. The product, GlcNAc2Man9Glc3, is transferred to nascent 
polypeptide.  
 
The enzyme responsible for the en bloc transfer is known as 
oligosaccharyltransferase (OST). An evolving view of OST has been discussed by 
Kelleher and Gilmore (Kelleher and Gilmore 2006). OST is a single polypeptide in 
prokaryotes, but exists as a multi-subunit enzyme complex in eukaryotes. The 
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subunits are most well studied in the yeast Saccharomyces cerevisiae, which are 
assembled in the form of Ost1p, Ost2p, Ost3p/Ost6p, Ost4p, Ost5p, Wbp1p, 
Swp1p, and Stt3p. According to protein database searches and biochemical studies, 
OST in higher organisms has very similar subunits compositions to yeast. Subunits 
homologues are ribophorin I (Ost1p), DAD1 (Ost2p), N33 (Ost3p)/IAP (Ost6p), 
Ost4p, OST48 (Wbp1p), ribophorin II (Swp1p) and Stt3p. An Ost5p homologue has 
been identified in metazoan organisms but biochemical evidence is yet to be 
obtained.  
 
The catalytic site of eukaryotic OST is in the Stt3p subunit, which is highly 
conserved among eukaryotes and is homologous to OST in archaea (AglB) and 
eubacteria (PglB) (Kelleher and Gilmore 2006, Huang, Bhaskaran et al. 2012). The 
focus of this thesis is N-glycosylation in eukaryotes. However, only one report about 
the structure of the C-terminal domain of yeast Stt3p has been found in the Protein 
Data Bank (Huang, Bhaskaran et al. 2012). Compared to its prokaryotic 
homologues (Igura, Maita et al. 2008, Maita, Nyirenda et al. 2010, Lizak, Gerber et 
al. 2011), yeast Stt3p C-terminal domain exclusively has an ER 
membrane-embedded region, which might make it closer to the lipid linked 
N-glycan precursor, so that the N-glycosylation could be more effective. In addition, 
the domains rich in β-sheet in prokaryotic Stt3p were not observed in the yeast 
counterpart. However, the acceptor binding site, the WWDYG motif, is conserved in 
both prokaryotic and eukaryotic organisms, and the 3-D structure surrounding the 
binding site is very similar, which suggest a common mechanism of 
acceptor-substrate interactions. A PglB structure in complex with an acceptor 
peptide (Lizak, Gerber et al. 2011) shows that the Asn-Xaa-Thr sequence motif is 
bound by the enzyme in an extended conformation. The –OH group on the Thr form 
hydrogen bonds with the side chains of the two Trp in the WWDYG motif. The 
interaction is stabilized by van der Waals contact between an Ile residue near the 
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motif and the Asn-Xaa-Thr sequence. The carboxylate groups of E319 and D56 
contact the –NH2 groups of Asn and a divalent medal ion, which twists the 
carboxamide group of the Asn side chain for nucleophilic attack during 
N-glycosylation.  
 
As shown in Figure 1.6, the precursor is trimmed and re-elongated. It appears that 
cells waste energy on the glycosylation steps in the ER, as all Glc residues and 
most Man residues on the precursor glycan are removed. However, studies have 
shown that the precursor, GlcNAc2Man9Glc3, is the most favourable donor for OST 
(Kelleher and Gilmore 2006). More importantly, the trimming of the precursor 
glycan is important for ER glycoprotein quality control, which ensures glycoproteins 
in the final product are correctly folded. Following the en bloc transfer of an 
N-glycan precursor to its target protein, the terminal α1-2 linked Glc residue is 
rapidly removed by ER glucosidase I, which prevents the re-binding of the N-Glycan 
by OST. The GlcNAc2Man9Glc2 then allows the binding by malectin (Schallus, 
Jaeckh et al. 2008), which can preferentially bind to incorrectly folded glycoproteins, 
prevent them from further processing along the ER-Golgi pathway, and initiate 
ER-associated degradation (ERAD) (Chen, Hu et al. 2011, Galli, Bernasconi et al. 
2011). When a glycoprotein passes the malectin quality control, another Glc residue 
is removed by ER glucosidase II. The product, GlcNAc2Man9Glc1 can be 
recognized by calnexin or calreticulin, which associates with a thioldisulfide 
oxidoreductase, ERp57 and a peptidyl prolyl isomerase, cyclophilin B. The complex 
of calnexin/calreticulin, ERp57 and cyclophilin B helps with the correct folding of the 
glycoprotein (Frickel, Riek et al. 2002, Kozlov, Bastos-Aristizabal et al. 2010). 
Calnexin/calreticulin will not bind the glycoprotein when the third Glc residue is 
removed by ER glucosidase II. At this moment, UDP-Glc:glycoprotein 
glucosyltransferase 1 (UGGT1) binds to the glycoprotein and determines its 
participation into the following pathway (Labriola, Cazzulo et al. 1995, Sousa and 
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Parodi 1995). If the glycoprotein is correctly folded, it will be released from UGGT1 
and enters normal processing. If the glycoprotein is incorrectly folded, a Glc residue 
is added back by UGGT1 and the glycoprotein is bound again by 
calnexin/calreticulin for refolding. This cycle can repeat to make sure that the 
glycoprotein is correctly folded. For some folding which cannot be corrected, the 
glycoproteins will be introduced to ERAD. A terminal Man residue in the middle arm 
of Man9 structure is removed by ER mannosidase I (Tremblay and Herscovics 
1999). After that, additional Man residues can be removed by ER mannosidase I 
(Hosokawa, Tremblay et al. 2003) or ER-degradation-enhancing 
α-mannosidase-like proteins (EDEM) (Olivari and Molinari 2007), or be removed by 
Golgi mannosidases in the Golgi complex and transported back to the ER 
(Kukushkin, Alonzi et al. 2011). When the α1-2 Man residues on the middle and 
right arm of a Man9 structure are removed and α1-6 Man residues are exposed, the 
trimmed glycan can be recognized by ERAD lectins OS-9 and XTP3-B 
(Christianson, Shaler et al. 2008, Hosokawa, Kamiya et al. 2010), which guide the 
export of the glycoprotein to the cytoplasm for degradation.                 
1.2.1.2 Further processing of N-glycans in the Golgi complex 
The glycoproteins which passed the ER quality control are further processed in the 
Golgi complex and three major types of N-glycans are produced: high mannose 
glyans, hybrid glycans and complex glycans. All these glycans share a common 
structure called the N-glycan core (Figure 1.5). The two branched mannoses on the 
core are α1-3 and α1-6 linked respectively, so they are called the 1-3 arm and 1-6 
arm respectively. High mannose glycans only have Man residues linked to the core, 
hybrid glycans have one or two Man residues on the 1-6 arm, and complex glycans 
do not have any Man residue attached to the core.  
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Figure 1.5 N-glycans share a common structure known as the N-glycan core 
A high mannose glycan, a hybrid glycan and a complex glycan are shown. The 
N-glycan core is highlighted in the yellow area. The differences of the three glycans 
are outside the core structure.  
 
The synthesis of high mannose, hybrid and complex glycans in mammals is shown 
in Figure 1.6. After the glycoprotein is transported to the cis Golgi apparatus, the 
removal of α1-2 linked Man residues continues by Golgi mannosidase IA, IB, and IC. 
If the mannosidase digestion is incomplete, a series of high mannose glycans with 
5-9 Man residues are produced. However, most mammanlian glycans are trimmed 
down to Man5. When the glycoprotein is transported to the medial Golgi apparatus, 
GlcNAc-transferase I (GlcNAc-T I) incorporates a GlcNAc residue onto the 1-3 arm 
of this glycan. Following the GlcNAc addition, either hybrid glycans or complex 
glycans can be synthesized. For the synthesis of hybrid glycans, the two Man 
residues on the 1-6 arm are retained and a Gal residue is added to the GlcNAc 
residue on the 1-3 arm usually by β1-4 Galactosyltransferase (β1-4 GalT) in the 
trans Golgi apparatus, resulting in a Galβ1-4GlcNAc substructure which is referred 
to as a LacNAc unit. The serial catalysis of β1-3 GlcNAc-T and β1-4 GalT can add 
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additional LacNAc units to the first LacNAc unit to produce a long antenna on a 
glycan. Also, hybrid glycans sometimes have two LacNAc-based antennae on the 
1-3 arm.  
 
For the synthesis of complex glycans, the two Man residues on the 1-6 arm are 
removed by Golgi mannosidase II and antennae are initiated on both the 1-3 and 
1-6 arms. Like the synthesis of the antenna on hybrid glycans, each antenna is 
initiated by a GlcNAc-transferase (GlcNAc-T) in the medial Golgi and is extended 
by Gal in the trans Golgi (Figure 1.6). Although complex glycans can have more 
than four antennae in some vertebrates (Yamashita, Kamerling et al. 1982, Taguchi, 
Kitajima et al. 1995), mammals commonly have a maximum of four antennae. 
Antennae can be modified with a variety of monosaccharides like Fuc, sialic acid, 
GalNAc and Gal. These modifications occur in the trans Golgi apparatus and result 
in many terminal structures (Figure 1.7), which bear variable functional roles. The 
core structure of hybrid and complex glycans can also be modified with Fuc, which 
in mammals, is attached at position 6 of the proximal GlcNAc (Figure 1.8). In 
addition, the β1-4 linked Man residue on the core structure can be modified with a 
β1-4 linked GlcNAc residue, which is catalyzed by GlcNAc-T III. This GlcNAc 
residue is called bisecting GlcNAc, which is different from the GlcNAc residues on 
the 1-3 and 1-6 arms in that it cannot be extended to form an antenna (Figure 1.8).  
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Figure 1.6 Processing of the N-glycan precursor 
After all Glc residues are trimmed, α1-2 linked Man residues are removed by 
mannosidases, producing a series of high mannose glycans. Antennae of hybrid 
and complex glycans are initiated by GlcNAc-Ts, which are often followed by β1-4 
GalT.  
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Figure 1.7 Common modifications of antennae 
Sialic acid, Fuc, Gal, and GalNAc can be incorporated to LacNAc units of antennae, 
resulting in a variety of terminal substructures.  
 
 
 
Figure 1.8 Incorporation of core Fuc and bisecting GlcNAc 
The core Fuc residue is linked to the GlcNAc residue at the reducing end in α1-6 
linkage, catalyzed by FucT-VIII. The bisecting GlcNAc is added in β1-4 linkage to 
the β1-4 linked Man residue by GlcNAc-T III. Bisecting GlcNAc cannot be extended 
to form an antenna. 
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1.2.3 O-glycosylation 
O-glycosylation is the attaching of glycans in an α-O-glycosidic linkage to the 
oxygen of the hydroxyl group on Ser or Thr residues. Unlike N-glycosylation, no 
consensus peptide sequences are found around O-glycosylation sites. In addition, 
O-glycosylation mainly occurs in the Golgi complex. It does not begin with the en 
bloc transfer of a glycan precursor. Instead, individual monosaccharides are 
sequentially incorporated to assemble O-glycans on glycoproteins.  
 
Several types of O-glycans have been discovered. One of the most common is 
mucin-type, which is generally found in mucous secretions, body fluids and plasma 
membranes (Van den Steen, Rudd et al. 1998). Mucin type O-glycans have been 
reported to contain at least eight core structures, named Core 1 to Core 8, although 
only Core 1 to Core 4 are widely distributed (Hanisch 2001). Core 1 and Core 2 are 
ubiquitous in mammalian tissue, while Core 3 and Core 4 have more restricted 
tissue specific expression (Hanisch 2001, Wopereis, Lefeber et al. 2006). The 
synthesis of all the eight core structures starts with the addition of a GalNAc to the 
hydroxyl group of Ser or Thr on a target glycoprotein (Figure 1.9). Then, different 
Core structures are synthesized by linking monosaccharide to the hydroxyl group at 
position C3, C6 or both on the GalNAc residue. Thus, the addition of β linked Gal 
and GlcNAc to the C3 of GalNAc result in Core 1 and Core 3 respectively, whilst 
further incorporation of a GlcNAc residue in β1-6 linkage results in Core 2 and Core 
4 respectively. Core 5 and Core 8 have an α linked GalNAc or Gal attached at C3 of 
the GalNAc residue, whilst substitution at C6 with β linked GlcNAc or GalNAc 
results in Core 6 and Core 7. Like N-glycans, O-glycan cores can be elongated with 
antennae (Figure 1.10). The antennae on O-glycans can be further modified to form 
the same terminal substructures as those found on N-glycans (Figure 1.7).     
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Figure 1.9 Biosynthesis of Core1 to 8 of mucin type O-glycans 
Core 1 to 4 are most commonly found, while Core 5 to 8 are less commonly found. 
The enzymes and sugar donors at each step are also shown.   
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Figure 1.10 Synthesis of antennae on O-glycan Core 1 to Core 4 
The core structures are highlighted in yellow. The antennae can be further modified 
to form terminal substructures shown in Figure 1.7. 
1.3 The immune system 
The immune system is a defense system which protects against pathogenic 
invaders. Vertebrates have two types of protection components: innate immunity 
and adaptive immunity. Innate immunity is less selective and its protection 
mechanisms are not specific to a particular pathogen, while adaptive immunity is 
more selective and protects against a specific pathogen.  
1.3.1 Innate immunity 
Innate immunity is the first defense line of the immune system, which can be 
divided into four types of defensive barriers: anatomic, physiologic, phagocytic and 
inflammatory. 
 
The anatomic barrier includes skin and mucous membranes. Skin works as a 
mechanical barrier which blocks the entry of pathogens. In addition, the sebaceous 
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glands of skin secrete sebum, which can inhibit the growth of microorganisms. 
Unlike skin which covers the exterior of the body, mucous membranes cover the 
inside of alimentary, urogenital and respiratory tract. The secretions from mucous 
membranes contain antibacterial or antiviral substances. The secretions can also 
inhibit the attachment of microbes to the tract. The cilia on mucous membranes are 
able to propel pathogens out of the body. The physiologic barrier protects against 
pathogens using extreme pH and various soluble factors, like lysozyme, interferon 
and complement. For example, the stomach maintains low pH conditions, so that 
few microbes can survive there, whilst lysozyme, which is found in mucous 
secretions and tears, hydrolyzes the peptidoglycan in the bacterial cell wall. 
Interferon is secreted by virus-infected cells and is able to induce a general antiviral 
activity of neighboring cells. The complement system comprises a group of proteins 
which can be activated by the innate or adaptive immune response. Complement in 
an active state can damage the membranes of pathogens or opsonize them for 
engulfment by cells in the phagocytic barrier. The phagocytic barrier contains 
monocytes, macrophages and neutrophils. Monocytes circulate in the blood and 
then migrate to different tissues, where they differentiate into tissue specific 
macrophages. Neutrophils are the most abundant leukocytes in the blood and they 
are normally the first to arrive at the site of infection. Cells in the phagocytic barrier 
ingest microorganisms and digest them.   
 
The inflammatory barrier protects against pathogens through the inflammatory 
response, which involves a complex series of events. Upon tissue damage, the 
blood vessels near the infection site widen, but the vessels removing blood from the 
site narrow, leading to engorgement of the vessels around the damage site, so that 
tissue redness is observed and tissue temperature is increased. In addition, the 
capillary network at the infection site becomes more permeable, which facilitates 
the migration of leukocytes and influx of fluids into the tissue and causes tissue 
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swelling. The migration of leukocytes from capillaries to tissue is a multistep 
process. Margination is the first step in which the cells adhere to the wall of blood 
vessels. Then the cells emigrate between the capillary endothelial cells into the 
tissue, which is known as extravasation. Finally, the cells go through the tissue to 
the site of infection through chemotaxis. After the leukocytes arrive at the damaged 
tissue, they start ingesting microorganisms.  
 
Many molecules in the innate immune system are able to recognize 
pathogen-associated molecular patterns (PAMPs), which are unique to pathogens. 
Common PAMPs include glycans, lipopolysaccharides(LPS), lipoproteins, proteins 
and nucleic acids from bacteria, viruses, parasites and fungi (Kawai and Akira 
2010). The molecules in the innate immune system that are able to recognize 
PAMPs are called pattern-recognition receptors (PRRs). Complement in the 
physiologic barrier described above is an example of soluble molecules that have 
pattern recognition properties. PRRs are also found on cell membranes, 
exemplified by toll-like receptors (TLRs), which recognize a large variety of PAMPs 
and induce anti-pathogen responses like inflammation (Kawai and Akira 2010). In 
addition, a large number of glycan binding proteins known as lectins serve as 
important PRRs in the immune system (Sancho and Reis e Sousa 2012).  
      
The four types of innate immunity barriers can usually clear most microorganism 
invaders. Pathogens which are able to pass the four barriers will encounter the 
adaptive immune system.        
1.3.2 Adaptive immunity  
Adaptive immunity is highly selective, so that it can recognize and clear a specific 
pathogen or foreign molecule (antigen). The specificity of adaptive immunity is so 
high that it can distinguish subtle differences among antigens. For example, 
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antibodies produced in adaptive immunity can distinguish the same protein with 
different posttranslational modifications, such as phosphorylation and glycosylation. 
Adaptive immunity can produce a large diversity of recognition molecules which can 
recognize numerous unique structures of antigens. Moreover, adaptive immunity 
has immunologic memory; memory cells can be generated during the first 
encounter of an antigen. If the antigen is recognized for the second time, the 
immune system reacts much faster and stronger.  
 
Two major groups of cells are involved in the adaptive immune response: antigen 
presenting cells (APCs) and lymphocytes. APCs include B cells, macrophages and 
dendritic cells (DCs). Lymphocytes consist of B cells, T cells and NK cells. B cells 
belong to both APCs and lymphocytes. Like other white blood cells, lymphocytes 
are produced in the bone marrow through haematopoiesis. After leaving the bone 
marrow, they circulate in the blood and lymphatic systems, and finally stay in 
lymphoid organs.   
 
B cells start to mature in the bone marrow. They express B cell receptors (BCRs) on 
their surface. A BCR contains a membrane-bound antibody, which is able to bind a 
particular antigen with a high degree of specificity. During the maturation of B cells 
in the bone marrow, random arrangements of gene segments occur, which results 
in BCRs with an enormous number of antigenetic specificities. However, each B cell 
expresses a unique BCRs on its surface with a single antigenic specificity. A B cell 
remains in a naïve state until its BCRs binds its target antigen. This binding, 
together with the involvement of other proteins and cells, triggers a primary 
response, in which the B cell proliferates and differentiates into an effector B cell 
(plasma cell) or a memory B cell. Plasma cells produce soluble antibodies against 
the antigen. Memory B cells have a much longer life span than plasma cells and 
remain in the body after the antigen is cleared. When the same antigen invades 
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again, a secondary response is induced by the memory B cells, which react against 
the antigen much faster and stronger than the primary response. The primary 
response normally takes 5-7 days before antibodies can be secreted, while the 
secondary response takes only 1-2 days and produces much higher levels of 
antibodies.  
 
T cells originate in the bone marrow but mature in the thymus. Like B cells, T cells 
express on the cell surface antigen-binding molecules known as T cell receptors 
(TCRs). Also similar to BCRs, TCRs have a large diversity of antigenic specificities 
produced by random rearrangements of TCR genes and each T cell expresses 
identical TCRs. However, TCRs are different from BCRs in that they cannot 
recognize soluble antigens. They only recognize degraded antigens presented by 
the major histocompatibility complexes (MHC), which are comprised of 
membrane-bound glycoproteins. There are two major types of MHC complexes 
called class I and class II. Class I MHC molecules are expressed in almost all 
nucleated cells. These molecules present endogenous peptide antigens, which are 
derived from proteins produced by host cells, viral proteins or cancer cells. In 
contrast, class II MHC molecules are only expressed by antigen presenting cells 
(APCs) and they recognize exogenous antigens from pathogens like bacteria or 
protozoa. These pathogens are ingested and digested by APCs, and the degraded 
peptides are presented on class II MHC molecules.   
  
Two types of T cells have been well defined: T helper (TH) cells and T cytotoxic (TC) 
cells. TH cells express the CD4 membrane glycoprotein and recognize antigens 
presented by class II MHC molecules, whereas TC cells express the CD8 
membrane glycoprotein and recognize antigens presented by class I MHC 
molecules. The interaction between TCRs and antigen-MHC molecules, together 
with other proteins, induces the activation of T cells and the production of effector T 
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cells. Different subsets of effector TH cells secret different cytokines, which play 
important roles in regulating other types of immune cells. For example, TH1 
secretes IL-2, IFN-γ, and TNF-β, which activate TC cells and macrophages to 
eliminate intracellular pathogens like viruses, TH2 secretes IL-4, IL-5 and IL-13, 
which mainly activate B-cells to produce antibodies against pathogens like parasitic 
helminths, and TH17 secretes IL-17, which is involved in the clearance of 
extracellular pathogens like bacteria and fungi (Goldsby, Kindt et al. 2000, 
Geijtenbeek and Gringhuis 2009, Basu, Hatton et al. 2013). Effector TC cells are 
called cytotoxic T lymphocytes (CTLs), which exhibit cytotoxic activity to kill cells 
presenting the same antigen on class I MHC molecules.   
1.3.3 Antibodies 
Antibodies are antigen binding glycoproteins expressed by B cells. They exist on B 
cell membrane or circulate in the blood. There are five classes of antibodies: IgG, 
IgA, IgD, IgM and IgE. All antibodies consist of two identical light (L) chains and two 
identical heavy (H) chains (Figure 1.11); the H chain has a higher molecular weight 
than the L chain. Each L chain is bound to an H chain through a disulfide bound. 
The two L chains are also linked by disulfide bonds, but the number of the bonds 
varies among different classes of antibodies. Each L chain contains a variable 
domain (VL) and a constant domain (CL), while each H chain contains one variable 
domain (VH) and three (for IgG, IgA and IgD) or four (for IgM and IgE) constant 
domains (CH) (Figure 1.11). A hinge region exists between CH1 and CH2 of IgG, IgA 
and IgD, which provides flexibility for these antibodies (Figure 1.11). The amino acid 
sequences in the variable domains vary greatly among antibodies. By contrast, far 
fewer differences are found in the constant domains of antibodies from the same 
class. The CL defines two types of light chain, κ and λ, while the CH defines five 
types of heavy chain, γ, α, δ, μ, and ε, which determine the five classes of 
antibodies (Table 1.3). An individual antibody has either κ or λ as the light chains, 
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but cannot have both.  
     
Table 1.3 Normal serum levels and chain compositions of human antibodies 
Class 
Normal serum 
level (mg/ml) 
Heavy 
chain 
Light chain Molecular composition 
IgG 13.5 γ κ or λ γ2κ2, γ2λ2 
IgA 3.5 α κ or λ (α2κ2)n, (α2λ2)n , n=1 - 4 
IgD 0.03 δ κ or λ δ2κ2, δ2λ2 
IgM 1.5 μ κ or λ (μ2κ2)n, (μ2λ2)n, n=1 or 5 
IgE 0.0003 ε κ or λ ε2κ2, ε2λ2 
 
The heavy chains determine the class of an antibody. Each antibody has one of the 
two light chains; no antibodies have both light chains. IgA and IgM can form 
polymers. The data in the table are from (Goldsby, Kindt et al. 2000).  
 
 
 
Figure 1.11 Structural representations of antibodies 
Each antibody consists of two identical L chains and two identical H chains. Each L 
chain is bound to an H chain through a disulfide bond. The two H chains are also 
linked by one or more disulfide bonds. Each H chain of IgG, IgA and IgD has three 
constant domains (CH1, CH2 and CH3). The CH1 and CH2 domain are linked by a 
hinge region. Each H chain of IgE and IgM has 4 constant domains (CH1, CH2, CH3 
and CH4). Disulfide bonds are found within each chain but are not shown here.   
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IgG is the most abundant antibody in the serum, while IgE is the least abundant 
(Table 1.3). IgG, IgD and IgE exist as monomers, but IgA and IgM exist as both 
monomers and polymers (Table 1.3, Figure 1.12). IgA in the serum exists mainly as 
a monomer, whereas in external secretions (secretory IgA) such as tears, milk and 
mucus, it exists as a dimer (Figure 1.12) or tetramer. Although IgA is not the most 
abundant antibody in the serum, it is the major antibody in external secretions. IgM 
monomer is a membrane bound antibody which serves as the major part of BCRs 
on B cells, while IgM pentamer is the first antibody produced against antigens in a 
primary response. The other classes of antibodies are produced by changing the 
constant region of the IgM μ chain for other classes of CH by a process referred to 
as class switching.   
 
Figure 1.12 IgM pentamer and secretory IgA dimer 
An IgM pentamer consists of five IgM monomer subunits linked together by disulfide 
bonds. A J chain links two subunits through disulfide bonds. A secretory IgA dimer 
consists of two IgA monomer subunits linked by a J chain through disulfide bonds 
and a secretory component which contains five immunoglobulin variable-type 
domains (Bonner, Almogren et al. 2009). IgM pentamer found in external secretions 
also contains a secretory component.  
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The variable regions on antibodies are responsible for recognizing and binding to 
antigens. The binding process can coat viral particles to prevent them from binding 
to host cells, which is exemplified by secretory IgA. However, antibodies generally 
do not just bind to antigens; following the binding process, the interactions between 
constant regions of antibodies and their receptors invoke variable effector functions. 
For example, the interaction between IgG γ constant region and Fcγ receptors 
(FcγRs) expressed on macrophages and neutrophils can promote phagocytosis of 
antigens. In addition, the linking of IgG γ constant region to FcγRs expressed on NK 
cells can induce antibody-dependent cell-mediated cytotoxicity (ADCC). This 
effector function triggers apoptosis of target cells bound by antibodies. Moreover, 
some complement proteins can bind to the constant regions of antibodies like IgG 
and IgM, and activate the complement system. The intensities of effector functions 
invoked by different classes of antibodies are variable. For example, IgM activates 
complement more efficiently than IgG. In addition, different classes of antibodies 
can induce different effector functions. For instance, the binding of the Igε constant 
region to FcεRs on mast cells can induce an effector function known as as an 
allergic response (Gould and Sutton 2008), which cannot be induced by other 
antibodies.   
1.3.4 Allergy 
Patients with allergy exhibit inappropriate responses to common antigens such as 
food and plant pollens, which can cause symptoms like sneezing and wheezing, as 
well as more severe symptoms such as asthma. Allergy is a common disease and 
is increasing in prevalence in industrial countries and urbanized areas of the 
developing countries (Robinson and Bradley 2010). For example, it is estimated 
that peanut and tree nut allergy tripled from 1997 to 2008 among American children 
(Sicherer 2012). One of the central players in allergic responses is IgE, which acts 
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as part of a protein network known as the IgE network (Gould and Sutton 2008). 
The other principal proteins in the network include FcεRI, CD23 and CD21. FcεRI is 
the high affinity Fc receptor for IgE, which has a Ka value of about 1010 M-1 (Gould 
and Sutton 2008). Human FcεRI exists in the form of tetramer (αβγ2) or trimer (αγ2). 
The αβγ2 is expressed on mast cells and basophils, while αγ2 is expressed in a wider 
range of cells including monocytes, eosinophils, and platelets (Kinet 1999). Mouse 
FcεRI only has the tetrameric structure expressed on mast cells and basophils 
(Kinet 1999). CD23 is the low affinity Fc receptor for IgE, which has a Ka value of 
about 106-107 M-1 (Gould and Sutton 2008). CD23 is different from almost all other 
antibody receptors in that it belongs to the C-type lectin superfamily (Ludin, 
Hofstetter et al. 1987). Lectins are proteins which are capable of binding glycans. 
The details of lectins in the immune system and their glycan ligands will be 
discussed in Section 1.4. CD23 is a membrane bound glycoprotein, which consists 
of three C-type lectin head domains linked to the cell membranes by a trimeric 
α-helical coiled-coil stock. It can be released from cell membranes by proteolysis 
which yields various soluble fragments (Weskamp, Ford et al. 2006, Lemieux, 
Blumenkron et al. 2007, Gould and Sutton 2008). However, the binding of CD23 to 
IgE is glycan independent and the binding can be inhibited by peptides from the Fc 
region, but not by glycans (Bettler, Maier et al. 1989, Vercelli, Helm et al. 1989, 
Richards and Katz 1990, Bettler, Texido et al. 1992), which is consistent with recent 
structural findings (Dhaliwal, Yuan et al. 2012). Whether glycans are involved in 
CD21-CD23 interaction has not been confirmed (Aubry, Pochon et al. 1994, Sun 
2006). The pathway of the IgE network is shown in Figure 1.13. The Fc region of 
IgE secreted by B cells binds to FcεRI expressed by APCs and mast cells. Binding 
of antigens (allergens) to the IgE V region cross links FcεRI receptors, which 
induces mast cell degranulation and the release of mediators involved in allergic 
symptoms. The cross linking of FcεRI receptors on APCs by allergen binding leads 
to the presentation of allergens to TH cells (TH2 in this case). Activated TH2 cells 
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secrete IL-4, IL-13 and express CD40L, which stimulate heavy-chain class 
switching in B cells from IgM to IgE. In addition, IL-4, IL-13 and CD40L induce the 
expression and release of CD23 from membranes. The binding of soluble CD23 to 
membrane IgE and CD21 triggers IgE synthesis. As a result, more IgE is produced 
which binds to more allergen and strengthens allergic responses.  
 
 
Figure 1.13 Allergic responses 
B cells secrete IgE which bind to FcεRI on mast cells and APCs. The binding of 
allergens to the variable regions of IgE cross links FcεRI and activates mast cells 
and APCs. Mast cells then secrete mediators which induce allergic responses. After 
FcεRI cross linking, APCs present allergens to TH2 cells. Activated TH2 cells secrete 
IL-4 and IL-13 and express CD40L, which stimulate class switching from IgM to IgE. 
In addition, the products of activated TH2 cells increase the expression of CD23, 
which can be released from membranes by protease. Soluble CD23 binds to CD21 
and membrane IgE on B cells and stimulates IgE production. More IgE is released 
and binds to allergens, which causes stronger allergic responses. Mast cells can 
also express IL-4, IL-13 and CD40L to stimulate IgE production.     
1.3.5 Immunodeficiency and autoimmunity  
The immune system does not function properly all the time. Failure of the immune 
system can cause two types of diseases. It may fail to protect the host against 
pathogens, causing immunodeficiency. It may also fail to discriminate between self 
and non-self and attacks the host it is protecting, causing autoimmunity.  
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One of the most common immunodeficiencies is acquired immunodeficiency 
syndrome (AIDS), which is caused by the infection of human immunodeficiency 
virus (HIV). However, there are another type of immunodeficiency caused by 
genetic defects, which are referred to as primary immunodeficiencies (PID). Many 
PID mutations have been discovered; there are more than 160 cases of 
immunodeficiencies in the online mendelian inheritance in man (OMIM) database 
(http://omim.org/). The severity of a PID depends on the number and type of 
components in the immune system affected by genetic defects. The defects 
involved in the early steps of hematopoiesis can cause very severe symptoms, as 
more types of cells in the immune system will be affected. For example, reticular 
dysgenesis (OMIM #267500) has defects in the mitochondrial adenylate kinase-2 
gene (AK2) and affects the generation of all leukocytes. Patients with this disease 
exhibit congenital agranulocytosis, lymphopenia, and lymphoid and thymic 
hypoplasia. They usually die in the first few weeks of life. However, mild symptoms 
are seen if limited immuno-components are affected. For example, patients with 
immunoglobulin A deficiency (OMIM #137100) show a decreased level of IgA. 
Although they are susceptible to respiratory and gastrointestinal infections, the 
disease is not fatal.  
 
As mentioned in Section 1.3.2, numerous BCRs and TCRs can be produced by 
rearrangements of gene segments, so that these receptors can bind to a large 
diversity of antigens. It is important to note that the rearrangement process also 
produces a large number of receptors which recognize self-antigens. Lymphocytes 
with self-active receptors can turn the immune system against the host. It is 
estimated that 20% to 50% of lymphocytes could have dangerous affinity for 
self-antigens (Goodnow 2007). Activation of these self-targeted lymphocytes can 
cause autoimmunity. Some autoimmune diseases are caused by a direct attack on 
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host cells. For example, in insulin-dependent diabetes mellitus (IDDM), self-active 
CTLs migrate into islets and attack beta cells, which is followed by the activation of 
macrophages, the release of cytokines and the production of auto-antibodies 
(Bluestone, Herold et al. 2010). This process finally damages beta cells and leads 
to a lack of insulin, which causes abnormal glucose metabolism. Another common 
example is rheumatoid arthritis. Auto-antibodies against the IgG Fc fragment and 
citrullinated peptides (ACPA) play important roles in pathogenesis of this disease 
(Scott, Wolfe et al. 2010).  
 
However, some other autoimmune diseases are not caused by direct attack. 
Instead, the auto-antibodies act as agonists or antagonists. In graves' disease, for 
example, the auto-antibodies bind and activate thyrotropin receptors on thyroid 
cells, which causes overproduction of thyroid hormones (Weetman 2000). By 
contrast, in myasthenia gravis, auto-antibodies bind to acetylcholine receptors, 
which masks acetylcholine binding sites and blocks muscle activation (Cavalcante, 
Bernasconi et al. 2012). It is important to note that although there is a high 
percentage of self-active lymphocytes, autoimmunity is only found in about 5% of 
people, mainly because there are several checkpoints in the immune system which 
are able to clear these lymphocytes or to keep them inactivated (Goodnow 2007).  
Glycans have also been found to play important roles in these checkpoints, details 
of which will be discussed in Section 1.4. 
1.4 Glycosylation and the immune system 
Glycosylation is of vital importance in both innate and adaptive immunity. Almost all 
key molecules in the immune system are glycosylated. Glycans are crucial for cell 
migration, cell-cell recognition and lymphocyte regulation (Haslam, Julien et al. 
2008). These functions are mainly executed through the interactions between 
glycans and a group of glycan binding proteins known as lectins. A large number of 
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animal lectins have been identified. In spite of the enormous diversity of structures, 
these lectins have two properties in common (Drickamer and Taylor 1993, Weis and 
Drickamer 1996). First, the glycan binding activity of a lectin can be ascribed to a 
small segment known as the carbohydrate-recognition domain. Second, lectins can 
be divided into a few families based on the sequences of these carbohydrate 
binding domains (CRDs) (Drickamer 1988). There are five major families of animal 
lectins, and three of them have been found to be highly involved in the immune 
system: C-type lectins, Siglecs and galectins (van Kooyk and Rabinovich 2008). 
1.4.1 Interactions between glycans and C-type lectins  
Ca2+-dependent (C-type) lectins are widely distributed in membranes, extracellular 
matrix and serum. They have a common sequence motif known as the C-type CRD 
(Drickamer 1988, Drickamer 1993). As they are named, C-type lectins need the 
involvement of Ca2+ to bind ligands. On the one hand, Ca2+ helps to stabilize the 
binding sites and fix the amino acids in a favourable position to interact with glycans 
(Weis and Drickamer 1996). In addition, Ca2+ directly binds to sugar through 
coordination bonds. C-type CRDs belong to a large family of protein domains 
known as C-type lectin-like domains (CTLD) which show a common protein fold and 
sequence similarity (Weis, Taylor et al. 1998, Drickamer and Dodd 1999, Dodd and 
Drickamer 2001, Sancho and Reis e Sousa 2012). More than 1000 proteins 
(including proteins deduced from genome sequences) have been computationally 
identified as members of the C-type lectin superfamily (Zelensky and Gready 2005). 
Not all members of this family bind glycans; some of them bind proteins, lipids and 
inorganic ligands (Sancho and Reis e Sousa 2012). Neverthelss, the most common 
function of C-type lectins in vertebrates is Ca2+-dependent glycan binding. The 
binding activity of a C-type CRD is largely determined by a three amino acid motif in 
the binding site. A CRD is mannose/fucose-specific if the binding site motif is EPN, 
whereas it is galactose-specific if the motif is QPD (Drickamer 1992). C-type lectins 
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not only recognise glycans on pathogens to trigger endocytosis, inflammation and 
antigen presentation, but also bind endogenous ligands and regulate immune 
reactions. The latter case is the focus of this thesis and is exemplified by two well 
studied examples: selectins and DC-specific intracellular adhesion molecule 
3-grabbing non-integrin (DC-SIGN).  
 
The best studied example is the role of selectin-glycan interactions in directing the 
migration of leukocytes from the vascular system to sites of infection or to lymph 
nodes. In order to exit the vascular system, free flowing leukocytes are first 
captured by vascular endothelium. After that, the leukocytes roll along the vessel 
wall and form an intimate contact with the vascular endothelium. This intimate 
contact enables the interaction between chemokines on endothelial cells and 
chemokine receptors on leukocyte surface. Signal transductions in the leukocytes 
are then triggered and integrins are synthesized on the surface of leukocytes, which 
bind integrin ligands such as immunoglobulin superfamily members intercellular 
adhesion molecule 1 (ICAM-1) or vascular cell adhesion molecule 1 (VCAM-1) on 
endothelial cells. The integrin-ligand interaction reduces leukocyte rolling speed 
and strengthens the adhesion of leukocytes to the vascular endothelium. Finally, 
leukocytes flatten and crawl along the endothelium and exit the vascular system. 
The capture and rolling of leukocytes on vascular endothelium are mediated by 
selectins. Three types of selectins have been identified in mammals, P-selectin, 
E-selectin and L-selectin. Each lectin has an N-terminal C-type CRD, followed by a 
EGF-like motif, a series of Sushi domains, a helical transmembrane domain and a 
cytoplasmic tail (McEver, Moore et al. 1995). The migration of leukocytes to sites of 
infection is directed by the the binding of P- and E-selectins on vascular 
endothelium to the ligands on leukocytes, whereas the migration of lymphocytes to 
lymph nodes (lymphocyte homing) is mediated by the interaction between 
L-selectin on lymphocytes and ligands on the endothelial surface of high endothelial 
venules (HEV). The expression of P- and E-selectins by vascular endothelium is 
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induced by inflammatory mediators (Collins, Read et al. 1995, Eppihimer, Russell et 
al. 1997), while the expression of L-selectin by leukocytes is in a constitutive 
manner (Lowe 2002).   
 
The selectin-ligand interaction is glycan-based. The role of glycans was proposed 
by an early observation that HEV retained its affinity to lymphocytes in 
Stamper-Woodruff assays, which leave glycans intact but destroy peptides or 
proteins (Stamper and Woodruff 1977). Additional evidence was seen in following 
studies which found some monosaccharides and polysaccharides were able to 
inhibit the binding of lymphocyte to HEV (Stoolman and Rosen 1983, Stoolman, 
Tenforde et al. 1984). Then, an in vitro study showed lymphocyte adhesion to HEV 
was disabled by sialidase treatment (Rosen, Singer et al. 1985), and similar results 
were observed in an in vivo study on mouse (Rosen, Chi et al. 1989), suggesting 
sialic acid is required for the adhesion. During the same period, the Sialyl Lewis X 
structure was identified in granulocytes (Fukuda, Spooncer et al. 1984, Fukuda, 
Bothner et al. 1985). Soon after, Sialyl Lewis X was identified as a common ligand 
for E- and P-selectins (Berg, Robinson et al. 1991), as well as L-selectins (Polley, 
Phillips et al. 1991). Studies at the same period showed that L- and P-selectin can 
also bind to sulfated molecules (Aruffo, Kolanus et al. 1991, Green, Tamatani et al. 
1992).  
 
It is important to note that selectins favorably bind to a limited number of ligands. 
E-selectin ligand-1 (ESL-1), human L-selectin, CD44 and P-selectin glycoprotein 
ligand-1 (PSGL-1) have been identified as ligands for E-selectins, CD24 and 
PSGL-1 have been indentified as a ligands of P-selectin, and GlyCAM-1, 
MAdCAM-1 and podocalyxin have been identified as ligands of L-selectin. ESL-1 
was discovered as an E-selectin ligand by affinity isolation using a recombinant 
E-selectin (Levinovitz, Muhlhoff et al. 1993). The isolation results showed ESL-1 
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was the only ligand detected on mouse neutrophils and a neutrophil progenitor cell 
line. In addition, the affinity is strictly Ca2+ dependent and requires sialic acid. 
Removal of N-glycans from ESL-1 disables its binding to E-selectin (Lenter, 
Levinovitz et al. 1994), which indicates N-glycans but not O-glycans carry the ligand 
activity. L-selectin was identified on human but not on mouse neutrophils as a 
ligand for E-selectin using the recombinant E-selectin affinity assay (Zollner, Lenter 
et al. 1997). L-selectin after endoglycosidase F treatment dose not show reduced 
binding to E-selectin, suggesting endoglycosidase F-sensitive N-glycans on are not 
required for binding. CD44 is a currently identified ligand for E-selectin. A study 
shows E-selectin binds specifically to CD44 isolated from G-CSF-differentiated 32D 
cells or from peripheral blood polymorphonuclear neutrophils (Katayama, Hidalgo et 
al. 2005). The study also shows the binding activity is mediated by sialylated and 
fucosylated N-glycans. An in vivo analysis in this study finds CD44 mediates slow 
leukocyte rolling on inflamed endothelium which expresses E-selectins. However, 
CD44 prepared from bone marrow stromal or brain endothelial cell lines does not 
exhibit affinity for E-selectin, which suggests cell specific glycosylation is crucial for 
selectin recognition.  
 
CD24 is a mucin-type glycosylphosphatidylinositol-linked membrane protein. Beads 
coated with neutrophil CD24 bind specifically to P-selectin (Aigner, Sthoeger et al. 
1997). The binding activity was not affected by endoglycosidase F digestion, which 
indicates the binding epitope is on O-glycans. PSGL-1 is a clearly defined selectin 
ligand (McEver and Cummings 1997). It shows affinity for E-selectin and serves as 
a major ligand for P-selectin. The early findings that P-selectin binds preferentially 
to PSGL-1 on human myeloid cell were revealed by ligand blotting and affinity 
chromatography experiments (Moore, Stults et al. 1992). PNGase F digestion 
apparently reduces the molecular weight of this ligand, but did not affect P-selectin 
binding. However, the binding is disabled by sialidase digestion, suggesting the 
52 
 
functional epitope is on sialylated O-glycans. Following this study, Sialyl Lewis X 
antigen was identified on this ligand one year later (Norgard, Moore et al. 1993). 
Additional studies found PSGL-1 is a heavily glycosylated sialomucin with a short 
C-terminal intracellular domain, a transmembrane domain which is followed by 
multiple decameric repeats and an N-terminal selectin-binding domain (Sako, 
Chang et al. 1993, McEver and Cummings 1997). Although the decameric repeats 
are heavily O-glycosylated, the O-glycans at T57 near the N-terminus of human 
PSGL-1 are key for P-selectin binding (Liu, Ramachandran et al. 1998). The 
O-glycans in the decameric repeats may help to keep this region uncoiled so that 
the N-terminal domain can stay away from cell surface for selectin binding 
(Sperandio, Gleissner et al. 2009). Besides glycosylation, tyrosine sulfation near the 
N-terminal is necessary for high affinity binding to P-selectin (Wilkins, Moore et al. 
1995). Although there are more than one ligand for E- and P-selectins, they may 
have different roles in leukocyte migration. For example, a study of E-selectin 
ligands found that PSGL-1 is involved in leukocyte capture, while ESL-1 and CD44 
are involved in the rolling velocity (Hidalgo, Peired et al. 2007).  
 
 
Figure 1.14 Structure of 6-sulfosialyl Lewis X, 6`-sulfosialyl Lewis X and 
6`,6-sulfosialyl Lewis X 
 
GlyCAM-1 is identified as a prominent HEV derived ligand for L-selectin using a 
soluble recombinant form of L-selectin (Imai, Singer et al. 1991). It was originally 
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named Sgp50, which means sulfated glycoprotein of 50 kDa. This glycoprotein was 
also identified as CD34. GlyCAM-1 is extensively O-glycosylated and sulfation of 
the O-glycans is essential for L-selectin binding (Imai, Lasky et al. 1993). Three 
types of sulfated Sialyl Lewis X have been discovered substantially on Core 2 
O-glycans: 6-sulfosialyl Lewis X, 6'-sulfosialyl Lewis X (the major type) and 
6,6'-bisulfosialyl Lewis X (Figure 1.14) (Hemmerich, Bertozzi et al. 1994, 
Hemmerich and Rosen 1994, Hemmerich, Leffler et al. 1995). The inhibition of Core 
2 O-glycan synthesis was predicted to hinder the binding activity of GlyCAM-1 and 
PSGL-1, as the binding epitopes are mainly synthesized on this type of glycan. 
Surprisingly, mice with C2GnT I deletion have reduced neutrophil recruitment to 
sites of inflammation, but did not exhibit reduced lymphocyte homing (Ellies, Tsuboi 
et al. 1998). This observation indicates that there are unknown mechanisms in HEV 
which are able to compensate for the C2GnT I deletion. Indeed, a subsequent study 
observed a group of novel Core 1 O-glycans which carry the sulfosialyl Lewis X 
structure on extended antennae for L-selectin binding (Yeh, Hiraoka et al. 2001). 
When GlyCAM-1 was identified as Sgp50, another sulfated glycoprotein with 
molecular weight of 90 kDa was observed in the same experiment and was named 
Sgp90 (Imai, Singer et al. 1991, Baumheter, Singer et al. 1993). This glycoprotein 
was later identified as CD34, which is also an important ligand for L-selectin. In the 
same year, another glycoprotein was identified, which is known as MAdCAM-1 
(Berg, McEvoy et al. 1993) and five years later, a new ligand which is similar in 
structure to CD34 was identified, which is called podocalyxin (Sassetti, Tangemann 
et al. 1998). Like GlyCAM-1 and CD34, MAdCAM-1 and podocalyxin are decorated 
with sulfated, sialylated O-glycans.  
 
Fucosylation is an essential step in the synthesis of the Sialyl Lewis X antigen. 
FucT-IV and FucT-VII deficient mice exhibit both impaired leukocyte recruitment 
and disabled lymphocyte homing (Homeister, Thall et al. 2001).  Abnormal 
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leukocyte migration is observed in these mice. In humans, congenital disorder of 
glycosylation type IIc (CDG IIc) is a disease caused by mutations in SLC35C1 
(OMIM #266265), which is a GDP-fucose transporter responsible for transporting 
GDP-fucose to the Golgi complex. GDP-fucose is a sugar donor for 
fucosyltransferases to incorporate Fuc residues into glycans, which is required for 
the synthesis of the Sialyl Lewis X antigen. Accordingly, markedly decreased 
neutrophil motility and recurrent infections are observed in patients with CDG IIc. 
Congenital disorder of glycosylation type IIf (CDG IIf) is a disease caused by 
mutations in SLC35A1 (OMIM #603585), which is a CMP-sialic acid transporter and 
provides the sugar donor for sialyltransferases in the Golgi complex. Patients with 
this disease display a lack of the Sialyl Lewis X antigen and show multiple recurrent 
bacterial infections.   
 
DC-SIGN is another important representative of the C-type lectin family which 
recognizes endogenous glycans. It was first identified in 1992 as a C-type lectin 
which binds high mannose glycans on HIV envelope glycoprotein gp120 (Curtis, 
Scharnowske et al. 1992). However, the name, DC-SIGN, was given eight years 
later when this lectin was identified as a DC-specific C-type lectin which had high 
affinity for intracellular adhesion molecule 3 (ICAM-3) expressed by resting T cells 
(Geijtenbeek, Torensma et al. 2000). Like the selectins described above, DC-SIGN 
can mediate cell migration, which is important for DCs to present antigens to T cells 
(Garcia-Vallejo, van Liempt et al. 2008). Immature DCs first migrate to sites of 
infection, where they ingest pathogens, process antigens and usually become 
mature. After that, DCs migrate to secondary lymphoid organs, where they present 
antigens to T-cells. DC-SIGN serves as an adhesion molecule which mediates the 
capture and rolling processes of DCs during migration (Garcia-Vallejo, van Liempt 
et al. 2008). The ligand for this adhesion is the Lewis Y antigen found on 
intracellular adhesion molecule 2 (ICAM-2), which is a glycoprotein expressed by 
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endothelial cells. Lewis Y contains two Fuc residues linked to the GlcNAc and Gal 
in α1-3 and α1-2 linkages respectively (Figure 1.7). FucT-I is identified as the 
enzyme which catalyzes the formation of the α1-2 linkage, as silencing of this 
glycosyltransferase results in a decrease in the adhesion of DCs to endothelial cells. 
FucT-IV is found to be the major enzyme which contributes to the α1-3 linked Fuc. 
When DCs arrive at lymph nodes and start presenting antigens to T cells, they need 
to contact T cells directly. DC-SIGN works again as an adhesion molecule to 
mediate the direct contact between DCs and T cells. Previous studies suggest one 
of the ligands involved in this contact is Lewis X on ICAM-3 expressed by T cells 
(Bogoevska, Nollau et al. 2007). DC-SIGN binds ICAM-3 with high affinity and 
initiates transient adhesion of DCs with T cells, which is important for formation of 
the immune synapse (Steinman 2000). Antibodies against DC-SIGN can inhibit 
DC-induced proliferation of resting T cells. Co-transfection studies demonstrated 
that FucT-IX is the major enzyme for catalyzing the addition of an α1-3 linked Fuc 
residue to form the Lewis X antigen. FucT-IV is involved, but it contributes to a 
significantly lesser extent. It is interesting that DC-SIGN cannot bind to ICAM-3 
expressed by lymphocytes in peripheral blood, suggesting that ICAM-3 on T cells in 
the lymph nodes has a different glycan profile.  
 
When DCs present antigens to native T cells, the maturational state of DCs is a 
decision maker in the T cell fate; immature DCs cannot sufficiently induce native T 
cells into effector T cells but could instead induce the production of regulatory T 
cells which display T cell tolerance (Jonuleit, Schmitt et al. 2000). Therefore, 
maturation of DCs before antigen presentation is important for the production of 
effector T cells to eliminate pathogens. Studies have found that neutrophils play one 
of the key roles in DC maturation (van Gisbergen, Geijtenbeek et al. 2005). 
Neutrophils are normally the first leukocytes to arrive at the site of infection. 
Activated neutrophils at the infected site release MIP-1α, MIP-1β and α-defensins. 
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These cytokines are responsible for instructing the migration of other leukocytes to 
the infected site, including immature DCs (Yang, Chen et al. 2000). These DCs 
interact with neutrophils through DC-SIGN. The ligand is a Lewis X structure on 
Mac-1, which is a glycoprotein expressed by activated neutrophils (van Gisbergen, 
Sanchez-Hernandez et al. 2005). Although it has not been confirmed whether the 
binding of DC-SIGN to Mac-1 can initiate signal transduction to induce DC 
maturation, (Bennouna and Denkers 2005), the contact between DCs and 
neutrophils could be important for TNF-α transmission, given that a low amount of 
TNF-α is produced by neutrophils. Mature DCs can induce the activation of either 
TH1 or TH2 cells. However, the crosstalk between neutrophils and DCs may instruct 
DCs to induce TH1 polarization (Bennouna, Bliss et al. 2003). It is interesting that 
Mac-1 expressed by other leukocytes cannot be bound by DC-SIGN, possibly 
because these leukocytes decorate Mac-1 with different glycans (van Gisbergen, 
Sanchez-Hernandez et al. 2005). N-glycomic analysis of monocyte and immature 
DCs detected few Lewis X structures (CFG data base: 
www.functionalglycomics.org), while N-glycomic data of neutrophils contain a large 
number of Lewis X epitopes (Babu, North et al. 2009).  
1.4.2 Interactions between glycans and Siglecs  
Siglecs are primarily expressed in the immune system and have specificity for sialic 
acid-containing glycans. The first Siglec was identified in 1989, when a sheep 
erythrocyte receptor on mouse macrophage was discovered to have specificity for 
sialylated glycans (Crocker and Gordon 1989). This receptor was also called 
sialoadhesin. Two years later, another Siglec known as CD22 was discovered 
(Stamenkovic, Sgroi et al. 1991). In the same year, CD22 was cloned and identified 
as a member of the immunoglobulin super family (IgSF) (Wilson, Fox et al. 1991). 
This is the first time an IgSF member was found to have sialic acid binding ability. 
Sialoadhesin was also soon identified as another member of IgSF (Crocker, 
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Mucklow et al. 1994). The same study found sialoadhesin to have sequence 
similarities to CD33 and mammalian myelin-associated glycoprotein (MAG), both of 
which were then confirmed to belong to the IgSF and to bind sialylated ligands 
(Kelm, Pelz et al. 1994, Freeman, Kelm et al. 1995). At that time, sialic acid binding 
lectins were either called I-type lectins or Sialoadhesins. In order to establish a 
generally accepted nomenclature to classify these lectins as a group, researchers 
in 1998 agreed with the name Siglec, which contains three key elements: sialic acid, 
immunoglobulin superfamily and lectin (Crocker, Clark et al. 1998). In the new 
nomenclature, sialoadhesin, CD22, CD33 and MAG are named Siglec-1, Siglec-2, 
Siglec-3 and Siglec-4 respectively. New Siglec members were suggested to be 
numbered in the order of discovery.  
 
Fifteen human Siglecs and five mouse Siglecs have been discovered in the immune 
system (Pillai, Netravali et al. 2012). All Siglecs have an N-terminal Ig-like V-type 
domain outside the cell, which contributes to sialic acid binding. This domain is 
projected away from the cell surface by variable numbers of Ig-like C2-type 
domains. Siglecs can be categorized into three groups according to their 
cytoplasmic motifs (Pillai, Netravali et al. 2012), which are likely to mediate cell 
signaling. The first group of Siglecs has neither the immunoreceptor tyrosine-based 
inhibitory motif (ITIM) nor the immunoreceptor tyrosine-based activating motif (ITAM) 
(Figure 1.15), and, therefore, mainly mediate cell adhesion. This group of lectins is 
made up of Siglec-1 and Siglec-4 in both human and mouse. The second group has 
one or more cytosolic ITIM motifs. In humans, Siglecs of this group include Siglec-2, 
-3, -5, -6, -7, -8, -9, -10, -11, -12, whereas in mouse Siglec-2, -E, -F, -G (Figure 1.16). 
Upon ligand recognition, receptors with ITIM motifs can result in phosphorylation of 
ITIM tyrosines often by a Src family kinase such as Lyn, and the recruitment of 
tyrosine phosphatases like SHP-1 or SHP-2 which lead to attenuation of signal 
transduction downstream of other activating receptors (Ravetch and Lanier 2000). 
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The third group of Siglecs can associate other membrane proteins like DAP12 that 
contain ITAM motifs. Human Siglecs in this group consist of Siglec-14, -15, and -16, 
while mouse Siglecs in this group consist of Siglec-3, -15, and -H (Figure 1.17). 
These Siglecs have a positively charged residue in the transmembrane domain, 
which can interact with the negatively charged residues in the transmembrane 
domain of DAP12. Phosphorylation of the tyrosine residues on ITAM motifs 
provides docking sites for the recruitment and activation of Syk family tyrosine 
kinases, which can activate or attenuate downstream signaling pathways of the 
immune system (Hamerman and Lanier 2006).  
 
As mentioned in Section 1.3.5, it is estimated that 20% to 50% of lymphocytes 
could have dangerous affinity for self-antigens (Goodnow 2007). Nevertheless, 
several checkpoints have been identified in the immune system which are able to 
clear these self-reactive lymphocytes or to keep them inactivated, so that 
autoimmunity is only found in about 5% of people. The interaction between Siglecs 
and sialic acid is usually involved in signal attenuation, which could be an important 
checkpoint to prevent autoimmunity. Although full details remain to be investigated, 
several current studies implicate Siglec-sialic acid interactions are involved in the 
attenuation of BCR and TCR signaling.      
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Figure 1.15 The first group of Siglecs is made up of Siglec-1 and Siglec-4 
The lectins have neither ITIM nor ITAM motifs. Siglec-1 has sixteen Ig-like C2-type 
domains and an Ig-like V-type domain. Siglec-4 has four Ig-like C2-type domains 
and an Ig-like V-type domain. The Ig-like V-type domain is responsible for sialic acid 
binding.    
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Figure 1.16 The second group of Siglecs in the human and mouse 
These Siglecs contain ITIM motifs. Siglec-2, also known as CD22, has three ITIM 
motifs, while the others have a single ITIM motif. All Siglecs contain one Ig-like 
V-type domain except Siglec-12 in humans, which contains two. Siglec-12 is a 
pseudogene in many human subjects. The in-frame version of Siglec-12 contains 
two Ig-like V-type domains which lack the arginine residue required for sialic acid 
binding (Mitra, Banda et al. 2011, !!! INVALID CITATION !!!). Different Siglecs have 
variable numbers of Ig-like C2-type domains.   
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Figure 1.17 The third group of Siglecs in the human and mouse 
A Siglec in this group can associate with DAP12, which is a dimer with two ITAM 
motifs in the cytosol. The association is mediated by the positively charged residues 
of Siglecs and the negatively charged residues of DAP12 in the transmembrane 
domain. Mouse Siglec-3 has a positive charge in the transmembrane domain, but 
its association with DAP12 has not been formally demonstrated. 
   
Siglec-2 belongs to the second group of Siglecs and binds glycans with α2-6 linked 
sialic acid (Sgroi, Varki et al. 1993, Sjoberg, Powell et al. 1994). It contains an 
Ig-like V-type domain followed by six Ig-like C2-type domains in the extracellular 
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area (Figure 1.16). Three ITIM domains are found in the cytosolic side. Several 
studies have shown CD22 is required for negative regulation of BCR signaling, 
according to the measurement of Ca2+ flux, which is a process downstream BCR 
signalling pathway. In different CD22 knockout mice, enhanced Ca2+ flux was 
observed upon BCR activation (O'Keefe, Williams et al. 1996, Nitschke, Carsetti et 
al. 1997). Other studies found CD22-deficient mice developed autoantibodies 
against double-stranded DNA, cardiolipin and myeloperoxidase (O'Keefe, Williams 
et al. 1999), suggesting a role of CD22 for the avoidance of autoimmunity. 
Autoimmunity symptoms are also observed in mice that lack Lyn or Shp-1, which 
are signal components downstream of the CD22 receptor (Hibbs, Tarlinton et al. 
1995, Nishizumi, Taniuchi et al. 1995, Pao, Lam et al. 2007). Previous data indicate 
that CD22 negatively regulates BCR signaling by binding to sialic acid containing 
glycans. Mice with mutations of the critical sites for sialic acid binding on CD22 
exhibit increased Ca2+ flux and CD22 tyrosine phosphorylation (Jin, McLean et al. 
2002). The same result was observed when synthetic sialosides were used to 
inhibit the lectin domain of CD22 on B cells (Kelm, Gerlach et al. 2002).  
 
Sialic acid on glycans can be naturally modified by 9-O-acetylation, which is a 
process of incorporating an acetyl group to the 9-OH position of sialic acid. This 
modification can mask CD22 recognition (Sjoberg, Powell et al. 1994). By contrast, 
sialic acid acetylesterase (SIAE) is an enzyme that is able to remove the 9-O-acetyl 
moiety and expose sialic acid to CD22 (Takematsu, Diaz et al. 1999). Mouse B cells 
with SIAE defects had a higher level of 9-O-acetylated sialic acid, enhanced BCR 
signaling, and autoantibodies against DNA and chromatin (Cariappa, Takematsu et 
al. 2009). In humans, functionally defective germline variants of SIAE indicate a 
genetic link to autoimmunity (Surolia, Pirnie et al. 2010). CMP-N-acetylneuraminic 
acid hydroxylase (CMAH) is an enzyme that converts CMP-NeuAc to CMP-NeuGc. 
Mouse CD22 preferentially binds to NeuGc and mice with CMAH deletion reveal a 
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low affinity for CD22, increased BCR signaling, and an enhanced Ca2+ flux (Naito, 
Takematsu et al. 2007, Cariappa, Takematsu et al. 2009).  
 
Some evidence also supports the attenuating roles of Siglecs in TCR signaling. 
Jurkat cells transfected with Siglec-7 or Siglec-9 exhibited phosphorylation of ITIM, 
recruitment of SHP-1, reduced phosphorylation of ZAP70 downstream of TCR 
signaling, and decreased transcriptional activity of nuclear factor of activated T cells 
(NFAT) (Ikehara, Ikehara et al. 2004). These observations suggest a negative role 
of Siglec-7 of Siglec-9 in T cell activation. NFAT activity increased when the 
conserved ligand binding site of Siglec-7 (Arg124) or Siglec-9 (Arg120) was 
mutated, suggesting that binding to sialic acid is required for optimal inhibition of 
TCR activity (Ikehara, Ikehara et al. 2004). At least 8 nonsynonymous SNPs have 
been detected in human Siglec-9. The A391C polymorphism in the DNA sequence 
leads to the Y131Q amino acid change in Siglec-9, which was speculated to result 
in a reduced binding activity to sialic acid (Cheong, Chang et al. 2011). Jurkat T 
cells transfected with the A391C mutant exhibited a reduced inhibition of ZAP-70 
phosphorylation and IL-2 production compared to cells transfected with the wild 
type Siglec-9 (Cheong, Chang et al. 2011). 
1.4.3 Interactions between glycans and galectins  
Galectins are a family of animal lectins that exhibit sequence similarity in the glycan 
binding site and preferentially bind to glycans with β-galactoside structures 
(Barondes, Castronovo et al. 1994). Galectins are widely distributed in animals 
ranging from sponges to mammals (Hirabayashi and Kasai 1993, Oda, Herrmann 
et al. 1993). Fifteen galectins have been identified in mammals, which are 
numbered from galectin-1 to galectin-15. They are divided into 3 types: proto-type, 
chimera-type and tandem repeat-type (Figure 1.18 A). The proto-type has 9 
members (galectin-1, -2, -5, -7, -10, -11, -13, -14, -15), each of which has a single 
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CRD, but can form dimers to have a bivalent binding affinity. The chimera-type has 
one member, galectin-3, which has a single CRD. However, the N-terminal region of 
galectin-3 is able to interact with each other to form oligomers to gain multivalent 
binding ability. The tandem repeat type has 5 members (galectin-4, -6, -8, -9, -12) 
and each of them has 2 CRDs for bivalent binding. Gal residues on LacNAc units 
are common ligands for galectins. However, the fucosylation and sialylation of 
LacNAc units, the length of antennae, and the number of branches of a glycan 
significantly affect the binding activities of galectins (Table 1.4). In addition, the 
members of the galectin family show different binding affinities for different glycan 
structures. These variable glycan-galectin interactions could regulate a large 
number of biological functions by cross-linking glycoproteins found on cell 
membranes (Figure 1.18 B) and extracellular matrix (ECM). The cross-linking 
process organizes the distribution of membrane receptors, regulates cell-cell and 
cell-ECM interactions, and plays important roles in cell survival, cell growth and cell 
adhesion, which are key processes in the immune system (Perillo, Marcus et al. 
1998, Rabinovich, Rubinstein et al. 2002, Liu 2005, Rabinovich, Toscano et al. 2007, 
Rabinovich and Toscano 2009). The functions of galectins in the immune system 
are summarized in Table 1.5. Galectin-1 and galectin-3 are the most extensively 
studied, and their functions are discussed below.  
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Figure 1.18 Structure and function of galectins 
(A) There are 3 types of galectins: prototype, chimera-type and tandem repeat-type. 
Proto-type and chimera-type have a single CRD, but proto-type can form dimers 
and chimera-type can form polymers to gain the ability of multivalent binding. The 
tandem repeat type has two CRDs. (B) Galectins link glycoproteins by binding to 
the LacNAc units which contain β-linked galactoses.     
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Table 1.4 Binding activities of some galectins 
Galectins Binding specificities 
Galectin-1 
Binds terminal Gal.  
Higher affinity for glycans with more branches.  
α2-6 sialylation can block binding.  
Galectin-2 
Binds terminal Gal.  
α1-2 fucosylation enhances binding affinity.  
α2-3 and α2-6 sialylation can block binding.   
Galectin-3 
Binds both terminal and internal Gal.  
Higher affinity for glycans with more LacNAc units or branches 
Can bind α2-6 sialylated poly-LacNAc, as internal Gal is available for binding.   
Galectin-4 High affinity for LacNAc units modified by α1-3 linked Gal and α1-2 linked Fuc.   
Galectin-5 
High affinity for multiantennary glycans with terminal LacNAc units, especially 
LacNAc units extended by α1-3 linked Gal. 
Galectin-7 
Binds to both terminal and internal Gal.  
Higher affinity for glycans with more branches 
Galectin-8 High affinity for LacNAc units modified by α1-3 linked Gal and α1-2 linked Fuc. 
Galectin-9 Binds to branched glycans with poly-LacNAc units. 
Galectin-10 Higher affinity for β-linked Man than that for β-linked Gal. 
Galectin-12 Binds to lactose. 
Galectin-13 High affinity for LacNAc units and Man containing structures. 
Galectin-14 
Binds to poly-LacNAc structures which are non-modified, α1-2 fucosylated or 
α2-6 sialylated.  
 
Data of this table are from (Demetriou, Granovsky et al. 2001, Rabinovich and 
Toscano 2009) 
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Table 1.5 Immuno-modulatory effects of some galectins 
Galectins Functions 
Galectin-1 
Induces apoptosis in thymocytes, T cells, B cells and macrophages 
Mediates B cell differentiation 
Inhibits T cell growth 
Mediates adhesion and cytokine secretion 
Enhances phagocytosis of neutrophils by phagocytes 
Induces oxidative burst in neutrophils 
Galectin-2 
Induces T cell apoptosis 
Mediates lymphotoxin-alpha secretion by macrophages 
Galectin-3 
Induces B cell differentiation 
Mediates T cell growth 
Induces T cell apoptosis 
Inhibits apoptosis in B cells, T cells and macrophages 
Mediates adhesion and cytokine secretion 
Induces phagocytosis and oxidative burst in neutrophils and macrophages 
Induces mast cell degranulation 
Galectin-4 
Induces T cell apoptosis 
Induces cytokine production by T cells 
Galectin-7 Induces cytokine production by T cells 
Galectin-8 
Induces adhesion of neutrophils to ECM 
Enhances B cell antigen presentation 
Induces T cell proliferation 
Induces apoptosis of thymocytes and Jurkat T cell 
Glalectin-9 
Induces T cell and B cell apoptosis 
Mediates cytokine secretion  
Mediate adhesion of eosinophils 
Mediates apoptosis of eosinophils 
Galectin-10 Essential for the functional properties of CD25+ Treg cells 
 
Data of this table are from (Liu 2005, Kubach, Lutter et al. 2007, Rabinovich, Liu et 
al. 2007, Tribulatti, Mucci et al. 2007, Norambuena, Metz et al. 2009, Tribulatti, 
Cattaneo et al. 2009, Yuseff, Pardo et al. 2012, Yamaguchi, Hiromasa et al. 2013).  
 
The ability to discriminate self and on-self is pivotal to the normal functioning of the 
immune system. Most self-reactive immune cells are deleted through apoptosis 
before they mature to attack their host. During T cell maturation in the thymus, only 
a small portion of thymocytes are able to survive and become naïve mature T cells. 
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Thymic epithelial cells play a crucial role in the selection process. Studies have 
found thymic epithelial cells express galectin-1, which induces apoptosis of 
immature thymocytes but leaves mature thymocytes intact (Perillo, Uittenbogaart et 
al. 1997). Different glycosylation on thymocytes is involved in this selective 
induction. Mature thymocytes express α2-6 linked sialic acid, which inhibits 
galectin-1 binding and reduces the apoptosis process (Amano, Galvan et al. 2003). 
In addition, the expression of C2GnT is higher in cortical thymocytes than in 
medullary thymocytes, which correlates with the fact that the immature thymocytes 
have higher affinity for galectin-1 than mature thymocytes. It is possible that 
branched Core 2 glycans have more Gal residues than Core 1 glycans (Earl, Bi et 
al. 2010). Self-reactive thymocytes may not be completely removed during 
development, so some mature T cells may escape from the thymus to attack 
self-antigens. In this case, galectin-1 continues to maintain self-tolerance by 
inhibiting proliferation or inducing apoptosis of activated T cells. Galectin-1 has 
been found to arrest the growth of several activated cell types, such as 
phytohemagglutinin (PHA)-activated human T cells, concanavalin A (Con 
A)-stimulated rat T cells, chicken activated lymphocytes and human leukemia T 
cells (Rabinovich, Rubinstein et al. 2002). Moreover, galectin-1 can induce the 
apoptosis of activated T cells (Perillo, Pace et al. 1995).  
 
Galectin-1 binds to a restricted set of glycoproteins on the T cell surface. Early 
studies found the binding of galectin-1 to T cells can be blocked by an antibody 
which recognizes Core 2 O-glycans on CD43 (Baum, Pang et al. 1995). CD43 is a 
heavily O-glycosylated protein which serves as one of the major galectin-1 ligands 
on T cells (Hernandez, Nguyen et al. 2006). T cells without CD43 decrease 
galectin-1 binding by about 50% and exhibit reduced apoptosis. It appears that 
Core 2 O-glycans on CD43 are required for binding. Surprisingly, further studies 
have shown that decoration of CD43 by either Core 1 or Core 2 O-glycans does not 
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make a big difference for galectin-1 recognition. One of the possible reasons is that 
the high density of Core 1 O-glycans on CD43 can compensate the lack of Core 2 
O-glycans. This also suggests that Core 2 glycans on glycoproteins with fewer 
O-glycosylation sites should be important for galectin-1 binding. Antibodies against 
the glycans on CD45 can abolish the binding of T lymphoblastoid cells to thymic 
epithelial cells (Baum, Pang et al. 1995). CD45 is a large transmembrane 
glycoprotein which can be expressed as different isoforms. The isoforms with large 
molecular weight contain more O-glycosylation sites. Core 2 O-glycans on CD45 
are required for galectin-1 induced apoptosis in cells expressing low molecular 
weight isoforms, whereas Core 1 O-glycans are sufficient for galectin-1 binding to 
cells expressing high molecular isoforms (Earl, Bi et al. 2010). Besides O-glycans, 
N-glycans CD45 are required for galectin-1 binding and α2,6 linked sialylation can 
dramatically reduce the binding affinity. CD3 and CD7 have also been identified as 
ligands for galectin-1. The binding leads to a dramatic change of organization of 
glycoproteins (Pace, Lee et al. 1999). CD45 and CD3 co-localize on large islands 
on apoptotic blebs protruding from the cell surface, whereas CD7 and CD43 
co-localize in small patches away from the membrane blebs. 
 
Galectin-3 has been discovered to signal apoptosis of human T leukemia cell lines, 
human peripheral blood mononuclear cells, and activated mouse T cells (Fukumori, 
Takenaka et al. 2003). Glycans on CD29, CD45 and CD7 are involved in this 
process. Besides inducing apoptosis, galectin-3 can prevent spontaneous TCR 
aggregation at the start of T cell activation and could arrest T cell proliferation when 
antigens have been cleared by effector T cells. The initiation of T cell activation 
requires TCR clustering at the antigen presenting site. The cross linking of TCRs by 
galectin-3 can restrict TCR mobility on the cell surface, which sets a threshold for 
TCR clustering (Demetriou, Granovsky et al. 2001). GlcNAc T V is an enzyme 
which initiates the formation of the β1-6 branch of N-glycans. Defects in this 
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enzyme could cause a reduced number of N-glycan branches and is expected to 
lower the threshold of TCR aggregation. Accordingly, GlcNAc T V knockout mice 
showed enhanced TCR clustering and susceptibility to autoimmune diseases.  
Enhanced TCR clustering was also observed when wild type T cells were treated 
with lactose which competes for galectin-3. At a late stage of T cell activation, 
galectin-3 binds to N-glycans on cytotoxic T lymphocyte antigen 4 (CTLA4) and 
increases CTLA4 retention on the cell surface (Lau, Partridge et al. 2007). CTLA4 is 
an inhibitory molecule for cell growth, so the binding process could arrest T cell 
proliferation when antigens have been cleared (Rabinovich and Toscano 2009).  
 
A large number of studies have found that galectin-3 can suppress apoptosis 
(Rabinovich, Rubinstein et al. 2002, Liu 2005). It is important to note that the 
suppression activity occurs intracellularly in a glycan independent manner (Liu, 
Patterson et al. 2002). As the focus of this thesis is glycans, the details of this 
process are not discussed.      
 
More than one galectin is involved in T cell apoptosis, but this does not mean a 
redundancy. These galectins are differently distributed and induce different death 
signals to remove self-active T cells. Galectin-1 and galectin-3 are highly expressed 
in thymus and lymph nodes (Stillman, Hsu et al. 2006). T cells maturate in the 
thymus. Early T cells (known as thymocytes) express neither CD4 nor CD8, so they 
are CD4-CD8- and are called double negative cells. Then both CD4 and CD8 are 
expressed. These CD4+CD8+ cells are called double positive cells. Finally 
thymocytes differentiate into CD4+ or CD8+ T cells, which are called single positive 
cells. Galectin-1 equally kills double-negative and double-positive human 
thymocytes, whereas galectin-3 preferentially induces apoptosis of double-negative 
thymocytes (Stillman, Hsu et al. 2006). In spite of the fact that both galectin-1 and 
galectin-3 bind to CD45, this ligand formed clusters upon galectin-1 binding but 
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remained uniformly distributed on the cell surface upon galectin-3 binding (Stillman, 
Hsu et al. 2006), indicating the two lectins kill T cells in different pathways. 
Galectin-2 is primarily expressed in the gastrointestinal tract (Sturm, Lensch et al. 
2004), where it binds glycans on CD29 and induces apoptosis in activated T cells 
(Sturm, Lensch et al. 2004). Galectin-4 is also expressed in the gastrointestinal tract. 
However, galectin-4 is different from galectin-2 in that it binds CD3 on activated 
T-cells. In addition, galectin-4 induced apoptosis via calpain-dependent pathways, 
while galectin-2 induced apoptosis via caspase-dependent pathways (Sturm, 
Lensch et al. 2004, Paclik, Danese et al. 2008). Finally, galectin-9 can bind the 
glycans on TIM3 and specifically induce the apoptosis of TH 1 cells (Zhu, Anderson 
et al. 2005).  
 
The functions of galectins on B cells are not as well studied as T cells. The binding 
of galectin-1 to CD45 expressed by Burkitt lymphoma B cells can induce cell death 
(Fouillit, Joubert-Caron et al. 2000). A recent study found galectin-3 is over 
expressed by diffuse large B-cell lymphoma cells (Clark, Pang et al. 2012). These 
cells secrete galectin-3 which then binds to the O-glycans on CD45 on the cell 
surface. However, when galectin-3 is removed from CD45 using the polyvalent 
glycan inhibitor GCS-100, the cells are sensitized to apoptosis and become 
susceptible to chemotherapeutic agents. Probably the outcome of galectin binding 
is determined by many factors such as cell types, type of galectins, the 
glycosylation of cell receptors, the cytoplasmic motif of the receptors, and other 
possible glycoproteins not yet identified (Perillo, Marcus et al. 1998). Studies have 
found galectin-1 is involved in early B cell development, but the process is glycan 
independent (Gauthier, Rossi et al. 2002). 
 
Galectins are closely involved in neutrophil migration and activation. Besides the 
roles of selectins in leukocyte migration to inflammatory sites described in Section 
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1.4.1, studies have shown galectins are involved in this process. Laminin is the 
most abundant glycoprotein in basement membranes. An early study found 
galectin-3 induces adhesion of human neutrophils to laminin (Kuwabara and Liu 
1996), which could affects neutrophils migration to target sites. Following studies in 
mouse models obtained consistent data, as galectin-3 null mutant mice exhibit a 
significantly reduced granulocytes recruitment compared to wild type mice (Colnot, 
Ripoche et al. 1998). In a Streptococcal pneumonia mouse model, the expression 
of galectin-3 in the alveolar space of streptococcus-infected lungs coincides well 
with the onset of neutrophil extravasation (Sato, Ouellet et al. 2002). Now, other 
galectins have been discovered to regulate the migration of neutrophils as well as 
other types of leukocytes in inflammation (Cooper, Iqbal et al. 2012). After 
neutrophils arrive at infected sites, they ingest pathogens and kill them using 
reactive oxygen species produced by NADPH-oxidase. Galectin-3 can activate 
NADPH-oxidase in exudated neutrophils and stimulate the production of 
superoxide (Yamaoka, Kuwabara et al. 1995, Karlsson, Dahlgren et al. 1998). The 
NADPH-oxidase in peripheral blood neutrophils does not react to galectin-3 binding. 
This may be a mechanism which assures that neutrophils are activated at the right 
location such as inflammatory or infected sites. Galectin-1 can also induce 
NADPH-oxidase, given that neutrophils have extravasated from blood to sites of 
infection (Almkvist, Dahlgren et al. 2002). However, the results suggest the 
receptors bound by galectin-1 are different from those bound by galectin-3.         
1.4.4 Glycosylation and antibody activities 
All antibodies are glycosylated. The diversity of glycans attached to the constant 
regions of antibodies makes these conserved regions heterogeneous. The glycans 
serve as important regulators for antibody activities. IgG has a single 
N-glycosylation site at Asn297 of the Fc region. It has long been known that patients 
with rheumatoid arthritis express higher levels of GlcNAc terminated N-glycans on 
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IgG (Parekh, Dwek et al. 1985). Another study soon observed reduced B-cell 
galactosyltransferase activity in this disease (Axford, Mackenzie et al. 1987). A 
follow up analysis found IgG fucosylation increased in the disease (Gornik, Maravic 
et al. 1999). The effector functions of IgG are largely dependent on its glycosylation. 
IgG Fc receptors cannot bind deglycosylated IgG (Anthony, Wermeling et al. 2012). 
In addition, sialic acid, core Fuc and bisecting GlcNAc on IgG glycans dictate the 
binding of IgG to its Fc receptors (Scallon, Tam et al. 2007, Anthony, Nimmerjahn et 
al. 2008). Sialylation or core-fucosylation of IgG glycans can decrease the Fc 
affinity for its receptors and significantly reduce antibody-dependent cell-mediated 
cytotoxicity (ADCC), while bisecting GlcNAc can enhance the affinity.  
 
Glycosylation also regulates activities of other classes of antibodies. For example, 
sialylation of serum IgA results in a longer half-life of this antibody (Basset, 
Devauchelle et al. 1999). For secretory IgA, the N-glycans on the secretary 
component (SC) and O-glycans on the constant region display a wide range of 
glycan epitopes, which provide binding sites for bacterial adhesins and inhibit the 
attachment of bacteria to epithelial surfaces (Royle, Roos et al. 2003). The glycans 
on serum IgA are normally fully processed, but the glycans on secretory IgA heavy 
chain are surprisingly truncated. Studies have found 52% of the N-glyans contain 
terminal GlcNAc and 12% are high mannose structures (Royle, Roos et al. 2003). 
Serum IgA is secreted by plasma cells in the spleen or lymph, whereas secretory 
IgA is found in tears, milk and mucus and is produced by plasma cells local to the 
sites of secretion. It is likely that the two groups of plasma cells have a different 
glycosylation machinery, so that different glycan profiles are observed in the heavy 
chain of the two types of IgA. The terminal GlcNAc and high mannose glycans are 
masked by the fully processed glycans on SC and cannot be bound by mannose 
binding lectins. It is proposed that the binding of pathogens to glycans on the SC 
could change the structure of IgA, so that the truncated glycans are exposed to 
74 
 
mannose binding lectins, which promote pathogen internalization and antigen 
presentation. Complex glycans on IgM provide binding sites for pathogens. For 
example the sialic acid residues on IgM are bound by viral hemagglutinin, which 
could help the agglutination of viral particles (Arnold, Wormald et al. 2007). The 
functions of high mannose glycans on IgM are not well studied. However, a recent 
study on membrane IgM showed that a higher proportion of high mannose glycans 
in the chronic lymphocytic leukemia correlates with relatively poor prognosis and 
enhanced BCR signaling (Krysov, Potter et al. 2010). Glycans on IgD are important 
for the assembly and secretion of IgD (Gala and Morrison 2002). IgE is the most 
heavily glycosylated antibody with as many as 7 potential N-glycosylation sites at 
the constant region. However IgE glycosylation is not well understood, mainly due 
to the extremely low abundance of IgE in the serum.  
1.5 Challenges in studying glycosylation 
The study of protein glycosylation developed slowly owing to its complexity. A single 
protein can be modified heterogeneously by glycans. On the one hand, there could 
be different glycans on each glycosylation site (micro-heterogeneity), for example 
human erythrocyte CD59 contains more than 100 different oligosaccharides on a 
single glycosylation site (Rudd, Morgan et al. 1998). On the other hand, the 
glycosylation sites of a protein may not be fully occupied, generating various 
combinations of site occupation (macro-heterogeneity). In addition, it is difficult to 
determine the structures of glycans. Unlike DNA and proteins, which only have 
linear sequence, glycans usually have branches. Moreover, as explained in Section 
1.1, glycosidic bonds linking two monosaccharides exist in multiple ways, as a 
monosaccharide has more than one hydroxyl group to form a glycosidic bond plus 
the glycosidic bond can have either α- or β-stereochemistry.   
 
Despite the availability of sensitive methods such as Real-time PCR and Western 
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blotting, which are able to analyze glyco-synthetic genes and their products, the 
glycosylation information that can be derived from this type of experiment is quite 
limited. First, there is no template for glycan synthesis. Despite the fact that genes 
can encode glycosyltransferases and glycosidases responsible for adding and 
removing monosaccharides during glycosylation, competition among these 
enzymes and their intracellular locations have great impacts on glycan synthesis. 
Moreover, glycosylation is regulated by the supply of sugar donors (Greig, 
Antonchuk et al. 2007), which are present in the cytoplasm and are required to be 
transported into the ER and the Golgi complex. Finally, the heterogeneity of glycans 
is affected by metabolism dynamics (Dennis, Nabi et al. 2009). The study of 
glycosylation depends on the continuing development of new technologies which 
are able to challenge these difficulties.  
1.6 Mass spectrometry 
Mass spectrometry (MS) is a state-of-the-art technology which is ideally suited to 
investigating glycosylation, owing to its ultra-high sensitivity and resolution, as well 
as its ability to analyze individual molecules in complex, heterogeneous mixtures. 
A mass spectrometer consists of three basic components: an ion source, a mass 
analyzer, and a detector. Mass spectrometers analyze gas phase ions, so 
molecules must be charged in the ion source before analysis. Mass analyzers use 
electromagnetic forces to manoeuvre the flight patterns of ions produced. As an ion 
with a specific m/z value flies in a unique way in a given electric or/and magnetic 
field, mass analyzers can separate an ionized molecule from others, and determine 
its mass-to-charge ratio (m/z) by analyzing the flight pattern of the ion. The signals 
of the ions are detected by the detector.  
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1.6.1 EI or CI coupled to magnetic sectors  
Early mass spectrometers were primarily equipped with an electron impact (EI) or 
chemical ionization (CI) ion source and a magnetic sector mass analyzer. EI 
ionization is a process of ionizing volatilized molecules with a beam of electrons 
from a hot wire filament, while CI ionizes molecules through ion-molecule reactions. 
EI or CI instrumentation could provide high quality data when it was used to study 
small chemicals. Common bio-organic compounds such as peptides and glycans 
were too large to be ionized, which vastly reduced the use of early mass 
spectrometry in biological sciences. However, derivatisation methods were 
developed to make peptides or glycans volatile for ionization. The first derivatisation 
method was outlined by Klaus Biemann in 1959, who reduced a tripeptide to amino 
alcohols and found the fragmentation during the ionization process provided 
valuable information about the peptide sequence. One breakthrough of peptide 
derivatisation was seen in 1972. Morris derivatized peptides in a short methylation 
step, and for the first time, developed a global strategy to sequence any 
protein-derived peptides by mass spectrometry (Morris 1972). After that, the 
strategy was used to sequence a number of biologically important proteins such as 
ribitol dehydrogenase (Morris, Williams et al. 1974), dihydrofolate reductase (Morris, 
Batley et al. 1974, Batley and Morris 1977) and chloramphenicol transacetylase 
(Shaw, Packman et al. 1979). Moreover, post-translational modifications were 
detected using this strategy. When the blood coagulation zymogen prothrombin 
was studied, γ-carboxylation of 10 glutamyl residues were detected in the 
N-terminal domain (Morris, Thompson et al. 1975), which are required for the 
calcium-dependent interaction with phospholipid. Foremost among the power of the 
MS strategy developed by Howard Morris was the ability to investigate protein 
glycosylation, which is the most complicated post-translational modification. A 
particular example was the study of anti-freeze 8 (AF8), which belongs to a group of 
77 
 
antarctic fish blood proteins with potential anti-freeze properties. AF8 had been 
known to be a glycoprotein, but the amino acid sequence, the glycan structures and 
glycosylation sites were unknown. Using EI-MS and CI-MS, the amino acid 
sequence and glycosylation of AF8 was determined (Morris, Thompson et al. 1978). 
It mainly consists of a mixture of three types of amino acid sequences and each Thr 
residue contains an O-linked disaccharide in the form of Gal1-3GalNAc. Despite 
these exciting progresses, the experiments require considerable expertise, and 
therefore were practiced almost exclusively in the lab of Morris.   
1.6.2 FD or FAB coupled to magnetic sectors 
Field desorption (FD) ionization was developed in the late 1950s (Beckey and 
Schulten 1975). It enabled the ionization of bio-organic molecules without 
vaporization. In a FD experiment, the sample solution was applied as a thin film 
onto the sharp tips of carbon “whiskers” coating a metal wire (FD emitter) and a 
high potential field was then applied between the wire and a counter-electrode a 
few millimeters away. A heating current was then passed through the wire. Once 
sample molecules were sufficiently mobile the electric force ejected them as ions 
for mass spectrometry analysis. In 1970s, the group of Morris combined FD and 
high field magnets. Remarkably, this instrument was able to analyze large 
molecules above 3000 amu, while the mass range of the typical double focusing 
magnet mass spectrometers at that time was below 1000 amu. In early 1980s, FD 
with high field magnets was used to study underivatized oligosaccharides with up to 
14 hexose units (Linscheid, Dangona et al. 1981). However, FD-MS was 
demanding and difficult to use by general laboratories.  
 
In the early 1980s, Barber and coworkers invented fast atom bombardment (FAB) 
(Barber, Bordoli et al. 1981), which made it possible to routinely determine the 
structure of large molecules, because the new ion source did not require the 
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technical expertise like those in EI, CI and FD-MS. FAB ionizes molecules using a 
beam of highly energetic atoms or ions to hit the surface of a viscous liquid matrix in 
which the sample was dissolved. This ion source coupled to high field magnets was 
extensively used for more than twenty years to characterize novel glyans from a 
wide range of samples. During this time robust approaches to characterizing 
glycans were made, such as experimental strategies, data analysis and the 
discovery of fragmentation patterns of glycans (Dell, Reason et al. 1994, Dell and 
Morris 2001). FAB was eventually superseded by the more powerful ionization 
technologies which are described in the following sections. However the sample 
and data handling methodologies devised for FAB mass spectrometry continue to 
be exploited with these newer ionization methods. 
1.6.3 Triple quadrupole  
When FAB mass spectrometers were being used in biological fields, high sensitivity 
was increasingly needed due to the limited availability of biologically important 
samples. Although magnetic sector specialists like Morris started building highly 
sensitive instruments in the 1980s and finally developed mass spectrometers which 
moved the sensitivity from picomole to femtomole level (Khoo, Sarda et al. 1995, 
Haslam, Coles et al. 1996), these instruments were expensive and had a very small 
market. A mass spectrometer with low cost and high sensitivity which was capable 
of analyzing relatively high molecular weight samples was needed. The seminal 
work which partially (see Section 1.6.4) satisfied the need was seen in early 1990s. 
Hunt used an electrospray ionization (ESI)-triple quadrupole mass spectrometer to 
achieve a sensitivity of subpicomole level, and successfully characterized MHC 
bound peptides (Hunt, Henderson et al. 1992, Hunt, Michel et al. 1992).  
 
The quadrupoles are the mass analyzers of the instrument Hunt used. The 
development of quadrupole mass analyzer was first reported in the 1950s by 
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Wolfgang Paul. A quadrupole (Q) mass analyzer has four parallel rods (Figure 1.19). 
One pair of diagonally opposite rods is positively charged and the other pair is 
negatively charged. A radio-frequency (RF) voltage and a direct voltage are applied 
to each pair of rods, which produces different electric fields. A specific electric field 
only allows an ion with a specific m/z to pass through the analyzer to be detected. 
Ions with other m/z values will not pass through the mass analyzer and cannot be 
detected. Therefore, the quadrupole mass analyzer can be used to separate an ion 
of interest from others. In order to determine the m/z of an ion, a quadrupole mass 
analyzer scans successively from low to high m/z values. When an ion signal is 
detected, the m/z value of the ion can be calculated based on the given electric 
field.  
 
 
Figure 1.19 The mechanism of the Quadrupole (Q) mass analyzer  
A mixture of two molecular ions with different m/z values are produced by an ion 
source. The two ions are introduced to a quadrupole mass analyzer. A specific 
electric field is generated by charging the four rods, which only allows A to pass 
through the analyzer to be detected. B is trapped by the analyzer.  
 
Although quadrupole instrumentation were developed as early as the 1950s, the 
magnetic sectors dominated mass spectrometers for the next three decades. One 
of the reasons is that quadrupoles have a lower mass range than magnetic 
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analyzers. The situation changed when the ESI technique was developed, which is 
able to produce ions with multiple charges. Higher charges of a molecular ion 
results in reduced m/z value. Therefore, ESI allows for the detection by the 
quadrupole of large molecules at a low m/z range.  
 
 
Figure 1.20 The mechanism of ESI 
A high voltage is applied to a spray needle and forces the sample solution from the 
LC system to emerge from the tip to form a Taylor cone. Charged drops then leave 
the tip. The drops explode into droplets due to an increase in electrostatic repulsion 
during an evaporation process under drying gas. As the drying and exploding 
continue, naked ions with multiple charges are produced, which are introduced to 
the mass analyzer.      
 
The ESI ion source was developed by Yamashita and Fenn (Yamashita and Fenn 
1984) and is widely used in modern mass spectrometers. The mechanism of ESI is 
shown in Figure 1.20. A high voltage is applied to a thin needle and charges the 
sample solution inside the needle. The solution emerges from the needle to form a 
Taylor Cone. Electrostatic repulsive forces drive the charges to the surface of the 
Taylor Cone. When the electrostatic repulsion exceeds the liquid surface tension, 
the charged sample droplets leave the needle and move towards a mass analyzer 
driven by an opposite voltage. Before reaching the entrance of the mass analyzer, 
the droplets evaporate under a drying gas. As the volume of a droplet decreases, 
the charge density increases and the electrostatic repulsion again exceeds the 
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surface tension, which causes explosion of the droplet, resulting in smaller droplets. 
As this process continues, molecular ions are finally generated. The ESI ion source 
is commonly connected to a LC system, which separates complex samples into 
different fractions for ionization. As fractionation and ionization occurs 
simultaneously, this method is called online LC-MS. 
 
In the ESI-triple quadrupole mass spectrometer, the first quadrupole works as an 
ion filter, which allows a selected ion to pass, the second quadrupole does not serve 
as a mass analyzer but as a collision cell which breaks the selected ion into 
fragments, and the third quadrupole scans to determine the m/z values of the 
fragments. As a result, the ESI-triple quadrupole is also known as ESI-QqQ. The q 
in the middle is in lower case to show it is a collision cell. The coupling of two mass 
analyzers in tandem to sequence biopolymers like that in ESI-triple quadrupole is 
referred to as MS/MS, which is explained in Figure 1.21. MS/MS is widely used by 
modern mass spectrometers to determine the sequences of biopolymers. Figure 
1.22 is schematic representation showing how MS/MS is used to sequence two 
oligomers. Oligomer 1 and oligomer 2 consist of three residues, A, B and C. A is the 
largest residue, whereas C is the smallest. The sequence of oligomer 1 is ABC, 
while the sequence of the other is BAC. They have the same molecular weight but 
generate different sets of fragments during MS/MS analysis. For oligomer 1, 
fragment A and fragment AB are generated, while for oligomer 2, fragment B and 
BA are generated. The sequence can be deduced by calculating the mass 
differences between two adjacent peaks. It is noteworthy to mention that this 
fragment based sequencing had been used in EI, CI, FD and FAB mass 
spectrometers. The difference is that the ionization processes of these early 
instruments were not as soft as ESI and MALDI, so that ions were broken during the 
ionization process (in-source fragmentation). 
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Figure 1.21 The mechanism of MS/MS  
Two mass analyzers are connected through a fragmentation cell. The ion of interest 
(the red ion in the figure) is isolated by the first mass analyzer, and is then 
fragmented in the fragmentation cell. The fragments are introduced to the second 
mass analyzer which measures the mass of each fragment.  
 
 
Figure 1.22 A schematic representation showing how MS/MS sequences and 
differentiates oligomers 
Oligomer 1 (ABC) and oligomer 2 (BAC) are introduced to MS/MS analysis. The 
breakages of linkages between residues produce fragment A and fragment AB for 
oligomer 1, but produce fragment B and fragment BA for oligomer 2. The sequence 
information can be obtained from the fragments and intact molecular ions. More 
importantly, exclusive fragments can be detected (fragment A for oligomer 1 and 
fragment B for oligomer 2) which can be used to differentiate the two polymers with 
the same molecular weight.  
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1.6.4 Q-TOF  
In spite of the desirable sensitivity of triple quadrupole, the resolution of this 
instrumentation was low. This problem became more severe when samples at 
sub-100-femtomole range were analyzed (Morris, Paxton et al. 1997). In order to 
maintain sensitivity on small amount of samples, the third quadrupole was set to 
maximize ion transmission, which sacrificed the resolving power and caused 
ambiguity in data interpretation. This problem was solved in the mid 1990’s by 
Morris (Morris, Paxton et al. 1997), who invented a novel geometry quadrupole 
orthogonal acceleration time-of-flight (Q-TOF) mass spectrometer, which is capable 
of sequencing biopolymers at low femtomole/attomole range with high resolution. 
This instrument is sometimes referred to as ESI-QqTOF, because it is most 
commonly fitted with an ESI ion source, and incorporates a quadrupole (Q) for ion 
selection, a collision cell (q) for ion fragmentation, and a TOF mass analyzer. Unlike 
the quadruple's scanning technique, TOF lets all ions strike the detecter so that 
stronger signals can be detected.  
 
During TOF analysis, all ions are accelerated into a field free flight tube. The m/z of 
an ion is measured according to the time it takes to reach a detector; the higher the 
m/z is, the longer the ion will take to be detected. The concept of TOF was 
proposed in 1940s and TOF analyzers were constructed in the 1950s. However, in 
the following three decades, magnetic sectors were preferentially chosen to 
assemble mass spectrometers, because the resolution of early TOF analyzers was 
very poor. In 1974, Boris A. Mamyrin invented the reflectron to push ions backwards 
to a detector. This process corrects the distribution of kinetic energy of ions and 
greatly improved the TOF resolution. However TOF analyzers took a long time to be 
accepted because their resolution and accuracy remained poor compared to other 
analysers. Their power was first fully realised in the Q-TOF instrument. This was 
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because the orthogonal installation of the TOF analyzer to the Q-TOF mass 
spectrometer guaranteed high resolution. The ions with the same m/z value ejected 
from the collision cell exhibit a wide distribution of space and velocities in the 
horizontal direction, but have a small space and velocity distribution in the vertical 
direction. As result, accelerating ions towards the TOF perpendicular to the 
quadrupole minimizes the affect of ion spread. The Q-TOF is one of the major 
modern mass spectrometers that has been extensively used to solve proteomic and 
glycoproteomic problems.    
 
The glycoproteomic data in the result section of this thesis were acquired using a 
Q-TOF mass spectrometer known as the API QSTARTM Pulsar Hybrid LC/MS/MS 
system (Figure 1.23). This instrument is based on the original Q-TOF geometry with 
several improvements. It has improved ion transmission and ion optics. In addition, 
it is equipped with a novel linear accelerating high pressure collision cell (LINAC) 
which is able to raise the pressure of the collision cell so that ion fragmentation and 
collection can be processed with high efficiency. Moreover, the ESI ion source is 
linked to a nano-LC system. Nano-electrospray ionization (nanoESI) ionizes 
samples in a smaller spay needle and at a lower flow rate than conventional ESI. It 
has a flow rate of nanoliters per minute and starts with droplets with about 0.15 mm 
in diameter, while conventional ESI has a flow rate of microliters per minute and the 
starting droplets have a diameter of about 1.5 mm (Karas, Bahr et al. 2000). 
NanoESI is able to analyze low concentrations of samples from a few microliters of 
solution (10–5-10–8 M) (Karas, Bahr et al. 2000). This is an essential advantage for 
the investigation of biological sample, because in many cases, only low volumes 
and amounts of biological samples are available. When the API QSTARTM Pulsar 
Hybrid LC/MS/MS system runs in the MS mode, the quadrupole and the collision 
cell work as an ion guide, which only introduces the intact ions from the ion source 
to the TOF analyzer for determination. In the MS/MS mode, the quadrupole serves 
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an ion filter and the collision is turned on, so a selected ion goes into the collision 
cell and gets fragmentated. The m/z values of the fragments are finally determined 
by the TOF analyzer.     
 
 
Figure 1.23 Schematic illustration of API QSTARTM Pulsar Hybrid LC/MS/MS 
system     
Ions from nanoESI are introduced to the quadrupole, which selects the ion of 
interest to be fragmented in the hexapole collision cell. The fragments are 
orthogonally pushed to the TOF mass analyzer. The reflectron at the end of flight 
tube pushes ions back to a detector and allows slower ions to catch up with faster 
ions of the same m/z value thus improving resolution.  
1.6.5 MALDI-TOF  
The matrix-assisted laser desorption/ionization (MALDI)-TOF mass spectrometer is 
another dominant type of instrument nowadays. It is equipped with a MALDI ion 
source, which was independently developed in the 1980s by Hillenkamp (Karas, 
Bachmann et al. 1985, Karas and Hillenkamp 1988) and Tanaka (Tanaka, Waki et al. 
1988). Tanaka and Fenn (the inventor of ESI mentioned in Section 1.63) won the 
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2002 Nobel Prize in chemistry "for their development of soft desorption ionisation 
methods for mass spectrometric analyses of biological macromolecules".  
 
Figure 1.24 displays a schematic representation of MALDI. Samples are dissolved 
and mixed with a large excess of low molecular weight matrix, which is able to 
absorb laser energy. The mixture is then spotted onto a MALDI plate. During the 
drying process, sample molecules are co-crystallized with the matrix. When a laser 
beam is shot at the sample-matrix crystals, a large amount of excitation energy from 
the laser is accumulated in the matrix, which leads to desorption of matrix and 
sample ions which are mostly singly charged. The details of the ionization process 
are not fully understood. Several studies suggest that ions could be formed by 
proton transfer and chemical processes between excited matrix and the sample 
(Zenobi and Knochenmuss 1998, Knochenmuss 2006). It is important to note that 
modern MALDI-TOF instruments do not accelerate ions from the plate to the TOF 
immediately after the pulse of laser desorption/ionization. A short time delay 
following ionization can compensate for ion energy spread and produce data with 
higher mass resolution (Karas 1997). This delayed extraction technique together 
with the reflectron discussed in Section 1.64 greatly improve the resolution of 
MALDI-TOF mass spectrometers.  
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Figure 1.24 A schematic representation of MALDI 
Irradiation of the crystals leads to absorption of laser energy by matrix, which when 
results in ionization of sample and matrix.  
 
MALDI-TOF instruments are easy to operate and do not require as strict sample 
preparation and separation. In addition, they are more salt tolerant, and are able to 
analyze complex mixtures. Therefore, MALDI-TOF is a quick and easy way to 
obtain a m/z profile of a given sample. The glycan profiles in the results section of 
this thesis were acquired using a MALDI-TOF instrument known as the 
Voyager-DETM STR system (Figure 1.25). The insertion of a time ion selector (TIS) 
and a collision cell in the flight path enables MS/MS analysis. The MS/MS analysis 
of glycans in this thesis was done using a 4800 MALDI TOF/TOFTM analyzer 
(Figure 1.26). In the MS/MS mode, the TIS is set open at a specific time, and 
therefore, allows an ion with a selected m/z value to go to the collision cell, where 
the ion is fragmented. After that, the fragments are accelerated again to the TOF 
mass analyzer for determination.  
 
MALDI-TOF mass spectrometers usually have a detector at the end of the flight 
tube as shown in Figure 1.25 and Figure 1.26. When the instrument runs in the 
reflectron mode, ions cannot hit this detector as the reflectron is turned on. However, 
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this detector starts collecting data when the instrument runs in the linear mode, as 
the reflectron is turned off. The linear mode is used to study intact proteins, as the 
reflectron mode losses efficiency for large molecules. The linear mode is often also 
used to analyse sialylated glycopeptides as sialic acid linkages may not survive in 
the reflectron mode. 
 
 
Figure 1.25 A schematic illustration of the Voyager-DETM STR 
A beam of laser shoots the sample-matrix crystals and ionizes the sample. The ions 
are pushed to the flight tube. The reflectron at the end of the tube pushes the ions 
backwards to a detector, which records the time of flight of each ion. The computer 
finally converts the time into m/z. 
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Figure 1.26 A schematic illustration of 4800 MALDI TOF/TOFTM analyser in MS/MS 
mode 
Ions produced in the ion source are pushed upwards. A collision cell is installed in 
the flight path. A time ion selector (TIS) at the bottom of the collision cell chooses an 
ion of interest to be fragmented. The fragments are accelerated towards a reflectron, 
which pushes the fragment ions downwards to a detector.  
1.6.6 Towards higher accuracy and resolution 
Accuracy and resolution are two important performance characteristics of a mass 
spectrometer. Accuracy shows how accurately an instrument can provide an m/z 
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value. Part per million (ppm) is a common terminology used to describe accuracy. 
For example, a mass spectrometer with an accuracy of 10 ppm means it can 
provide information on a 1000 Da molecule with an error of just 0.01 Da. Resolution 
shows the resolving power of a mass spectrometer to distinguish between ions of 
different m/z values. A mass spectrometer with high resolution is able to distinguish 
two ion peaks with a very small m/z difference. By contrast, the two peaks will 
merge together and lead to ambiguity if an instrument with low resolution is used. 
M/ΔM is most commonly used to define resolution. In this definition, M is the m/z 
value of a peak, while ΔM is the full width at half maximum (FWHM) of this peak. 
The MALDI-TOF and Q-TOF mass spectrometers described above usually have an 
accuracy of 10 ppm and a resolution up to 15 000, which is able to solve numerous 
problems involved in the study of peptides, glycans and glycopeptides.  
 
However, mass spectrometers with ultra-high accuracy and resolution can reduce 
ambiguities during data analysis. More importantly, recent mass spectrometry 
studies on proteins are almost invariably using a bottom-up strategy, which involves 
digesting proteins into smaller peptides before analysis. Proteins are identified and 
quantified according to the peptide sequences and quantities. Although this 
peptide-centred strategy has played important roles in protein investigation and 
systems biology (Cox and Mann 2011), it does have drawbacks. Identified peptides 
can cover a small portion of a whole protein sequence. As a result, the bottom-up 
strategy has a protein interface problem particularly in higher eukaryotic organisms 
(Nesvizhskii and Aebersold 2005), which means different proteins or protein 
isoforms can share one or more peptide sequences and lead to difficulties in 
unambiguous protein characterization. In the case of post translational 
modifications (PTM), although the bottom-up strategy can identify a PTM on an 
isolated peptide, it is difficult to confirm PTM combinations on a whole protein.  
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Contrary to the bottom-up strategy, the top-down strategy starts by analysing an 
intact protein and then fragments the protein for further investigation (Ahlf, Thomas 
et al. 2013). This strategy has the potential to distinguish protein isomers and to 
determine PTM combinations. Defining an intact protein requires data with 
ultra-high accuracy and resolution, which can be achieved using a FT-ICR mass 
spectrometer (Bogdanov and Smith 2005). This mass spectrometer is equipped 
with a type of mass analyzer known as ion trap, which traps ions in a confined 
space. The FT-ICR ion trap confines ions by oscillating electric fields perpendicular 
to a static magnetic field, which cause ions to move in spiral patterns. The m/z 
values are determined according to ion cyclotron frequencies, which are 
Fourier-transformed into mass spectra. However, this instrument is expensive and 
difficult to maintain, which restricts its laboratory use. Recently, novel improvements 
have been made to improve the Q-TOF design to build higher performance mass 
spectrometers. For example, the Bruker maXis UHR qTOF MS has a resolution up 
to 50 000 and an accuracy around 1 ppm. This instrument has shown its merit for 
the top-down analysis of 30-80 kDa proteins (Fornelli, Parra et al. 2013). Similar 
resolution and accuracy have also been achieved by AB SCIEX TripleTOF 5600 
system and Waters SYNAPT G2, which can potentially be used for top-down 
analysis.  
 
The development of orbitrap mass spectrometers by Thermo marks a breakthrough 
in top-down study (Perry, Cooks et al. 2008). The orbitrap mass analyzer was first 
reported by Alexander Makarov (Makarov 2000). It consists of a spindle-like central 
electrode and a barrel-like outer electrode, which is able to generate an 
electrostatic potential to trap ions. In commercial instruments, ions are injected into 
the orbitrap by a C-trap, which ensures ion packets with small spatial and temporal 
distributions. Ions in the orbitrap undergo both rotational motion round the central 
electrode and harmonic axial motion along the axis of the electrode. The frequency 
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of axial oscillation of an ion is proportional to (m/z)-1/2. A detector records the 
frequency in the form of an image current, which is Fourier-transformed into a mass 
spectrum. This type of measurement is much cheaper than FT-ICR but can drive 
resolution above 100 000 and accuracy below 1ppm. The orbitrap has shown its 
power in top-down analysis of a glycosylated monoclonal antibody, which has a 
molecular weight up to around 150 kDa (Fornelli, Damoc et al. 2012).  
 
Ion traps can not only determine m/z values of ions, but also select and store an ion 
of interest to enable MSn analysis. The MS/MS analysis is also referred to as MS2 
analysis, which selects an precursor ion, breaks it into fragments, and determines 
the m/z ratios of the fragments. Following this route, in MS3 analysis, a fragment 
from a precursor is selected for another round of breakage to give further structural 
details. More structural information can be obtained when this process goes on to 
MS4 , MS5, and even higher. MSn analysis is especially important for the elucidation 
of glycan structures, which have branches and variable linkages. The best way to 
reach MSn is not to build a large and expensive instrument with a number of mass 
analyzers, but to use an ion trap. An ion of interest can be selected and fragmented 
in the ion trap. Then, in the same trap, a fragment of interest can be selected for 
further fragmentation. This process can theoretically repeat as many times as 
needed before the final fragments are introduced to the next mass analyzer for m/z 
determination. 3-D quadrupole ion trap (QIT) and 2-D linear trap quadrupole (LTQ) 
are two common ion traps used for MSn analysis. Both of them trap ions by constant 
and oscillating electric fields, but LTQ has advantages in higher ion storage capacity, 
reduced space-charge effect, and faster scan times. 
1.7 Glycomics 
By analogy to proteomics, glycomics is the investigation of the total set of glycans 
(glycome) in a given sample. It was not until the development of modern mass 
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spectrometry that glycomic analysis became possible. Similar to proteomics which 
needs reduction and carboxymethylation of proteins to facilitate protein 
identification, glycomics also requires modification of natural glycans. 
Permethylation has been proved to be a key derivatization of glycans before mass 
spectromic investigation. Studies have shown that permethylation can stabilize 
glycans, increase ionization efficiency, and facilitate structural and quantitative 
analysis (Dell 1987, Dell, Reason et al. 1994, Wada, Azadi et al. 2007). After 
permethylation, glycans are usually detected in the form of [M+Na]+ ions in 
MALDI-MS. 
 
A glycomic investigation has two major goals: structural analysis and quantitative 
analysis. 
1.7.1 Structural analysis     
1.7.1.1 Deduction of putative structures 
In order to define the structure of each glycan in a sample, m/z values of glycans 
are first measured by MS analysis. As the masses of monosaccharides are known, 
possible monosaccharide compositions of a glycan can be calculated. High mass 
accuracy can result in fewer possible monosaccharide compositions, which 
facilitates putative structure deduction. For example, if a permethylated human 
N-glycan with an m/z value of 2605.299 is analyzed. When accuracy is 0.500 Da, 
which can be easily achieved by most mass spectrometers, there are 3 possible 
monosaccharide compositions (Figure 1.27). If the accuracy reaches to 0.001 Da, 
which can be achieved by FT-ICR and orbitrap mass spectrometers, there is only 1 
possible monosaccharide composition (Hex5HexNAc4NeuAc1dHex1). However, 
high accuracy is not required in most cases to deduce putative structures if the 
glycan biosynthetic pathway is known. For the 3 possible monosaccharide 
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compositions shown in Figure 1.27, when the human N-glycosylation pathway is 
taken into consideration, only the second composition is possible, which is the 
same as the composition calculated based on an accuracy of 0.001 Da. There are 
three putative sequences for this composition, excluding linkage isomers. The three 
glycans are structural isomers with the same molecular weight. The only difference 
is the location of the Fuc residue. The mixture of the three isomers will form a single 
peak in MS analysis, but they can be differentiated by MS/MS analysis.  
    
 
Figure 1.27 The power of good mass accuracy in determining the structures of 
glycans 
If a human N-glycan has a m/z of 2605 after permethylation, mass spectrometry is 
able to limit the measuring error to 0.5 Da and only 3 possible monosaccharide 
compositions can be found. When human N-glycan biosynthesis pathway is taken 
into consideration, only one monosaccharide composition is possible which has 
three putative structures excluding linkage isomers.    
1.7.1.2 Differentiation of structural isomers by MS/MS 
MS/MS is able to determine the structure of a glycan by breaking it into fragments 
and then measuring the m/z value of each fragment. The basis of MS/MS analysis 
is that different glycan structures will produce different sets of fragments. The m/z 
values of these fragments constitute fingerprints of specific glycan structures. The 
nomenclature for oligosaccharide fragments is shown in Figure 1.28 (Domon and 
Costello 1988). Fragments that contain the non-reducing ends are designated as A, 
B and C ions, while those that contain the reducing end are named X, Y and Z ions. 
95 
 
The A and X ions are produced by cross-ring cleavage and are labeled by 
numbering each ring bond. Studies have found that the most common cleavages 
occur at the reducing end of sialic acid and HexNAc residues (Dell, Reason et al. 
1994).  
 
 
Figure 1.28 Nomenclature for glycan fragments of a native tri-saccharide 
Permethylated glycans are designated in the same way. Fragments containing the 
non-reducing ends are designated as A, B and C ions. Fragment with the reducing 
ends are named X, Y and Z ions. The A and X ions are produced by cross-ring 
cleavage and are labeled by numbering each ring bond. 
 
Although glyan sequence isomers have the same molecular weight, they will 
generate different fragment patterns in MS/MS analysis. Figure 1.29 shows the 
fragmentation of the three putative glycans mentioned in Figure 1.27. Common 
cleavages are annotated for each isomer. Each of the three glycans has exclusive 
fragments; the first isomer has specific fragments at m/z 1021 and 1607, the 
second isomer has m/z 660 and 1968, while the third isomer has m/z 474 and 2154. 
Detection of specific fragments can be used to prove the presence of a glycan 
isomer. 
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Figure 1.29 Isomers can be differentiated by MS/MS analysis 
Common B and Y ions are annotated for three glycan isomers. The m/z of the 
exclusive ions for each permethylated isomer are highlighted in red.  
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1.7.2 Quantitative analysis 
Quantitative determination of changes of glycosylation is essential for comparing 
glycomes from different samples. Two main strategies are available for quantitative 
analysis: label free approaches and stable isotope labelling approaches.     
1.7.2.1 Label free quantitative analysis  
Label free quantification is extensively used because this method has been proved 
to be reliable with both standard glycoproteins (Wada, Azadi et al. 2007) as well as 
in a large number of variable biological samples. Mass spectrometry provides not 
only the m/z values but also the ion intensities of glycans. Label free quantification 
determines relative quantities of different glycans by comparing their ion intensities. 
It is critical to permethylate glycans before analysis (Dell, Reason et al. 1994, Wada, 
Azadi et al. 2007, Babu, North et al. 2009, Orlando 2010). This derivatization step 
results in more uniform ionization, because highly polar –OH and –COOH groups 
on natural glycans are converted into chemically homogeneous –OCH3 and 
-COOCH3 groups respectively. Moreover, natural glycans, especially those with 
sialic acid, are susceptible to in-source fragmentation during MS analysis, which 
interferes with quantification analysis, whereas permethylated glycans are stable in 
MS analysis. A study of neutrophil glycans showed the reliability of quantitative 
analysis of permethylated glycans (Babu, North et al. 2009). The two normal 
neutrophil samples were from donors in different countries; one was from the UK, 
while the other was from the US. However, very similar glycan profiles were 
obtained. Results from another independent report also revealed a similar glycan 
profile of normal neutrophils (Hayee, Antonopoulos et al. 2011).   
 
It is important to note that ion intensities are not only determined by glycan 
abundances but also affected by many other factors such as ionization method and 
instrument response. In addition, the molecular weight, monosaccharide 
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composition and configuration of a glycan can affect the ionization efficiency. In a 
mixture of glycans, a high abundance glycan may be detected with a low ion 
intensity if this glycan is difficult to form ions, whereas a low abundance glycan may 
show a high ion intensity if it is easy to form ions. As a result, the ratio of ion 
intensities (also known as relative intensities) of two glycans is usually not the same 
as the ratio of their quantities. Nevertheless, a change in the ratio of ion intensities 
does reflect a change in glycan quantities. A recent study shows that if ion 
intensities of glycans with similar structures and within a short mass range are 
compared, the ratios of ion intensities are very close to the ratios of glycan 
quantities (Wada, Azadi et al. 2007). In this study, a quantitative profiling of 
N-glycans was performed by multiple institutions. An IgG sample and a transferrin 
sample were sent to each institution for N-glycomic analysis. Although different 
instruments were used, the results showed that MALDI-MS analysis of 
permethylated glycans generated stable and consistent data. More importantly, the 
MALDI-MS data can be correlated to HPLC quantitation, which is a generally 
accepted method for glycan quantification (Wada, Azadi et al. 2007). If the sample 
is a mixture of isomers, the exclusive fragment ions for each isomer can be 
detected during MS/MS analysis. In this case, an increase of either isomer will raise 
the intensity of its specific fragments, which means the relative intensity of the 
specific ions can be used to compare the abundances of the isomers (North, 
Jang-Lee et al. 2010). Quantitative analysis shows the increases or decreases of 
glycans in a sample, which reveals the changes of glycosylation steps in the ER 
and Golgi complex. Figure 1.30 is a schematic example which shows how 
quantitative data of mass spectrometry reflect the changes of fucosylation and 
sialylation of glycans in a patient. The percentile ion intensities of three glycans are 
shown in a control and a patient. From glycan A to glycan B and glycan C, there is 
one more Fuc and Sia respectively. The intensity ratio of glycan B and glycan C to 
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glycan A is lower in the patient compared to that in the control. Therefore, the 
incorporation of Fuc and Sia decreases in the patient.    
 
 
 
Figure 1.30 A schematic example showing how ion intensities reflect the changes of 
glycosylation 
From glycan A to glycan B and glycan C, there is one more Fuc and Sia respectively. 
The intensity ratio of glycan B and glycan C to glycan A is lower in the patient 
compared to that in the control. Therefore, the incorporation of Fuc and Sia 
decreases in the patient.   
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1.7.2.2 Stable isotope labelling quantitative analysis 
Molecules with different isotopes have similar ionization rates but different masses. 
This property can be used for accurate quantification of glycans by mass 
spectrometry. Usually, light isotope and heavy isotope are separately incorporated 
into glycans of two samples. The glycans are then combined and introduced to MS 
for analysis. A light peak and a heavy peak are detected for each glycan and the 
ratio of ion intensities of the two peaks accurately reflects the relative quantity 
(Figure 1.31) (Alvarez-Manilla, Warren et al. 2007).   
Several ways have been developed to incorporate stable isotopes into glycans. 
Reductive amination has long been used to add tags to the reducing terminus of 
glycans for structural and quantitative analysis using hydrophilic interaction liquid 
chromatography (HILIC), high performance liquid chromatography (HPLC) or 
capillary electrophoresis (CE) (Ruhaak, Zauner et al. 2010). This reaction can also 
be used to incorporate isotopes into glycans. For example, in a tetraplex tagging 
strategy (Bowman and Zaia 2007), four isotopic tags with different deuterated forms 
were synthesized: d0, d4, d8 and d12, which contain 0, 4, 8, 12 deuterium atoms 
respectively. These tags can be used to label four glycan samples and to analyze 
their relative quantities at the same time. However, the tags cannot normally be 
used on O-glycans, because O-glycans are usually removed from glycoproteins by 
reductive beta-elimination, which reduces the reducing ends. Another way to 
incorporate isotopes into glycans is permethylation, during which light methyl iodide 
(ICH3) and heavy methyl iodide (I13CH3 or ICD3) are used to label two samples 
(Alvarez-Manilla, Warren et al. 2007, Kang, Mechref et al. 2007). After 
permethylation, the two samples are combined and analyzed by MS for quantitative 
analysis. This method can label both N-glycans and O-glycans, but the mass shift 
from a light peak to a heavy peak varies depending on the numbers of –OH groups 
of a glycan, which makes data analysis inconvenient.  
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Figure 1.31 MALDI-TOF MS analysis of an isotope labelled glycan  
The glycan was labelled with either 12C or 13C methyl iodide (Alvarez-Manilla, 
Warren et al. 2007). The m/z of the light glycan is 926.3, while the m/z of the heavy 
glycan is 940.3. The light glycans and the heavy glyans were mixed at different 
proportions: 9/1 (A), 7.5/2.5 (B), 1/1 (C), 2.5/7.5 (D), 1/9 (E). The ratios of ion 
intensities well reflect the glycan proportions.  
Both labeling methods described above incorporate isotopes after glycans are 
released from glycoproteins. However, there are usually several sample handling 
processes before this step, such as cell homogenization, glycoprotein enrichment, 
trypsin digestion, or glycopeptide preparation. Experimental variabilities tend to 
occur during these processes. If isotopes can be incorporated at the beginning of 
experiment, different samples can be mixed in the first step and experimental 
variabilities can be significantly minimized. For example, isotopic detection of amino 
sugars with glutamine (IDAWG) is a recently developed in vivo labelling method 
(Orlando, Lim et al. 2009), which incorporates isotopes into glycans by cell 
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metabolism. Glutamine with 14N-labeled side chain (amide-14N-Gln) and that with 
15N-labeled side chain (amide-15N-Gln) are given to two groups of cells. The amide 
side chain of Gln is the only nitrogen source for the biosynthesis of amino sugars, 
such as GlcNAc, GalNAc and sialic acid (Figure 1.32). During cell culture, the 
incorporation of one 15N-amino sugar into a glycan during the glycosylation pathway 
results in 1 Da of mass increase. There are usually several amino sugars in a 
glycan, so several Da of mass increase will be observed in a 15N labelled glycan. In 
vivo labelling can also be used to investigate the dynamics of glycan turnover in 
cells. In this case, cells are first cultured in medium containing light Gln and then 
switched to medium containing heavy Gln. After that, the half-lives of glyans can be 
determined by measuring the ratios of heavy glycans and light glycans at different 
time points.  
 
            
Figure 1.32 IDAWG labelling strategy 
When cells are given Gln(15N), 15N is metabolically incorporated into sugar donors 
UDP-GlcNAc, UDP-GalNAc, and CMP-Sia. During glycosylation, the addition of 
one of these heavy sugar donors into a glycan will result in 1 Da mass increase 
compared to cells which are given Gln(14N).  
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Isotope labelling has shown its accuracy in standard glycans and glycoproteins. 
However, it is not as widely used as the label free method. One of the reasons is 
that this method is much more expensive than the label free method. For example, 
the price of ICD3 is about 10 times the price of ICH3. In addition, most current 
glycomic problems can be solved by the label free method. Moreover, isotope 
labelling methods have been applied to relatively few applications in glycomics. 
Therefore it is not yet known whether this method will still be accurate and reliable 
in a wide range of real biological samples, such as human neutrophils. Human 
neutrophils express a large number of N-glycans with complicated branching, 
fucosylation and sialylation. The combination of light and heavy labelled neutrophil 
glycans will double the number of peaks in an already very crowded spectrum. As a 
result, peak overlap will inevitably occur, which will make data analysis ambigious. 
1.8 Glycoproteomics 
In spite of the fact that mass spectrometry is used in both glycomics and proteomics, 
glycomics only analyzes the complexity of glycans without investigating which 
protein the glycans are from, while proteomics focuses on the proteins in a given 
sample, ignoring glycosylation of these proteins. Glycoproteomics is the study of 
both glycans and proteins. The final goal of glycoproteomics includes identifying 
glycoproteins and glycosylation sites, and determining glycan structures at each 
glycosylation site on individual glycoforms. However, this goal cannot be achieved 
at present. The key problem is that glycosylation is the most complicated 
posttranslational modification. The determination of glycan populations at individual 
sites in a particular glycoprotein is certainly achievable with current technology but it 
is still a challenging task. Assigning all the glycans back to their sites on all proteins 
of a sample will make the challenge exponentially greater. As a result, 
glycoproteomic studies usually focus on a single or a limited number of 
glycoproteins. The glycoprotein of interest is digested into peptides and 
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glycopeptides. The peptides can be analyzed using a proteomic approach for 
protein identification. The analysis of glycopeptides can give glycosylation data at 
each site on the protein provided all glycopeptides are observed and each contains 
a single glycosylation site. 
1.8.1 MS analysis of glycopeptides 
The attaching of a glycan to a glycopeptide results in an increase in molecular 
weight. This mass increase can be detected in MS analysis, so the putative glycan 
structure at a glycosylation site can be deduced. However, during MS analysis, 
peptides are easier to ionize than glycopeptides, so the signals of glycopeptides are 
usually suppressed by peptide signals in a mixture from a protease digest. In 
addition, each glycopeptide can contain a large variety of glycans, which results in 
the distribution of a glycopeptide component into several peaks, so each peak is 
detected at a much lower signal intensity. Even when peptides are removed from 
glycopeptides, the mixture of different glycopeptides could lead to similar masses, 
which results in ambiguous annotation during data analysis.  
 
LC and nanoLC is an effective system which not only separates glycopeptides from 
peptides but also separates different glycopeptides (Kapron, Hilliard et al. 1997, 
Chalabi, Panico et al. 2006, Canis, McKinnon et al. 2012, Harrison, Hitchen et al. 
2012), so that the detection of glycopeptides and the annotation of MS data can be 
facilitated. Usually, a peptide backbone which has different glycans attached tends 
to be eluted at a similar time during LC separation. As a result, if a peptide with a 
glycan is observed, this peptide with other glycans can usually be found shortly 
before or after this peak. Glycopeptides can be analyzed using both off-line and 
on-line LC-MS. For the former case, LC fractions are immobilized on a MALDI plate, 
so each fraction can be re-analyzed if required. However, studies have found that 
MALDI-MS will cause losses of sialic acid from glycopeptides due to in-source 
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decay and post-source decay (Karas, Bahr et al. 1995, Qin and Chait 1997, Harvey 
1999, Harrison, Hitchen et al. 2012). As a result, if sialylation is the focus of study, 
on-line LC-MS is a better choice, as ESI can keep sialic acid during MS analysis.  
 
The m/z of a glycopeptide is determined by the molecular weight of both peptide 
backbone and the glycan attached, so the analysis of glycoproteomic data is more 
difficult and time consuming than glycomic data analysis. As a result, a glycomic 
analysis of a glycoprotein is usually done before glycoproteomic experiments. 
Glycomic data can provide a library of glycans on the glycoprotein, so that 
glycoproteomic data analysis can be greatly facilitated (Garner, Aguilar et al. 2010, 
Canis, McKinnon et al. 2012).   
1.8.2 MS/MS analysis of glycopeptides  
Glycopeptides are fragmented during MS/MS. If desirable fragmentation can be 
achieved, the fragments of glycans will provide information about their structures, 
while the fragments of peptides will reveal the amino acid sequence of a 
glycopeptide, as well as the location of glycosylation sites. However, such a case 
rarely occurs. Fragmentation either favors glycosidic bonds or peptide bonds, which 
provides partial information on a glycopeptide.    
 
The most commonly used MS/MS technique is collision induced dissociation (CID). 
CID mainly produces fragments via cleavages of the most labile bonds based on 
vibrational excitation. Glycosidic bonds are usually more susceptible to cleavage 
than peptide bonds, so glycan fragments often dominate the CID spectra (Carr, 
Huddleston et al. 1993, Wuhrer, Catalina et al. 2007, Canis, McKinnon et al. 2012, 
Harrison, Hitchen et al. 2012). CID usually produces glycan fragments such as 
HexNAc (m/z 204), HexNAc-H2O (m/z 186), HexNAc-2H2O (m/z 168) and the 
LacNAc unit (m/z 366), which can be used as glycopeptide diagnostic ions 
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(Huddleston, Bean et al. 1993, Harrison, Hitchen et al. 2012). In addition, CID 
fragmentation of N-glycopeptides produces a set of cleavages on Asn and the first 
GlcNAc (Figure 1.33) (Wuhrer, Balog et al. 2005, Canis, McKinnon et al. 2012). 
These fragment ions include [peptide+H-17]+ which is a loss of amine, [peptide+H]+, 
[peptide+H+83]+ which is the peptide plus a 0,2X cross-ring cleavage of the GlcANc, 
and [peptide+H+203]+ which is the peptide plus the GlcNAc. The ion source can 
also affect CID fragmentation. A glycoproteomic study of recombinant mouse 
α-dystroglycan compared CID MS/MS spectra from MALDI and ESI ion source. In 
the MALDI-MS/MS spectrum, the major fragments are losses of glycan residues 
from a glycopeptide (Figure 1.34). However, in the ESI-MS/MS spectrum, the major 
ions are carbohydrate fragments at low mass range (Figure 1.35).  
 
 
 
Figure 1.33 MALDI-MS/MS with CID fragmentation of a N-glycopeptide from human 
human von Willebrand factor 
The peptide sequence is IGEADFNR. [peptide+H-17]+ is at m/z 904.3, [peptide+H]+ 
is at m/z 921.3, [peptide+H+83]+ is at m/z 1004.5, and [peptide+H+203]+ is at m/z 
1124 (Canis, McKinnon et al. 2012). 
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Figure 1.34 MALDI-MS/MS with CID fragmentation of a glycopeptide from a 
recombinant mouse α-dystroglycan 
The peptide sequence is GAIIQTPTLGPITR. The precursor peak is observed at 
m/z 2555.2. The spectrum is dominated by the losses of glycan residues from the 
precursor peak (m/z 1987, m/z 2149, m/z 2352, m/z 2393) (Harrison, Hitchen et al. 
2012).   
 
 
                                   
Figure 1.35 ESI-MS/MS with CID fragmentation of a glycopeptide from recombinant 
mouse α-dystroglycan 
The peptide sequence is GAIIQTPTLGPITR. The spectrum is dominated by the 
carbohydrate fragments at low m/z range (m/z 204.11) with losses of H2O (m/z 
186.10 and m/z 168.08) (Harrison, Hitchen et al. 2012). 
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Complementary to CID, electron-transfer dissociation (ETD) is a MS/MS technique 
developed recently that preferentially produces fragmentation along peptide bonds, 
leaving glycans intact (Syka, Coon et al. 2004). The mechanism of ETD is 
analogous to an earlier MS/MS method known as electron capture dissociation 
(ECD) (Zubarev, Kelleher et al. 1998). ECD fragmentation is not produced by 
vibrational energy but by the reaction of low-energy electrons with multiply 
protonated peptides or proteins thereby quenching one positive charge and 
producing a radical cation. Subsequent breakage occurs along the peptide 
backbone and does not affect posttranslational modifications. However, ECD at 
present can only be used in the FT-ICR, which is a very expensive instrument. In 
2004, the triple quadrupole developer Hunt (Section 1.6.3) reported an ECD like 
dissociation using anions as vehicles for transferring electrons to multiply charged 
peptides (Syka, Coon et al. 2004). This new MS/MS method is known as ETD, 
which can be used in low cost mass spectrometers. An example of ETD 
fragmentation of a glycopeptide is shown in Figure 1.36 (Wuhrer, Catalina et al. 
2007). The spectrum is dominated by c, z ions of peptide fragmentation and few 
glycan fragments are observed. ETD may produce sufficient peptide fragment ions 
for confident peptide sequencing and accurate assignment of glycosylation sites but 
this method is neither as sensitive nor as reliable as CID. Nevertheless, in 
favourable cases, combining CID and ETD could provide both glycan and peptide 
fragmentation for a full annotation of a glycopeptide.  
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Figure 1.36 ETD MS/MS of a glycopeptide 
ESI-MS/MS with ETD of the Ser295-Arg313 from HRP (Wuhrer, Catalina et al. 
2007). The major fragments are c, z ions produced by the breakages of peptide 
bonds. The glycan remains intact. 
1.9 Glycoinformatics  
Manual annotation of MS data is a laborious task, which is a severe bottleneck that 
hinders high-throughput glycomic research. Recently, several types of software 
have been developed to analyze MS results automatically. GlycoMod (Cooper, 
Gasteiger et al. 2001) and Glyco-peakfinder (Ranzinger, Maass et al. 2006, Maass, 
Ranzingei et al. 2007) can calculate monosaccharide composition of a glycan 
according to its m/z. Cartoonist (Goldberg, Sutton-Smith et al. 2005) is an 
innovative tool developed by the CFG. This software is able to annotate MS peaks 
from a library of 2800 biosynthetically plausible cartoons constructed by about 300 
archetypal structures. Several attempts to interpret MS/MS data by software have 
been reported, but each of them can only be used in restricted situations and the 
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results are not always accurate. As a result, the structural information hiding in the 
MS/MS data is usually obtained using both software tools and the knowledge of 
researchers. Therefore, semi-automatic tools have been developed, among which 
Glycoworkbench (Ceroni, Maass et al. 2008) is one of the most widely used due to 
its friendly interface and multiple functions, such as calculating glycan compositions, 
searching for glycan structures in databases and computing fragments for selected 
structures.  
 
Another development of glycoinformatics is the emergence of glycan databases. 
The earliest one is the Complex Carbohydrate Structure Database (CCSD) (Lutteke, 
Bohne-Lang et al. 2006), which is also known as CarbBank because of the retrieval 
software to access the data. The CarbBank stopped updating in the first half of the 
1990s but it is still the largest publicly available database. The 
GLYCOSCIENCES.de portal makes use of CarbBank as well as other databases 
such as NMR spectra, 3D coordinates, masses of theoretically calculated 
fragments, glycans contained in PDB, and 3D conformational maps for many 
glycosidic linkages (Lutteke, Bohne-Lang et al. 2006). KEGG has established the 
relationship between glycan structures and the boisynthetic pathways (Altermann 
and Klaenhammer 2005). GlycoEpitope (Kawasaki, Nakao et al. 2006) database 
presents carbohydrate antigens and antibodies. EUROCarbDB (von der Lieth, 
Freire et al. 2011) aimed to build the foundations for glycan databases and 
bioinformatics tools, and to establish formats for data exchange. CFG (Raman, 
Venkataraman et al. 2006) provides glycan profiling of N- and O-linked glycans in 
mice and human as well as results of glyco-gene microarray, lectin microarray and 
glycan related mouse phenotypes. 
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1.10 Study of glycosylation in the immune system 
As discussed in Section 1.4, glycosylation plays multiple important roles in the 
immune system. With state-of-art mass spectrometry, the study of glycosylation in 
the immune system is greatly facilitated. Over the past decade, mass spectrometric 
strategies have been used for screening populations of N- and O-glycans in the 
immune system (Haslam, Julien et al. 2008). One of the greatest achievements was 
the establishment of the CFG in 2001 with $34m ‘glue’ grant funding from the 
National Institute of General Medical Sciences. The CFG has obtained glycomic 
data from human neutrophils, monocytes, B-cells, T-cells, NK-cells, dendritic cells 
and mast cells, as well as murine neutrophils, macrophages and NK-cells. These 
results are freely available in the online database 
(www.functionalglycomics.org/static/index.shtml). The CFG database also provides 
glycan microarray, gene microarray of glycan biosynthesis and glycan binding 
proteins, as well as mouse phenotypes from gene knockouts involved in glycan 
biosynthesis and binding.  
 
Glycan screening results have found different cells of the immune system express 
different glycan profiles. For example, human neutrophils express N-glycans which 
are dominated by tri- and tetra-antennary structures with high sialylation and 
core/terminal fucosylation (Babu, North et al. 2009). MS/MS analysis reveals that 
the prominent fucosylated terminal structure on neutrophils is the Lewis X epitope; 
few sialyl Lewis and no Lewis Y epitopes were detected (Babu, North et al. 2009). 
Basophils, eosinophils and mast cells are involved in allergic responses. Glycomic 
analysis of the three groups of cells showed N-glycan profiles dominated by core 
fucosylated structures with lower sialylation and terminal fucosylation (North, von 
Gunten et al. 2012). Many glycans have bisecting structures in these cells, which 
were not detected in neutrophils. Basophils have a significant amount of terminal 
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GlcNAc residues, eosinophils contained hybrid glycans, and mast cells express a 
small amount of mono-antennary glycans. Cells of the immune system at different 
status also express different glycans. For example, activation of murine CD4+ and 
CD8+ T cells led to a dramatic decrease in α2-6 linked NeuGc on N-glycans and 
correspondingly an increase in Galα1-3Gal substructure (Comelli, Sutton-Smith et 
al. 2006).    
 
The structural and quantitative data provided by glycomic and glycoproteomic 
analysis provide key information for studying functions of glycosylation in the 
immune system. For example, a glycomic study found mouse CD4+ and CD8+ T 
cells exhibited a switch of NeuAc to NeuGc after 24 hours of activation, which well 
explained a reduced affinity for anti-NeuGc antibody and a down regulation of 
CMP-N-acetylneuraminic acid hydroxylase in activated mouse T cells 
(Redelinghuys, Antonopoulos et al. 2011). New discoveries were obtained in 
PSGL-1 glycoprotein by a recent glycomic and glycoproteomic study (Lo, 
Antonopoulos et al. 2013). As discussed in Section 1.4.1, PSGL-1 is the most 
relevant glycoprotein ligand for selectin binding during leukocyte migration to sites 
of infection. In spite of many O-glycosylation sites, it is only the O-glycan with the 
Sialyl Lewis X antigen at T57 near the N-terminus of human PSGL-1 that is key for 
selectin binding (Liu, Ramachandran et al. 1998). Interestingly, the recent glycomic 
analysis found that glycans near the N-terminus also contained di-sialylated T 
antigen. Glycoproteomic investigation confirmed the presence of the di-sialylated T 
antigen at T57.  
        
Glycomic and glycoproteomic data can be very useful for the study of 
glycosyltransferases. One of the best examples is a glycoproteomic study of CD8β 
(Moody, North et al. 2003). CD8β is the β chain of CD8αβ heterodimers, which 
serve as co-receptors of TCRs. Previous studies had found immature thymocytes 
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had a higher affinity to antigen-MHC I molecules than mature thymocytes, and had 
implied that sialylation of O-glycans on CD8β could decrease CD8 αβ-MHC I avidity 
(Casabo, Mamalaki et al. 1994, Moody, Chui et al. 2001). Accordingly, ST3Gal-I, 
which sialylates Core 1 glycans, was found to decrease CD8αβ-MHC I interaction. 
A glycoproteomic analysis finally provided a physical nature of CD8β glycosylation, 
which detected non-sialylated Core 1 glycans only on immature thymocytes (Moody, 
North et al. 2003). An O-glycomic investigation of the maturation of monocyte 
derived DCs also serves as a good example of glycomics providing biological 
insights (Julien, Grimshaw et al. 2007). MS analysis of monocytes and immature 
DCs detected high levels of core 1 and core 2 O-glycans, while in mature DCs, a 
dominance of core 1 structures and a dramatic decrease in core 2 structures were 
detected. The glycomic results were consistent with the expression of 
glycotransferases. It has been known that the ratio of ST3Gal I to C2GnT1 defines 
the ratio of core1 to core 2 structures. In mature DC, ST3Gal I mRNA relative to 
C2GnT1 mRNA increased by a 100-fold.  
 
Moreover, if genes selected for study do not encode glycosyltransferases or 
glycosidases, glycomic and glycoproteomic approaches become a considerably 
more promising strategy. A recent glycomic study of g6pc3 gene mutations serves 
as a good example for this case. Researchers have identified a group of patients 
suffering from neutropenia whose disease was caused by a mutation in the gene 
encoding glucose-6-phosphatase catabolic-3 (g6pc3) (Hayee, Antonopoulos et al. 
2011), an ER resident enzyme which is responsible for converting 
glucose-6-phosphate into glucose, which is then transported from the ER to the 
cytosol. Surprisingly, glycomic analysis showed the addition of galactose in the 
biosynthesis pathway was hindered (Figure 1.37); these patients had N-glycans 
with agalactosylated tetra-antennary structures which were not detected in healthy 
controls (indicated by red peaks). In addition, the profile of O-glycans revealed the 
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adding of galactose on the Core 2 antenna obviously decreased. No previous 
studies showed the g6pc3 could affect the incorporation of Gal residues into 
glycans. For the first time, this glycomic analysis provides clues that g6pc3 may be 
involved in galactose metabolism and galactosylation of glycans. This study also 
shows the power of mass spectrometry for the investigation of novel immune 
disorders.  
 
 
Figure 1.37 Glycomic analysis of a patient with g6pc3 mutation 
Glycomic analysis N-glycans (A, B) and O-glycans (C, D) of healthy neutrophils (A, 
C) and those with g6pc3 mutation (B, D), in which N-glycans were truncated and 
new glycans appeared (B), and agalactose Core 2 O-glycans increased (D) (Hayee, 
Antonopoulos et al. 2011).  
1.11 Aims of this thesis 
The major aim of this thesis is to investigate glycosylation in immune disorders 
using mass spectrometric strategies.  
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The specific aims include:  
1. Glycomic investigation of a novel hyper IgE syndrome, which is linked to 
mutations in phosphoglucomutase 3 (Chapter 3).   
2. Using a glycoproteomic strategy to study the IgE glycosylation of novel hyper 
IgE syndrome, and compare the results with atopic IgE glycosylation 
(Chapter 4).   
3. Using glycomic and glycoproteomic strategies to investigate a novel 
congenital disorder of glycosylation which causes immunodeficiency 
(Chapter 5).  
4. Glycomic analysis of engineered IgGs for treating auto-immune diseases 
(Chapter 6).  
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2 Materials and methods 
2.1 Materials  
2.1.1 Biological samples  
For the study of hyper IgE syndrome (Chapter 3) and IgE glycosylation (Chapter 4), 
sera/plasma, urine, EBV treated B cells and neutrophils were kindly provided by 
Prof. Bodo Grimbacher from the Centre of Chronic Immunodeficiency (CCI), 
University Medical Center Freiburg. The serum sample for the study of a novel 
congenital disorder of glycosylation was kindly provided by Prof. Hudson Freeze 
from Sanford Children’s Health Research Center, Sanford-Burnham Medical 
Research Institute. Engineered IgGs were kindly provided by Dr. Mike Clark from 
the Department of Pathology, University of Cambridge and Prof. Richard J. Pleass 
from Liverpool School of Tropical Medicine. EBV treated B cells were cultured, 
washed three times with phosphate-buffered saline and centrifuged at 800 X g to 
get cell pellets. Neutrophils were harvested by Ficoll density gradient centrifugation. 
Engineered hexameric IgG1 Fc provided by Prof. Richard J. Pleass was produced 
by CHO cells and isolated according to the report (Mekhaiel, Czajkowsky et al. 
2011), while engineered IgG1 molecules provided by Dr. Mike Clark were produced 
by rat myeloma cell line YB2/0 and isolated according to the report (Armour, Clark 
et al. 1999). All samples were prepared in the collaborators’ labs, shipped to 
Imperial College in dry ice, and stored in -80 °C before analysis.  
2.1.2 General chemicals and reagents 
18 MΩ.cm3 distilled/deionised (MilliQ®) water was produced by the Purite Neptune 
ultrapure water purification system from Purite Ltd (Oxfordshire, UK). Methanol 
(MeOH), acetonitrile, ammonia, chloroform, dimethylsulphoxide (DMSO), 
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propan-1-ol, ammonium hydrogen carbonate, sodium hydroxide (NaOH), acetic 
acid and trifluoroacetic acid were from Romil (Cambridge, UK). Idoacetic acid, 
potassium borohydride, sodium acetate, 2-amino-2-hydroxymethyl-propane-1,3-diol 
(Tris), α-cyano-4-hydroxycinnamic acid (α-CHCA),  2,5-Dihydroxybenzoic acid 
(DHB) were from Sigma-Aldrich (Poole, UK). 3-[(3-Cholamidopropyl) 
dimethylammonio]-1-propanesulfonate hydrate (CHAPS) and dithiotheritol were 
from Roche Applied Science (East Sussex, UK). Sodium chloride was from Rose 
chemicals (London, UK). Methyl iodide was from Alfa Aesar (Lancaster, UK). 8 M 
guanidine hydrochloride (GuHCl) was from Thermo scientific (Loughborough, UK). 
Ethylenediaminetetraacetic acid (EDTA) and formic acid were from Fluka (Poole, 
UK).  
2.1.3 Enzymes and antibodies 
Trypsin used for glycomic analysis and Jack bean α-mannosidase were from 
Sigma-Aldrich (Poole, UK). Sequencing grade tyrpsin and chymotrypsin were from 
Promega (Hampshire, UK). PNGase F (cloned from Flavobacterium 
meningosepticum and expressed by E.coli) was from Roche Applied Science (East 
Sussex, UK). Sialidase A (cloned from Arthrobacter ureafaciens and expressed in 
E.coli) was from Europa Bioproducts Ltd (Cambridge, UK). Anti-IgE antibody (IgE 
(4F4): sc-51994, mouse monoclonal antibody raised against IgE of human origin) 
was from Santa Cruz Biotechnology (Heidelberg, Germany).  
2.1.4 Equipments and consumables 
Vibra-Cell™ homogenizer, multi-tube vortexer, Falcon tubes, galss culture tubes 
(13X100 mm Corning, 7.5 ml), screw caps (disposable phenolic GPI 13-415 
threaded with PTFE liner) and glass Pasteur pipettes were from VWR International 
Ltd (Lutterworth, UK). Lo-bind® Eppendorfs tubes were from Sigma-Aldrich (Poole, 
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UK). Thermo Savant SPD121P Speed Vac concentrator, Thermo Savant ModuloD 
freeze dryer, Slide-A-Lyzer® dialysis cassettes (3.5 kDa molecular weight cut off), 
and Pierce® Direct IP Kit were from Thermo Scientific (Basingstoke, UK). Oasis® 
HLB and Sep-Pak C18 Classic cartridges were from Waters Ltd (Hertfordshire, UK). 
Novex® NuPAGE® SDS-PAGE Gel System was from Invitrogen Ltd (Paisley, UK).    
2.2 Methods 
 
 
Figure 2.1 An overview of methods 
An overview of the glycomic and (glyco)proteomic methods used in this thesis. The 
sections describing the methods are shown.  
120 
 
 
The methods are mainly based on a previous report (North, Jang-Lee et al. 2010). 
Figure 2.1 is an overview of the methods used in this thesis. For the glycomic 
analysis of engineered antibodies, Intravenous immunoglobulin (IVIG), sera and 
plasma were reduced to cleave S-S bridges, carboxymethylated to protect Cys, and 
tryptic digested into (glyco)peptides. PNGase F was used to release N-glycans 
from glycopeptides. The free N-glycans were separated from peptides and were 
either directly subjected to permethylation or digested by glycosidases before 
permethylation. Permethylated glycans were purified and analyzed by mass 
spectrometry. In case of the other samples, before the reduction and 
carboxymethylation step, EBV treated B cells and neutrophils were homogenized to 
obtain free (glyco)proteins, Tamm-Horsfall glycoprotein (THP) was prepared by salt 
precipitation from urine, highly abundant serum glycoproteins such as IgG and 
transferrin were prepared from gel bands of serum SDS-PAGE, and IgE (low level 
serum glycoprotein) was enriched by immunoprecipitation before SDS-PAGE. If a 
sample was only used for glycomic analysis, Trypsin from Sigma-Aldrich was used 
for digestion. If a sample is used for (glyco)proteomic analysis, sequencing grade 
tyrpsin and/or sequencing grade chymotrypsin from Promega was used to digest 
the samples into (glyco)peptides, which were then subjected to mass spectrometry 
analysis.   
2.2.1 Cell homogenization 
In order to clean the sonicator, the tip of the sonicator was immersed into ultra-pure 
water in a Falcon tube and was sonicated for 10 s at 20 Amps on continuous mode. 
The step was repeated in a tube of 33.33% ultra-pure water, 33.33% methanol and 
33.33% formic acid. Then, the tip was immersed in a tube of ultrapure water and 
washed in a sonication bath for 10 min. After that, the first step was repeated in the 
following solutions: (a) water, (b) methanol, (c) 50% (v/v) chloroform in methanol, (d) 
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methanol, (e) H2O (twice). Finally, the tip was sonicated for 60 s at 20 Amps in an 
empty Falcon tube.  
 
Cell pellets were suspended in 1.5 – 2 ml homogenisation buffer (25 mM TRIS, 150 
mM NaCl, 5 mM EDTA and 1% CHAPS, pH 7.4), sonicated for 10 s on continuous 
mode at 40 amps, and paused for 15 s in ice. The step was repeated four to five 
times.  
 
The homogenized cell sample was transferred to a Slide-A-Lyzer® dialysis cassette 
and dialysed against 4.5 L of dialysis buffer (50 mM ammonium hydrogen 
carbonate, pH 7.5) at 4 °C for 48 h. The dialysis buffer was replaced regularly at 
every 12 h. Once dialysis was complete, the sample was transferred into a 15 ml 
Falcon tube, covered with perforated Parafilm and lyophilized in Thermo Savant 
ModuloD freeze dryer before reduction and carboxymethylation (Section 2.2.5).  
2.2.2 THP preparation  
THP was prepared according to a previous report with some modifications (Tamm 
and Horsfall 1952). The pH of urine samples was adjusted to 7.0. NaCl was added 
to a final concentration of 0.58 M. The samples were then incubated at 4 °C 
overnight and centrifuged at 800 g for 10 min. The supernatant was discarded. The 
precipitant was washed with 0.58 M NaCl twice, dissolved in ultrapure water, and 
then dialyzed and lyophilized as the method described in Section 2.2.1 before 
reduction and carboxymethylation (Section 2.2.5).  
2.2.3 Preparation of IgE  
IgE was enriched from serum using Pierce® Direct IP Kit. The experiment was done 
according to the manufacturer’s instructions with a few modifications. The anti-IgE 
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antibody was immobilized on beads in the following steps. First, 30 ul AminoLink 
Plus Coupling resin was added into a Pierce Spin Column and centrifuged at 1000 g 
for 1 min to remove the liquid. The resin was washed twice with 300 ul 1 X Coupling 
Buffer. Then, 185 ul H2O, 15 ul 20 X Coupling Buffer and 100 ul Anti-IgE antibody 
was added onto the resin in the column. 4.5 ul sodium cyanoborohydride was then 
added and incubated at room temperature for 90 min in a rotator. The spin column 
was centrifuged at 1000 g for 1 min and the flow-through was discarded. The resin 
was washed twice with 300 ul 1 X Coupling Buffer and 300 ul of 1X Quenching 
Buffer. After that, 300 ul of 1X Quenching Buffer and 4.5 ul of sodium 
cyanoborohydride were added to the resin, followed by incubation at room 
temperature for 15 min on a rotator. The liquid was removed from the column by 
centrifuging at 1000 g for 1 min. Finally, the resin was the washed once with 300 ul 
of 1 X Coupling Buffer and 6 times with 200 ul washing solution.  
 
Once the immobilization was completed, the resin was added to 600 ul of 
serum/plasma and incubated at 4 °C overnight on a rotator. IgE was eluted using 75 
ul Elution Buffer. The buffer was added to the resin and incubated for 10 min at 
room temperature before centrifuging. The elution was lyophilized before 
SDS-PAGE analysis.  
2.2.4 SDS-PAGE 
SDS-PAGE was done using Novex® NuPAGE® SDS-PAGE Gel System according 
to the product instructions. Serum samples were mixed with NuPAGE® LDS Sample 
Buffer, NuPAGE® Reducing Agent and deionized water. After incubation at 70 °C for 
10 min, the samples were loaded to 4% - 12% Novex® NuPAGE® Bis-Tris Mini Gels, 
and run at 200 V constant in MOPS SDS Running Buffer. IgE samples enriched by 
immunoprecipitation were dissolved in NuPAGE® LDS Sample Buffer and deionized 
water, and were incubated at 70 °C for 10 min. Then the samples were loaded to 
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Novex® NuPAGE® 3% - 8% Tris-Acetate Mini Gels, and were run at 150 V constant 
in Tris-Acetate SDS Running buffer. Gels were stained using Novex® Colloidal Blue 
Staining Kit. 
2.2.5 Reduction and carboxymethylation 
Different protocols were used for in-solution experiment and in-gel experiment. If 
samples were not in gel bands, they were subjected to the in-solution experiment. 
The samples were mixed with 500 ul 2 mg/ml dithiotheritol in 0.6 M Tris, 4 M GuHCl, 
pH 8.5, and incubated at 50 °C for 2 h. After that, 12 mg/ml Idoacetic acid in 0.6 M 
Tris, pH 8.5 was added and incubated at room temperature for 90 min in the dark. 
The samples were dialyzed and lyophilized as the method described in Section 
2.2.1.  
 
Samples in gel bands were subjected to the in-gel experiment. The gel bands were 
chopped into 1 mm X 1 mm pieces. The gel pieces were destained at room 
temperature using 200 ul 50 mM ammonium hydrogen carbonate, pH 8.4 for 5 min 
and mixed with 200 ul acetonitrile for another 5 min. The supernatant was discarded. 
The two steps were repeated until the gel pieces were completely destained. The 
destained gel pieces were dried on a Thermo Savant SPD121P Speed Vac, and 10 
mM dithiotheritol in ammonium hydrogen carbonate, pH 8.4 was added and 
incubated at 56 °C for 30 min. Then the dithiotheritol solution was removed. The gel 
pieces were washed and shrunk using 200 ul acetonitrile, and dried in the Speed 
Vac. The dried gel pieces were re-swelled by adding 200 ul 55 mM idoacetic acid in 
50 mM ammonium hydrogen carbonate pH 8.4, and incubated in the dark for 30 
min. Finally, the idoacetic acid solution was removed, the gel pieces were shrunk 
using 200 ul acetonitrile, and dried in the Speed Vac.  
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2.2.6 Typsin or chymotrypsin digestion, (glyco) peptide 
purification 
The trypsin reaction buffer was 50 mM ammonium hydrogen carbonate, pH 8.4. If 
samples were not in the gel, in-solution digestion was used. Each sample was 
dissolved in the reaction buffer, mixed with 1/50 (w/w) of trypsin, and incubated at 
37 °C overnight. The reaction was terminated by heating at 100 °C for 2 min. For 
in-gel digests 1/50 (w/w) of trypsin was added to the dried gel pieces and incubated 
for 37 °C overnight. For chymotrypsin digestion the reaction buffer was 50 mM 
ammonium hydrogen carbonate, pH 7.8, and 1/20 (w/w) of chymotrypsin was 
added to each sample and incubated at 37 °C overnight.   
  
After in-solution digestion, Oasis® HLB cartridges were used to remove hydrophilic 
contaminants from (glyco)peptides. The cartridge was attached to a 5 ml glass 
syringe and conditioned by sequentially eluting with 5 ml methanol, 5 ml 5% acetic 
acid (v/v), 5 ml propan-1-ol and 15 ml 5% acetic acid (v/v). One drop of acetic acid 
was added to each sample. After the sample was loaded, the cartridge was washed 
with 20 ml 5% acetic acid (v/v), and eluted sequentially with 4 ml 20%, 40% and 
100% (v/v) propan-1-ol in 5% acetic acid. The three fractions were collected, 
reduced in the Speed Vac, combined and lyophilized.  
 
After in-gel digestion, the supernatant (containing peptides and glycopeptides) was 
transferred to a new tube. 50 ul of 0.1% (v/v) trifluoroacetic acid was added to the 
gel pieces and incubated at 37 °C for 10 min, followed by the addition of 100 ul 
acetonitrile and incubation at 37 °C for 15 min. The supernatant (containing 
peptides and glycopeptides) was pooled with the previous supernatant. This step 
was repeated twice and the supernatant was pooled. The combined supernatant 
was reduced to 10 ul in the Speed Vac.  
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2.2.7 PNGase F digestion, purification  
The glycopeptide prepared by protease digestion were mixed with 5 - 8 U of 
PNGase F in 50 mM ammonium hydrogen carbonate, pH 8.4, incubated at 37 °C 
for 24 h, lyophilized and dissolved in 200 ul 5% acetic acid (v/v). The released 
N-glycans were separated from peptides using Sep-Pak C18 Classic cartridges. 
The cartridge was conditioned in the same way as described in Section 2.2.6. The 
sample was loaded and N-glycans were eluted with 5 ml 5% acetic acid (v/v), the 
volume was reduced in the Speed Vac, and the sample was finally lyophilized.  
2.2.8 Glycosidase digestion 
For Sialidase A digestion, free glycans were dissolved in 50mM sodium acetate, pH 
5.5, and digested using 170 mU Sialidase A at 37 °C for 24 h. For α-mannosidase 
digestion, free glycans were dissolved in 50 mM sodium acetate, pH 5.0 and 
digested by 1 U of α-mannosidase at 37 °C for 24 h. After digestion, the samples 
were lyophilized.      
2.2.9 Permethylation, purification 
3 pellets of NaOH per sample were ground in a mortar. 3 - 5 ml DMSO was added 
to suspend the NaOH powder. The slurry was added to the lyophilized N-glycans, 
vortexed, mixed with 500 ul methyl iodide, and incubated on an multi-tube vortexer 
at room temperature for 30 min. The reaction was terminated by dropwise addition 
of 3 ml water. Permethylated N-glycans (hydrophobic) were extracted using 1 ml 
chloroform. The chloroform layer was washed 3 times with 4 ml water, dried under 
nitrogen and dissolved in 100 ul methanol followed by adding 100 ul H2O to make a 
50% final methanol concentration.  
 
Permethylated N-glycans were further purified using Sep-Pak C18 Classic 
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cartridges. The cartridge was conditioned by sequentially washed with 5 ml 
methanol, 5 ml H2O, 5 ml acetonitrile, and 15 ml H2O. The sample was loaded, 
washed with 5 ml H2O, eluted by 15%, 35%, 50% and 75% acetonitrile. The 
elutions were collected, reduced by the Speed Vac and lyophilized.  
2.2.10 Glycomic analysis 
Lyophilized N-glycans were dissolved in 10 ul methanol. 1 ul of the glycans was 
mixed with 1 ul of 10 mg/ml DHB in 80% (v/v) methanol, spotted on a MALDI plate, 
and dried at room temperature. Normally, the Voyager-DE STR MALDI-TOF 
(Perspective Biosystems, Hertfordshire, UK) was used for MS analysis and 4800 
MALDI-TOF/TOF™ Analyzer (Applied Biosystems, Darmstadt, Germany) was used 
for MS/MS analysis. For glycans prepared from in-gel experiments, both MS and 
MS/MS analysis were performed on the 4800 MALDI-TOF/TOF™ Analyzer, 
because this instrument has higher sensitivity than Voyager-DE STR and is able to 
detect the tiny amount of glycans from a single gel band. Glycomic data were 
analyzed using Data Explorer (Applied Biosystems, Darmstadt, Germany). Spectra 
were compared to find out presence or absence of glycan structures as well as 
changes of relative intensities. The comparison of relative intensities follows the 
example shown in Figure 1.30. The ratios of intensities of glycans with similar 
structures, within a short mass range and along the glycosylation pathway (eg: 
adding a Fuc or LacNAc unit etc) were compared. As glycomic data acquired using 
the same protocol and the same instrument are very stable, the changes of ratios 
which were more than 20% were considered as significant.     
2.2.11 (Glyco)proteomic analysis 
For combined analysis of peptide finger print (PMF) and MS/MS, (glyco)peptides 
were mixed with α-CHCA matrix (10 mg/ml in 50% acetonitrile, 0.05% trifluoroacetic 
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acid), spotted on a MALDI plate, and analyzed using 4800 MALDI-TOF/TOF™ 
Analyzer. The data was analyzed using GPS Explorer™ Software (Applied 
Biosystems, Darmstadt, Germany).   
 
For offline nano LC-MS, (glyco)peptides were dissolved in 30 ul 0.1% (v/v) 
trifluoroacetic acid. 10 ul was injected to an Ultimate 3000 (LC Packings, Dionex, 
Sunnyvale, CA) equipped with a Pepmap analytical C18 nanocapillary column (15 
cm length, 75 mm internal diameter). The sample was loaded and eluted using 
Solvent A (0.1% trifluoroacetic acid (v/v) in 2% (v/v) acetonitrile) and Solvent B 
(0.1% trifluoroacetic acid (v/v) in 90% (v/v) acetonitrile) with a gradient of 0% - 60% 
solvent B over 36 min at a flow rate of 0.3 ul/min. The fractions were mixed with 
α-CHCA matrix (3 mg/ml in 50% acetonitrile, 0.05% trifluoroacetic acid) and spotted 
on a MALDI plate by a Probot (LC Packings, Dionex, Camberley, UK). The dried 
spots were analyzed by 4800 MALDI-TOF/TOF™ Analyzer. The data was analyzed 
using GPS Explorer™ Software. 
 
For online LC-MS, samples were dissolved in 30 ul 0.1% formic acid. The (glyco) 
peptides were separated by a Pepmap C18 nanocapillary column (15 cm length, 75 
mm internal diameter) fitted to a nano-HPLC system (LC Packings, Dionex, 
Camberley, UK). The elution was carried out using sovent Solvent A (0.05% (v/v) 
fromic acid in 95.5% (v/v) water/ acetonitrile solution) and Solvent B (0.04% (v/v) 
formic acid in 95.5% (v/v) acetonitrile/water solution).  The fractions were 
introduced to the API QSTARTM Pulsar Hybrid LC/MS/MS system (Applied 
Biosystems/MDS Sciex, Toronto, Canada). The data was analyzed using Analyst 
QS Software (Applied Biosystems, Darmstadt, Germany). 
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3 Glycomic analysis of a novel hyper IgE 
syndrome 
3.1 Background 
Hyper-IgE syndrome (HIES) is a primary immunodeficiency disorder that is 
characterized by dramatically elevated IgE levels, eczema, recurrent 
staphylococcal skin infections and pulmonary infections (Yong, Freeman et al. 
2012). This immune disorder was first discovered in 1966 by Davis and colleagues, 
who described two girls suffering from recurrent staphylococcal abscesses, 
pneumonia, and neonatal-onset eczematoid rash (Davis, Schaller et al. 1966). The 
disease was further charactered in 1972 by Buckley and colleagues, who noted 
distinctive facial features and elevated IgE levels (Buckley, Belmaker et al. 1972). In 
1999, researchers at the NIH found hyper-IgE syndrome shows an autosomal 
dominant inheritance pattern (Grimbacher, Holland et al. 1999). It was not until 
2007 that dominant-negative mutations in signal transducer and activator of 
transcription 3 (STAT3) were found to be responsible for the majority of cases of 
autosomal dominant hyper-IgE syndrome (AD-HIES) (Holland, DeLeo et al. 2007, 
Minegishi, Saito et al. 2007). In parallel, Renner and colleagues discovered 
autosomal recessive hyper IgE syndrome (AR-HIES) in 2004, which is different 
from AD-HIES in that the patients do not have non-immunological symptoms like 
distinctive facial features (Renner, Puck et al. 2004). In 2009, mutations in dedicator 
of cytokinesis protein 8 (DOCK8) were found to account for the majority of AR-HIES 
(Engelhardt, McGhee et al. 2009, Zhang, Davis et al. 2010).  
 
Recently, seven patients have been discovered to suffer from hyper IgE syndrome 
by Professor Bodo Grimbacher at University Medical Center Freiburg. Surprisingly, 
none of them carry mutations in STAT3 or DOCK8. Instead, their disease is linked 
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to mutations in PGM3 (phosphoglucomutase 3). The pedigrees and mutations are 
shown in Figure 3.1. Two patients are found in Family 1 with the mutation Leu83Ser 
at the catalytic domain. Four patients are found in Family 2 with Glu340 deleted at 
the sugar binding domain. Family 3 has one patient with a mutation Asp502Tyr in 
the PO4- binding domain. The patients in Family 2 displayed more severe 
symptoms. For example, they are more likely to have developmental delay and 
psychomotor retardation, and exhibit more severe hypotonia. Two patients in Family 
2 have died (No.13, No.14, Figure 3.1). No.13 died from septicemia associated with 
a severe bout of diarrhoea at the age of 14 months. Her twin sister No.14 died most 
probably due to a septicemia at the age of 13 months. Western blotting showed that 
patients in Family 2 had a dramatic decrease in PGM3 level, while the level of 
PGM3 does not change significantly in the patients from the other families (Figure 
3.1).  
 
The function of PGM3 is to catalyze the inter-conversion of GlcNAc-6-phosphate 
and GlcNAc-1-phosphate, producing the precursor for synthesizing UDP-GlcNAc. 
Impairment of PGM3 is therefore predicted to result in reduced levels of 
UDP-GlcNAc. Because UDP-GlcNAc is a substrate widely required to synthesize 
multiple types of oligosaccharide, abnormal glycosylation could be a feature of 
novel hyper IgE syndrome. To investigate this, glycomic methodologies were used 
to analyse the following samples from patients with PGM3 mutations: Epstein–Barr 
virus (EBV) treated B cells, neutrophils, plasma/serum samples, and Tamm-Horsfall 
Protein (THP). 
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Figure 3.1 Pedigrees, mutations, and Western blot results of the PGM3 patients 
from three families named Family 1, 2, and 3 
Circles and squares means female and male respectively. Solid squares and circles 
indicate affected individuals with AR-HIES, half solid ones denote heterozygous 
family members, and open ones are healthy members with wild type PGM3. 
Slashes indicate deceased individuals. Double horizontal lines indicate 
consanguinity marriage. Small black dots mean miscarriages. Asterisks indicate the 
genotype was confirmed by DNA sequencing. Family 1 has two patients with 
Leu83Ser mutation at the catalytic domain. Family 2 has four patients with Glu340 
deletion at the sugar binding domain. Family 3 has one patient with Asp502Tyr 
mutation at the PO4- binding domain. Epstein–Barr Virus (EBV) treated B cells 
were used for Western blot for Family 1 and Family 2. T cells of the patient in 
Family 3 were used for Western blot. A DOCK8 deficient (PGM3 wild type) T cell 
line was used as the control. The patients in Family 2 show decrease in PGM3 level. 
Data for this figure were kindly provided by Professor Bodo Grimbacher (Sassi, 
Lazaroski et al. 2014).   
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3.2 Results 
3.2.1 Glycomic analysis of EBV treated B cells 
B cells were prepared from blood samples, immortalized by EBV infection, and 
cultured to produce enough cell counts for glycomic analysis. Figure 3.2 shows the 
N-glycan analysis of EBV treated B cells from a control (A), a patient from family 1 
(B) and a patient from family 2 (C). Hybrid glycans and complex glycans are 
displayed. Most glycans were fucosylated. In the control and the patient from family 
1, the highest peak was at m/z 2850, which was a bi-antennary glycan. The 
incorporation of one and two LacNAc units into this glycan produces glycans at m/z 
3300 and m/z 3749 respectively. The intensity ratios of m/z 3300 and m/z 3749 to 
m/z 2850 were lower in the patient than those in the control, which reveals a 
decrease in the addition of LacNAc units in the patient (Figure 3.2 A, B). Hybrid 
glycans in both the healthy control and the patient had low intensities compared to 
the complex glycans. Surprisingly, the patient from family 2 exhibited a dramatic 
increase in hybrid glycans, illustrated by the peaks at m/z 3014, m/z 2809, m/z 2652, 
m/z 2605, m/z 2448, m/z 2478 and m/z 2564 (Figure 3.2 C). All the complex 
glycans decreased in this patient compared to these hybrid glycans. The glycan 
branches of human B cells are not well defined. Although glycans with three (m/z 
3300) or four LacNAc units (m/z 3749) relative to the bi-antennary glycan at m/z 
2850 decreased in the patient in family 1, where these LacNAc units are attached is 
unclear. This is the why we located these extra groups above a bracket. As a result, 
whether the m/z 3300 was a tri-antennary glycan or a bi-antennary glycan with an 
extended antenna was unknown at this point. The signal at m/z 3749 had the same 
ambiguity. Therefore, MS/MS was used for a further study of the two peaks. Their 
MS/MS results are shown in Figure 3.3 and Figure 3.4 respectively. In the patient, 
both results showed a higher ratio of extended antenna to non-extended antenna.  
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Figure 3.2 Glycomic analysis of EBV treated B cells of PGM3 patients 
MS analysis of EBV treated B cells from a control (A), a patient from Family 1 (B) 
and a patient from Family 2 (C). Peaks are annotated with putative structures 
according to the molecular weight and the glycan biosynthetic pathway. The m/z 
values of hybrid glycans are in blue. The m/z values of complex glycans with two, 
three and four LacNAc units are in red, green and orange respectively.   
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Figure 3.3 MS/MS of m/z 3300 of EBV treated B cells of PGM3 patients 
MS/MS result of m/z 3300 in a control (A) and the patient from Family 1 (B). 
Fragments with loss of extended antenna and a single LacNAc unit are shown. 
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Figure 3.4 MS/MS of m/z 3749 of EBV treated B cells of PGM3 patients 
MS/MS of m/z 3749 in a control (A) and the patient from Family 1 (B). Fragments 
with loss of extended antenna and a single LacNAc unit are shown. 
 
Nine repeats of MS/MS analysis of the two peaks are displayed in Figure 3.5, which 
shows the results were stable and consistent. The MS/MS results support that there 
were fewer tri-antennary and tetra-antennary glycans at m/z 3300 and m/z 3749 
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respectively in the patient, so the reduction in m/z 3300 and m/z 3749 was probably 
caused by a decrease in the synthesis of tri- and tetra-antennary glycans. 
 
 
 
Figure 3.5 9 repreats of MS/MS analysis of m/z 3300 and m/z 3749 of EVB treated 
B cells of PGM3 patients 
The loss of extended antenna relative to the loss of a single LacNAc unit from 9 
MS/MS repeats of m/z 3300 (A) and m/z 3749 (B) in a control and the patient from 
Family 1. Relative to the loss of the mono-LacNAc unit, the loss of extended 
antenna was significantly higher in the patient in MS/MS analysis of m/z 3300 
(two-sample t-test, p=1.5X10-10) and that of m/z 3749 (two-sample t-test, 
p=1.1X10-7).  
3.2.2 Glycomic analysis of neutrophils 
Neutrophils are the most abundant leukocytes in the blood, so they are easy to 
collect. In addition, published data (Babu, North et al. 2009, Hayee, Antonopoulos 
et al. 2011) have shown that neutrophils express a large number of N-glycans and 
the N-glycan profiles are considerably stable among different healthy donors. For 
these reasons, neutrophils can be used as a desirable model to study how the 
PGM3 mutation could affect the glycosylation in the immune system. The complex 
glycans of neutrophils from a control (A), a patient from family 1 (B) and a patient 
from family 3 (C) are shown in Figure 3.6. Compared to the control, the patient from 
family 1 had lower ratios of m/z 3054 and m/z 3504 to m/z 2605 (Figure 3.6 A, B). 
The glycans at m/z 3054 and m/z 3504 contain one and two extra LacNAc units 
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compared to the glycan at m/z 2605, so the lower ratios in the patient reveal a 
decrease in the incorporation of LacNAc units. The same case occurred at m/z 
3229 and m/z 3678, when they are compared to m/z 2779 (Figure 3.6 A, B). The 
patient from family 3 showed similar results. The relative intensity of m/z 3054 and 
m/z 3504 to m/z 2605 were 19% and 12% respectively in this patient, while the two 
relative intensities in the healthy control were 29% and 26% respectively (Figure 3.6 
A, C). However, relative to m/z 2779, m/z 3229 and m/z 3678 did not decrease 
significantly; the relative intensity of m/z 3229 was 16%, and m/z 3678 10%, while 
those in the healthy control were 18% and 14% respectively (Figure 3.6 A, C). It is 
possible that sialylation might have affected the analysis of LacNAc addition. In 
order to get rid of potential sialylation interference, the neutrophil N-glycans were 
treated by Sial A to remove all sialic acid residues before MS analysis. The results 
are shown in Figure 3.7. A more significant reduction of the incorporation of LacNAc 
units was observed in both patients. For example, m/z 2867, m/z 3317, m/z 3766 
(not observed in panel C) and m/z 4215 (not observed in panel C) decreased 
relative to m/z 2418. The addition of terminal Fuc residues also decreased in the 
patients, which is exemplified by the peak at m/z 2779 relative to m/z 2605, at m/z 
3229 and 3403 relative to m/z 3055, and at m/z 3678 and m/z 3852 relative to m/z 
3504. This decrease was clearly observed after Sial A digestion, such as the peaks 
from m/z 2867 to m/z 3042, and those from m/z 3143 to m/z 3317, then to m/z 3491 
(not observed in panel C). More examples of decreased incorporation of terminal 
Fuc residues can be found in the patient from family 1 (Figure 3.7B). 
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Figure 3.6 Glycomic analysis of neutrophils of PGM3 patients 
MS analysis of neutrophil glycans from a control (A) (Babu, North et al. 2009), the 
patient from Family 1 (B) and a patient from Family 3 (C). Peaks are annotated with 
putative structures according to the molecular weight and the glycan biosynthetic 
pathway. The m/z values of glycans with two, three and more than three LacNAc 
units are in red, green and orange respectively.  
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Figure 3.7 Glycomic analysis of Sial A treated neutrophils of PGM3 patients 
MS analysis of Sial A treated neutrophil glycans from a control (A) (Babu, North et al. 
2009), the patient from Family 1 (B) and the patient from Family 3 (C). Peaks are 
annotated with putative structures according to the molecular weight and the glycan 
biosynthetic pathway. The m/z values of glycans with two, three and more than 
three LacNAc units are in red, green and orange respectively.  
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In order to check whether the decrease in LacNAc units was caused by a reduction 
of branches, m/z 3229 was selected for MS/MS analysis. The results are shown in 
Figure 3.8. This peak was a mixture of a tri-antennary glycan which had an 
exclusive fragment at m/z 2128 and a bi-antennary glycan with an extended 
antenna which had the specific fragment at m/z 2142. The intensity of m/z 2128 
was lower than that of m/z 2142 in the patients, particularly in the patient from family 
1. The MS/MS results suggest that the patients had fewer tri-antennary glycans, 
even though the peak at m/z 3229 did not change much in the patient from family 3 
in the MS analysis (Figure 3.6 C). Previous studies showed neutrophils tend not to 
attach sialic acid and terminal Fuc to the same antenna (Babu, North et al. 2009). 
MS/MS analysis of m/z 3229 in our data yielded the same result (Figure 3.8). This is 
one of the reasons we chose this peak for MS/MS analysis. When the mass of each 
antenna is different from others in an individual glycan, it is usually possible to 
obtain exclusive fragments for each structure.  
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Figure 3.8 MS/MS of m/z 3229 of neutrophils of PGM3 patients 
MS/MS analysis of m/z 3229 in a control (A), the patients from Family 1 (B) and 
Family 3 (C). Fragmentation is interpreted on the cartoons at the top. Excusive 
fragments (m/z 2128 and m/z 2142) for each structure are highlighted in red. The 
control data were kindly acquired by Dr. Simon North.  
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3.2.3 Glycomic analysis of plasma/serum samples 
Plasma/serum samples were collected for glycomic analysis, because they are 
commonly used in clinical tests. Figure 3.9 displays the glycan profiles of two serum 
samples from a control and a patient of Family 1 respectively. The spectra were 
dominated by bi-, tri- and tetra-antennary glycans commonly with fucosylation and 
sialylation. High mannose glyans were also observed at such as m/z 1580, 1784, 
1988 and 2192, but they had low intensity relative to complex glycans. No 
significant differences were observed among tri-/tetra- antennary glycans. For 
bi-antennary glycans, relative to the peak at m/z 1836, the peaks at m/z 2040 and 
m/z 2244 decreased in the patient (Figure 3.9 B). As the glycans at m/z 2040 and 
m/z 2244 contain one and two extra Gal residues respectively compared to the 
glycan at m/z 1836, this decrease suggests that the incorporation of Gal residues is 
reduced in the patient.  
 
A plasma sample from Family 2 was collected for analysis. Haemolysis had 
occurred when the blood sample from Family 2 was received. As a result, a control 
plasma was prepared from a healthy blood sample which also had haemolysis. The 
results are shown in Figure 3.10. Similar to the serum samples described above, 
the incorporation of Gal residues decreased in the patient among the bi-antennary 
glycans at m/z 1836, m/z 2040 and m/z 2244. A hybrid glycan was detected in the 
patient at m/z 2186 and m/z 2390 respectively. This peak was not seen in the 
patient from Family 1.  
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Figure 3.9 Glycomic analysis of serum samples of PGM3 patients 
N-glycan profiles of serum samples from a control (A and C) and a patient from 
Family 1 (B and D). Peaks are annotated with putative structures according to the 
molecular weight, the glycan biosynthetic pathway and previous studies. 
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Figure 3.10 Glycomic analysis of plasma samples of PGM3 patients 
N-glycan profiles of plasma samples from a control (A and C) and a patient from 
Family 2 (B and D). Peaks are annotated with putative structures according to the 
molecular weight, the glycan biosynthetic pathway and previous studies. 
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The two highest bi-antennary peaks were at m/z 2040 and m/z 2244, and the 
highest peak among tri-/tetra-antennary glycans was at m/z 3777. The three peaks 
were selected for MS/MS analysis. The MS/MS fragmentation of m/z 2040 and m/z 
2244 is shown in Figure 3.11. In the MS/MS analysis of m/z 2040, the fragments at 
m/z 474, m/z 1589, m/z 486 and m/z 1577 confirmed that this glycan had a core 
Fuc structure. The peak at m/z 2244 was also confirmed to be a core Fuc glycan, as 
fragments at m/z 474 and m/z 1793 were detected. However, the glycan at m/z 
3777 had the Fuc residue at the antenna, as fragments at m/z 1021, m/z 2778 and 
m/z 3500 were detected (Figure 3.12). 
 
 
Figure 3.11 MS/MS of m/z 2040 and m/z 2244 of a plasma sample 
MS/MS analysis of m/z 2040 (A) and m/z 2244 (B) of a control plasma sample is 
shown. Fragments at m/z 474, m/z 1589, m/z 486 and m/z 1577 provide strong 
evidence that the glycan at m/z 2040 had core Fuc structure. Fragments at m/z 474 
and m/z 1793 provide strong evidence that the peak at m/z 2244 was a core Fuc 
glycan. Results of the other serum/plasma samples exhibited similar fragmentation 
and are not shown here. 
146 
 
 
Figure 3.12 MS/MS of m/z 3777 of a serum sample 
MS/MS analysis of a serum glycan at m/z 3777 from a patient of Family 1 is shown. 
The fragment at m/z 1021, m/z 2778 and m/z 3500 provided strong evidence that 
the Fuc residue was at the antenna. Results of the other serum/plasma samples 
exhibited similar fragmentation and are not shown here. 
3.2.4 Glycomic analysis of Tamm-Horsfall Protein (THP) 
Decreases in tri-/tetra-antennary glycans were observed in both EBV treated B cells 
and neutrophils, which suggests the synthesis of tri-/tetra-antennary glycans in 
these cells is sensitive to PGM3 mutation. In order to check whether glycoproteins 
from other organs are also sensitive to the mutation, THP was prepared for 
glycomic analysis, because previous studies have shown THP has high abundance 
of glycans with three or four antennae (Afonso, Charlwood et al. 1981, 
Serafini-Cessi, Malagolini et al. 1984, Hard, Van Zadelhoff et al. 1992, van Rooijen, 
Voskamp et al. 1999, Parsons, Stein et al. 2007). Figure 3.13 shows the N-glycans 
147 
 
of THP from a healthy control (A, C) and a patient from family 1 (B, D). Tri- and 
tetra-antennary structures containing terminal sialic acid dominated the spectra, but 
they did not decrease significantly in the patient. Sial A was used to remove 
possible interferences of sialic acid, so that the comparison of the changes of tri- 
and tetra-antennary glycans could be easier. Figure 3.14 shows Sial A treated 
N-glycans from this glycoprotein. Most sialic acid was removed except four low 
intensity peaks, three of which were found in the healthy control (m/z 3749, m/z 
3994, m/z 4239), and one of which was present in the patient (m/z 3749). The data 
was simplified by Sial A, but tri- and tetra-antennary glycans still did not change 
obviously in the patient. THP of the other patient from Family 1 was also collected 
for analysis but gave similar results, so it is not presented here.  
 
We considered the possibility that some of the signals assigned to tri- and 
tetra-antennary glycans in the patient might actually be bi-antennary glycans with 
extended antenna. For example, the peak at m/z 2693 (Figure 3.14) which is a 
tri-antennary glycan in the healthy control, with each antenna containing one 
LacNAc unit, could be a bi-antennary glycan in the patient with one antenna having 
a single LacNAc unit and the other having two, if the THP glycosylation in the 
patient was affected by PGM3 mutation. Therefore, m/z 2693 was selected for 
MS/MS analysis. Figure 3.15 shows the MS/MS analysis of a Sial A digested glycan 
at m/z 2693 from the healthy control (A) and a patient from Family 1 (B). Fragments 
at m/z 935 and m/z 1781 must have been detected if this peak had contained a 
bi-antennary glycan. However, none of the two fragments were present (Figure 
3.15). The glycan was confirmed to be a tri-antennary structure with core Fuc. The 
other patient gave a similar result, which is not included here.  
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Figure 3.13 Glycomic analysis of THP of a PGM3 patient 
THP N-glycans from a healthy control (A, C) and a patient from Family 1 (B, D) 
were analyzed. Peaks are annotated with putative structures according to the 
molecular weight, the glycan biosynthetic pathway and previous studies.  
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Figure 3.14 Glycomic analysis of Sial A treated N-glycans from THP of a PGM3 
patient 
Sial A treated THP N-glycans from a healthy control (A) and a patient from Family 1 
(B) were analyzed. Peaks are annotated with putative structures according to the 
molecular weight, the glycan biosynthetic pathway and previous studies.  
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Figure 3.15 MS/MS of m/z 2693 of Sial A treated THP N-glycans 
MS/MS analysis of m/z 2693 from a healthy control (A) and a patient from Family 1 
(B) are shown. Fragment at m/z 2242 indicate the Fuc residue was in the Core 
structure. The absence of fragments at m/z 935 and m/z 1781 provides strong 
evidence that extended antennae did not exist in the glycans.  
3.3 Discussion 
3.3.1 PGM3 and N-glycan branching 
Unlike other human PGM enzymes that act on Glc phosphate, PGM3 acts on 
GlcNAc phosphate, which gives PGM3 an alternative name AGM1. The function of 
PGM3 is to interconvert GlcNAc-6-phosphate and GlcNAc-1-phosphate, providing 
the precursor for synthesizing UDP-GlcNAc. Mutations in PGM3 could reduce the 
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supply of UDP-GlcNAc for GlcNAc transferases, which are responsible for 
incorporating GlcNAc residues into multiple glycan structures. A mouse model with 
Pgm3 mutations has been reported (Greig, Antonchuk et al. 2007). A decrease in 
UDP-GlcNAc, changes in glycosylation, and abnormal haematopoiesis and 
development were observed in the mutant mice. Here, for the first time, we present 
data showing changes in glycosylation associated with PGM3 mutations in humans. 
We found tri-/tetra-antennary glycans of EBV treated B cells and neutrophils 
decreased in all patients, which is consistent with the Km values of the enzymes 
responsible for initiating antennae. There are several GlcNAc transferases involved 
in initiating N-glycan branches (Figure 1.6). However, GlcNAc-T VI is not found in 
humans but in chicken and fish (Schachter 2000). In addition, GlcNAc-T Vb is 
mainly expressed in the brain and testis (Kaneko, Alvarez-Manilla et al. 2003). As a 
result, in most human tissues, the N-glycan antennae are usually initiated by 
GlcNAc-T I, II, IV and V. The four enzymes initiate the first, the second, the third and 
the fourth antenna respectively. Their Km values are 0.04, 0.96, 5.0 and 11.0 mM 
respectively (Lau, Partridge et al. 2007, Dennis, Nabi et al. 2009) (Figure 3.16). As 
a high Km value for an enzyme means a low affinity for its substrate and thus a low 
catalytic activity, the synthesis of tri-/tetra-antennary glycans, which requires the two 
GlcNAc transferases with the highest Km values (IV and V), is expected to be most 
impaired in the patients (Figure 3.16). Accordingly, the N-glycan profiles of EBV 
treated B cells and neutrophils showed a decrease in tri-/tetra-antennary glycans 
(Figure 3.2, Figure 3.6, Figure 3.7). As discussed in Section 1.4.3, glycan branches 
are important for galectin binding. One of possible explanations is that abnormal 
organization of membrane receptors of the patients’ leukocytes, which could be one 
of the causes for the disease.  
 
MS/MS analysis of glycans with three or four LacNAc units detected fewer 
branches and more extended antennae in the patients (Figure 3.3, Figure 3.4 and 
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Figure 3.8), which means it is more difficult for the patients to start the third and the 
fourth antenna than to extend an existing antenna. This observation is consistent 
with previous studies which have shown the enzyme involved in extending 
antennae (β1-3 GlcNAc-T) has a low Km value (0.17 mM UDP-GlcNAc) (Holmes 
1988). For the MS/MS analysis of m/z 3300 and m/z 3749, the fragments with the 
loss of extended antennas result in exclusive peaks for bi-antennary glycans. 
However, the loss of a single LacNAc unit can occur in both bi-antennary and 
tri-/tetra-antennary glycans, which means the fragment with the loss of one LacNAc 
can not well reflect the quantities of tri- or tetra-antennary glycans. For this reason, 
9 independent MS/MS experiments were performed, and statistical analysis 
showed the result was consistent (Figure 3.5).  
 
 
Figure 3.16 PGM3 and N-glycan branching 
Key steps are highlighted by red arrows. Enzymes (GlcNAc-T I, GlcNAc-T II, 
GlcNAc-T IV, and GlcNAc-T V) and their Km values (mM UDP-GlcNAc) are shown 
in the steps involved in the initiation of antennae (Lau, Partridge et al. 2007, Dennis, 
Nabi et al. 2009). A high Km value suggests a low catalytic activity, so the initiation 
of tri-/tetra-antennary glycans is most likely to be affected by PGM3 mutation.   
 
Tri-/tetra-antennary glycans in the plasma/sera and THP did not change 
significantly in the patients. This is consistent with the mouse model of Pgm3 
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mutation, which exhibits a universal reduction of UDP-GlcNAc, but not wholesale 
changes of protein glycosylation. It is possible that liver and kidney may have other 
pathways to compensate for the PGM3 mutation. For example, a previous study 
found GalNAc-1-phosphate kinase was highly expressed in the pig kidney 
(Pastuszak, Drake et al. 1996), which indicates the kidney might have an alternative 
pathway to synthesize UDP-GlcNAc, because this enzyme is able to synthesize 
GalNAc-1-phosphate from GalNAc and the product can be used to generate 
UDP-GlcNAc. 
3.3.2 Glycomic data and clinical observations  
The glycomic analysis revealed correlations between glycan profiles and clinical 
observations. In the case of the patient from Family 2, a decrease in all complex 
glycans and a substantial increase in hybrid glycans was observed in EBV treated B 
cells (Figure 3.2). A hybrid glycan was also detected in the plasma (Figure 3.9), 
which rarely contains hybrid glycans. According to the glycosylation pathway, these 
results suggest the synthesis of bi-antennary glycans was also hindered, which 
then caused the accumulation of hybrid glycans (Figure 3.16). It is possible that the 
mutation in Family 2 was so severe that the UDP-GlcNAc reduced to a level that 
was able to affect GlcNAc-T II (Figure 3.16). This is supported by Western blot data 
which found a dramatic decrease in PGM3 protein for the patient from Family 2 
(Figure 3.1). In addition, the patients in Family 2 exhibited a more pronuounced 
decrease in PGM3 enzymatic activity. The glycomic data also correlates with the 
clinical findings that patients in this family exhibited more severe symptoms and two 
identical sisters have passed away (Figure 3.1).   
 
Tri-/tetra-antennary glycans in the plasma/sera and THP did not change 
significantly in the patients. THP is expressed by the kidney. The clinical studies 
have not found abnormal symptoms in the kidney, which is consistent with the 
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glycomic results. It is easy to collect plasma or serum samples, so human sera and 
plasma are well studied in both glycomic and proteomic fields. According to 
proteomic studies, there are two major sources for plasma or serum glycoproteins, 
B cells and the liver (Anderson and Anderson 2002). B cells secrete antibodies into 
the blood while the liver secretes most other proteins. By this reason, the N-glycans 
detected in the plasma mainly come from either the antibodies or the glycoproteins 
secreted by the liver. Antibodies contain high abundances of bi-antennary glycans 
commonly with core Fuc, bisecting GlcNAc or terminal GlcNAc, but do not usually 
have tri- or tetra-antennary glycans (Fukuta, Abe et al. 2000, Wang, Nakouzi et al. 
2003, Huhn, Selman et al. 2009, Hayee, Antonopoulos et al. 2011). However, 
glycoproteins from the liver can have tri- and tetra-antennary glycans, but hardly 
contain core Fuc or bisecting GlcNAc (Park, Yoon et al. , Yoon, Park et al. , Higai, 
Azuma et al. 2003, Kolarich, Weber et al. 2006, Fenaille, Le Mignon et al. 2007, 
Harazono, Kawasaki et al. 2008, Imre, Kremmer et al. 2008, Klein, Michalski et al. 
2010). Therefore, the tri- and tetra-antennary glycans observed in Figure 3.9 and 
Figure 3.10 were most likely from the liver. These glycans should not have core Fuc 
structures, which is exemplified by the MS/MS analysis of m/z 3777, which 
confirmed the location of the Fuc residue was at an antenna (Figure 3.12). The 
clinical studies have not found symptoms in the liver, which coincides with our 
glycomic data of the plasma and serum samples.  
 
Studies of sera/plasma found a decrease in galactosylation among glycans at m/z 
1836, m/z 2040 and m/z 2244 (Figure 3.9, Figure 3.10). All the three glycans had 
core Fuc structures (Figure 3.9, Figure 3.10, Figure 3.11), which means they were 
from antibodies. IgG is the most abundant antibody in the serum. Previous studies 
have shown glycans at the three peaks almost disappeared in sera with IgG 
depletion (Klein, Michalski et al. 2010). Therefore, the three glycans were mainly 
from IgG. It has been known that a decrease in IgG galactosylation has correlation 
155 
 
with various inﬂammatory diseases (Parekh, Dwek et al. 1985). Clinical studies 
have discovered recurrent infections in the PGM3 patients, which may cause 
inflammation and, therefore, might have served as one of the factors for the 
decrease in IgG galactosylation. In order to provide further evidence to support the 
correlation between infection and reduced IgG galactosylation, IVIG pooled from 
3,000 American healthy donors was compared with that pooled from 300 Malawian 
donors with malaria and possibly other infections. The glycomic results showed a 
significant decrease in galactosylation of the Malawian IVIG (Figure 3.17), which 
was similar to the PGM3 patients. As discussed in Section 1.4.1 and 1.43, 
fucosylation and LacNAc units are important for the migration and activation of 
neutrophils. Reduced fucosylation and branching were observed in neutrophils of 
the PGM3 patients (Figure 3.6, Figure 3.7), which could have been one of the 
reasons why they suffered from recurrent infections. 
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Figure 3.17 Glycomic analysis of IVIG samples 
An IVIG pooled from 3000 American healthy donors (A) and an IVIG pooled from 
300 Malawian patients with malaria and possibly other infections (B) were analysed. 
Reduced galactosylation was observed in the Malawian IgG. 
3.3.3 Glycosylation and elevated IgE 
All the PGM3 patients exhibited extremely high levels of serum IgE. Studies have 
revealed that the TH1/TH2 balance plays a triggering role in allergy, which is 
accompanied by an elevation of IgE (Romagnani 2004). TH1 and TH2 cells develop 
from the same native TH cells during antigen presentation. TH1 polarization is 
followed by secretion of IL-2, IFN-γ, and TNF-β, which promotes TC cells and 
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macrophages to eliminate intracellular pathogens (Section 1.3.2). However, TH2 
polarization favours the secretion of IL-4 and IL-13, which are involved in the 
production of IgE (Figure 1.13). The interactions between neutrophils and DCs may 
instruct DCs to induce TH1 polarization (section 1.41). The reduction of neutrophil 
fucosylation and branching suggests fewer neutrophils migrated to sites of infection, 
and, therefore, caused reduced interactions between neutrophils and DCs, which 
might have hindered TH1 polarization and facilitated TH2 polarization. 
 
CD23 and CD21 are two components of the IgE network (Figure 1.13). The binding 
of soluble CD23 to CD21 and membrane IgE on B cells can stimulate IgE 
production. CD23 contains three C-type lectin domains, while CD21 is a highly 
glycosylated protein which contains as many as 11 potential glycosylation sites 
(Gould and Sutton 2008). It is possible that CD23 binds CD21 through the 
interaction between the C-type lectin domains and the N-glycans. Studies showed 
that the binding of CD23 to CD21 was strongly inhibited in CD21-transfected K562 
cells treated by tunicamycin (Aubry, Pochon et al. 1994), which is able to block the 
synthesis of all N-glycans. Therefore, the hyper IgE syndrome with PGM3 
mutations may have atypical glycosylation on CD21, which might enhance the 
affinity of CD21 for CD23. 
 
Previous studies have shown FCER1A is related to total serum IgE levels. 
Investigation of FCER1A SNPs in American, Polish and Korean populations 
reported FCER1A polymorphisms correlates with serum IgE levels (Shikanai, 
Silverman et al. 2002, Potaczek, Sanak et al. 2006, Bae, Kim et al. 2007, Potaczek, 
Sanak et al. 2007, Palikhe, Kim et al. 2008). In addition, GWAS (genome-wide 
association studies) results have shown FCER1A is a genetic determinant for 
serum total IgE levels (Potaczek and Kabesch 2012). FCER1A encodes FcεRIɑ, 
which is the IgE binding subunit of FcεRI. Human FcεRIɑ has a short sequence with 
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257 amino acid residues, but contains as many as 7 potential N-glycosylation sites. 
Structural analysis of FcεRIɑ found all the 7 sites are glycosylated and the glycans 
buried many amino acid residues (Figure 3.18). These glycans might be one of the 
regulators of IgE production.  
 
 
Figure 3.18 N-glycosylation of human FcεRIɑ and the amino acid residues masked 
by glycans 
FcεRIɑ has 7 N-glycosylation sites and the glycans on each site are highlighted with 
different colours. In a and b, the protein is shown as a grey ribbon and glycans as 
colored bonds. A CPK representation is shown in c and d. The protein atoms buried 
by the glycans are highlighted. This figure is taken from Garman, Sechi et al 
(Garman, Sechi et al. 2001). 
3.3.3 Future perspectives 
PGM3 mutations in the patients are predicted to have a profound impact on 
O-GlcNAcylation. Indeed O-GlcNAcylation is known to be hypersensitive to 
UDP-GlcNAc concentration (Hart, Slawson et al. 2011). This important type of 
protein modification is the incorporation of O-GlcNAc onto serine or threonine 
residues of nuclear and cytoplasmic proteins, catalysed by an enzyme known as 
O-linked N-acetylglucosaminyl transferase (OGT) (Hart, Slawson et al. 2011). 
Another enzyme, known as O-GlcNAcase (OGA), is able to remove the O-GlcNAc 
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from modified proteins (Hart, Slawson et al. 2011). Similar to phophorylation, 
O-GlcNAcylation is highly involved in controlling gene expression and signal 
transduction (Hart, Slawson et al. 2011). It is noteworthy that the mouse model with 
hypomorphic mutations in Pgm3 has decreased O-GlcNAcylation (Greig, 
Antonchuk et al. 2007). As a result, impairment of O-GlcNAcylation could be a 
cause of immune diseases in the patients. Nuclear factor-kappaB (NF-κB) is a 
transcription factor that is critical for lymphocyte activation and proliferation, as well 
as cytokine production. In most cell types, NF-κB exists as a dimer consisting of a 
P50 subunit and a P65 subunit (Ozcan, Andrali et al. 2010). The dimer is bound by 
inhibitor IκB and remains in the cytoplasm. O-GlcNAcylation of P65 subunit can 
result in a disruption between NF-κB and IκB, an increase in the migration of NF-κB 
to the cell nucleous, and an enhanced NF-κB trascriptional activity (Yang, Park et al. 
2008).  
 
However, studying O-GlcNAcylation is difficult. In spite of the fact that a few 
antibodies for O-GlcNAcylation have been developed, they have low binding 
affinities and can only be used for the study of highly abundant proteins with 
multiple O-GlcNAcs (Hart, Slawson et al. 2011). In addition, there are no 
site-specific antibodies for site mapping (Hart, Slawson et al. 2011). Mapping 
O-GlcNAcylation sites is difficult even for mass spectrometry, because the linkage 
between an O-GlcNAc and a peptide is very lable and the O-GlcNAc is generally 
eliminated during CID MS/MS sequencing, leaving no information on the site of 
modification (Section 1.8.2). ETD is able to keep O-GlcNAc while sequencing 
peptides (Section 1.8.2) and could be used to investigate the change of 
O-GlcNAcylation in the patients in future work if O-GlcNacylated proteins can be 
isolated in sufficient quantities for glycoproteomic analysis.    
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The scope of the PGM3 studies is limited by the availability of human samples. After 
MS and MS/MS analysis of N-glycans, little is left for studying glycan linkages, 
which could have provided deeper insights into glycosylation. In addition, PGM3 
mutation could affect O-glycosylation; studies have found C2GnT, the enzyme 
responsible for initiating Core 2 O-glycans, has the Km at least 1 mM UDP-GlcNAc 
(Schachter, Brockhausen et al. 1989, Yang, Qin et al. 2003). It has been found that 
the activity of this enzyme is involved in leukocyte trafficking (Ellies, Tsuboi et al. 
1998) and T cell apoptosis (Galvan, Tsuboi et al. 2000). Therefore, it is important to 
study the O-glycosylation in the PGM3 patients, particularly those from Family 2, as 
their mutation could affect GlcNAc-T II, whose Km is 0.96 mM UDP-GlcNAc. 
However, no O-glycomic data was obtained, although experiments were tried on a 
limited amount of samples, because O-glycomic analysis requires larger sample 
amounts than N-glycomic studies. Measuring the concentration of UDP-GlcNAc 
could reflect the activity of PGM3 enzyme in the patients. Again, due to the lack of 
samples, the experiment could not be performed. These experiments could be done 
if enough samples are collected in the future.  
3.4 Summary 
A novel hyper IgE syndrome was discovered in three independent families recently. 
The disease is linked to mutations in PGM3. The mutations are L83S, E340 deletion, 
and D502Y in Family 1, Family 2 and Family 3 respectively. The function of PGM3 
protein is to catalyze the reversible conversion of GlcNAc-6-P and GlcNAc-1-P, 
providing the substrate to synthesize UDP-GlcNAc. The supply of UDP-GlcNAc has 
a significant impact on cellular glycosylation. N-glycans from the patients were 
analyzed by highly sensitive Mass Spectrometry. The results of EBV treated B cells 
and neutrophils showed a decrease in tri-/tetra-antennary glycans in the patients, 
which is consistent with the high Km values of GlcNAc-T IV and V for UDP-GlcNAc. 
The EBV treated B cells of Family 2 showed a substantial increase in hybrid 
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glycans. In addition, a hybrid glycan was observed in the plasma from Family 2. 
These observations suggest the mutation in Family 2 is more sever, which is 
consistent with Western blot data and clinical findings. A reduction in fucosylation 
was observed in neutrophils, which suggest impaired neutrophil migration to sites of 
infection. Decreased galactosylation was observed in patients’ IgG, which correlates 
with recurrent infections.  
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Chapter 4 
 
Glycomic and glycoproteomic analysis of 
human IgE 
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4 Glycomic and glycoproteomic analysis of 
human IgE  
4.1 Background  
IgE is the most heavily glycosylated antibody, which has as many as seven 
potential glycosylation sites in ε chain C region at Asn21, 49, 99, 146, 252, 264 and 
275 (Figure 4.1). This antibody plays a key role in allergic responses (Section 1.3.4). 
However, during the course of this thesis work, little was known about the 
glycosylation of this antibody, due to its extremely low level in serum (0.0003 mg/ml) 
(Table 1.3). Some patients with myeloma disease, as well as the patients with 
allergy or hyper IgE syndrome exhibit elevated levels of serum IgE, which enables 
the preparation of IgE samples for analysis. In the 1970s, monosaccharide 
compositions at each potential glycosylation sites on a myeloma IgE were 
measured (Table 4.1) (Dorrington and Bennich 1978). The results showed high 
variations of glycosylation among the seven sites. For example, Asn264 was not 
glycosylated. Only Man and GlcNAc residues were detected at Asn275, suggesting 
that this site is modified by high mannose glycans. In addition, Asn99 and Asn146 
had a trace amount of fucosylation but high sialylation. By contrast, Asn21 and 
Asn49 had higher levels of fucosylation but lower sialylation. However, the problem 
of this study is that the monosaccharide compositions cannot tell the exact glycan 
structures at each site. In 2004, an IgE from an atopic patient was analyzed using 
HPLC (Arnold, Radcliffe et al. 2004), which gives an overall profile of N-glycans on 
IgE (Table 4.2). Twenty two glycans were detected, which included both high 
mannose glycans and complex glycans. Most glycans were sialylated, which 
consisted of more than 75% of the glycan pool. Almost 60% of glycans in the glycan 
pool were core fucusylated, and 13% glycans in the glycan pool contained bisecting 
GlcNAc. However, the data cannot tell how these glycans are distributed on each 
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glycosylation site on IgE.  
 
Figure 4.1 Sequence of human Ig ε chain C region 
The sequence is from http://www.uniprot.org/uniprot/P01854. The potential 
glycosylation sites are indicated by red arrows.  
 
Table 4.1 Monosaccharide compositions at each glycosylation site on Ig ε chain C 
region of a myeloma IgE 
Glycosylation site Fuc Man Gal GlcNAc Sia 
Asn 21 1.3 3.3 2.5 3.9 0.5 
Asn 49 1.5 3.8 2.7 5.0 0.7 
Asn 99 trace 3.3 2.6 3.8 2.3 
Asn146 trace 3.0 2.4 3.5 2.1 
Asn 252 0.7 3.4 2.1 3.3 1.3 
Asn 275 nil 5.7 trace 2.0 nil 
 
The trimethylsilyl (TMS) derived monosaccharides from each site were analyzed 
using gas-liquid chromatography (GLC). Asn264 is not occupied by glycans. Data 
are from (Dorrington and Bennich 1978). 
 
 
165 
 
 
Table 4.2 Glycan profiling of an atopic IgE using HPLC 
Structure % Glycan pool Structure % Glycan pool Structure % Glycan pool 
 0.3 
 
1.0 
 
8.2 
 0.4 
 
1.1 
 
8.3 
 
0.5 
 
1.2 
 
11.0 
 
0.5 
 
1.3 
 
11.3 
 
0.7 
 
1.4 
 
18.1 
2X
 
0.7 
 
1.6 
 
25.1 
 
0.7 
 
2.2   
 
0.8 
 
3.7   
 
Both high mannose and complex glycans were observed. Sialylation, core 
fucosylation and bisecting GlcNAc were commonly found. Data are from (Arnold, 
Radcliffe et al. 2004). 
 
The aim of our hyper IgE syndrome study was to find the glycan profile at each IgE 
glycosylation site.  Two IgE samples were prepared from sera for analysis; one 
was from a patient with atopic dermatitis, while the other one was from a PGM3 
patient. The IgE samples were prepared by a modified immunoprecipitation method, 
and then digested by trypsin or chymotrypsin. For glycomic analysis, glycans were 
released from the glycopeptides, permethylated and analyzed using the 4800 
MALDI TOF/TOFTM Analyzer. For glycoproteomic analysis, the glycopeptides were 
analyzed using an API QSTARTM Pulsar Hybrid LC/MS/MS system.  
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4.2 Results 
4.2.1 Preparation and proteomic identification of IgE 
IgE was prepared from serum/plasma samples using immunoprecipitation. There 
are two types of immunoprecipitation: classic immunoprecipitation and direct 
immunoprecipitation. With the former one immobilizes antibodies to beads via 
protein A/G, while the later one immobilizes antibodies on beads covalently through 
a chemical reaction. Data from the supplier of the immunoprecipitation kit indicate 
that classic immunoprecipitation has the better antigen yield. However, severe 
contamination of IgG was observed in our experiment when the classic method was 
used, although an IgG depletion step was added before the immunoprecipitation. In 
the SDS-PAGE analysis, the IgE band almost merged with the IgG band (data not 
shown). It is very likely that serum IgG bound to protein A/G on the beads and was 
co-eluted with IgE. As a result, the direct method was chosen for IgE preparation. 
IgG contamination was dramatically reduced and was clearly separated from IgE in 
SDS-PAGE gel (Figure 4.2). A clear band was observed between 160 kDa and 220 
kDa, which is close to the molecular weight of IgE (190 kDa). Both bands were 
identified as human IgE by proteomic analysis using the 4800 MALDI TOF/TOFTM 
Analyzer (Table 4.3, Table 4.4). The two IgE bands were subjected to glycomic and 
glycoproteomic analysis.  
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Figure 4.2 SDS-PAGE of immunoprecipitated IgE 
600 ul of serum from an atopic patient and 600 ul of plasma from a patient with 
hyper IgE syndrome were used to prepare IgE. Elutions of immunoprecipitation 
were analyzed by non-reduced SDS-PAGE in 3-8% Tris-acetate gel with 
Tris-acetate running buffer. Lane 1: Control resin. Lane 2: Immunoprecipitated IgE. 
A band was observed between 220 kDa and 160 kDa in Lane 2, which is consistent 
with the molecular weight of IgE.    
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Table 4.3 Proteomic identifcation of IgE prepared from an atopic serum 
 
The protein in the gel band was digested by trypsin. The peptides were extracted 
for MALDI MS and MS/MS analysis.  
 
Table 4.4 Proteomic identifcation of IgE prepared from a PGM3 patient 
 
The protein in the gel band was digested by trypsin. The peptides were extracted 
for MALDI MS and MS/MS analysis.  
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4.2.2 Glycomic analysis of IgE 
The IgE gel bands were in-gel digested by trypsin. The (glyco) peptides were 
extracted from the gel and glycans were removed using PNGase F. Permethylated 
glycans were analyzed using the 4800 MALDI TOF/TOFTM Analyzer. The N-glycan 
profile of the atopic IgE is shown in Figure 4.3. Both high mannose and complex 
glycans were detected. Man5 and Man6 are the major components of the high 
mannose glycans. Lower abundances of Man7, Man8 and Man9 were observed. A 
tri-antennary glycan was detected at m/z 3055. All the other complex glycans had 
bi-antennary structures and most of them are sialylated and core fucosylated, 
especially the three glycans at m/z 2605, m/z 2850 and m/z 2967, which were 
detected with high abundance. Bisecting glycans were commonly observed, like 
glycans at m/z 2489, m/z 2850. Another bisecting glycan with two sialic acids was 
found at m/z 3212 with low intensity. Incompletely processed glycans with terminal 
GlcNAc were detected at m/z 1836, m/z 2040 and m/z 2285. Two non-fucosylated 
complex glycans were detected at m/z 2431 and m/z 2792 with low intensity. The 
N-glycan profile of the IgE from a patient with PGM3 mutation is shown in Figure 4.4. 
The glycosylation of this IgE is very similar to that of the atopic IgE.  
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Figure 4.3 Glycomic analysis of the atopic IgE 
Both high mannose glycans and complex glycans were observed. The complex 
glycans are highly sialylated and fucosylated. Glycans were permethylated and 
data were acquired in the form of [M+Na]+ ions. Peaks were annotated with putative 
structures according to the molecular weight and the glycan biosynthetic pathway of 
human B cells.  
 
 
 
Figure 4.4 Glycomic analysis of the IgE from a PGM3 patient 
Both high mannose glycans and complex glycans were observed. The complex 
glycans are highly sialylated and fucosylated. Glycans were permethylated and 
data were acquired in the form of [M+Na]+ ions. Peaks were annotated with putative 
structures according to the molecular weight and the glycan biosynthetic pathway of 
human B cells. 
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4.2.3 Glycoproteomic analysis of IgE 
The IgE (glyco)peptides produced by trypsin or chymotrypsin were analyzed using 
the API QSTARTM Pulsar Hybrid LC/MS/MS mass spectrometer. Glycosylation at 
Asn21 and Asn49 were detected in two chymotryptic glycopeptides, while 
glycosylation at Asn99, Asn252, and Asn275 were detected in three tryptic 
glycopeptides (Table 4.5). Asn264 was detected in a tryptic peptide, but no 
glycosylation was observed. The peptide with Asn146 was not detected in either the 
trypsin or the chymotrypsin digestion products.  
 
Table 4.5 IgE glycopeptides mapped by on-line LC-MS 
 
The glycosylation sites are highlighted in red. The position of each site on Ig ε chain 
C is shown above.    
4.2.3.1 Glycosylation at Asn21 
Glycosylation at Asn21 of the atopic IgE is shown in Figure 4.5. The glycopeptides 
were detected in three fractions eluted between 37.5-38.5 min (fraction A), 40-41 
min (fraction B), and 43-45 min (fraction C) respectively. All glycans are fucosylated, 
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bi-antennary structures. No sialylation was observed in fraction A (Figure 4.5 A), 
while mono-sialylation and bi-sialylation were observed in fraction B and fraction C 
respectively (Figure 4.5 B and Figure 4.5 C). Glycosylation at Asn21 of the IgE from 
the PGM3 patient is shown in Figure 4.6. Similar to the results of the atopic IgE, the 
glycopeptides were detected in three fractions. Fraction A is eluted between 30.5 
min and 31.5 min, which contained non-sialylated glycans (Figure 4.6 A), fraction B 
is between 32.5 min and 33.5 min, which contained mono-sialylated glycans (Figure 
4.6 B), and fraction C is between 35 min and 37 min, which contains bi-sialylated 
glycans (Figure 4.6 C). The glycan profile in each fraction is similar to that in the 
atopic IgE.  
 
The data suggested that glycopeptides with more sialic acid residues were eluted 
later. But it appears that there were exceptions. For example, non-sialylated 
glycans were also observed in Figure 4.5 B and Figure 4.6 B (m/z 1198.13+, m/z 
1265.83+). However, the extracted-ion chromatogram (XIC) data suggest that the 
two glycopeptides were eluted in two fractions. The first fraction was fraction A (XIC 
data not shown here), while the second fraction was co-eluted with their 
mono-sialylated counterparts at m/z 1295.23+ and m/z 1362.93+ respectively (Figure 
4.7), which strongly supports that the glycopeptides at m/z 1198.13+ and m/z 
1265.83+ in fraction B were mono-sialylated in the nanoLC system, but the sialic 
acid residues were lost in the MS system due to in-source fragmentation. The 
mono-sialylated glycopeptides observed in Figure 4.5 C (m/z 1295.23+, m/z 
1362.93+) and Figure 4.6 C (1362.93+) were co-eluted with their bi-sialylated 
counterparts and were also probably from in-source fragmentation (Figure 4.8). A 
small amount of incompletely processed structures were detected, like m/z 
1533.12+ and m/z 1614.12+ in fraction B. The XIC show they were also probably the 
in-source fragments of their fully processed counterparts (Figure 4.9).  
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Figure 4.5 Glycosylation of the atopic IgE at Asn 21 
The ions are in the form of M+nHn+. Glycopeptides were detected in 3 fractions. 
Fraction A was eluted from 37.5 min to 38.5 min (panel A), fraction B was eluted 
from 40 min to 41 min (panel B), and fraction C was from 43 min to 45 min (panel C). 
The glycan structures were deduced according to the molecular weight and 
N-glycosylation pathway of human B cells. Non-sialylated glycans were observed in 
fraction A, mono-sialylated glycans were detected in fraction B, and bi-sialylated 
glycans were in fraction C. All glycans are fucosylated.  
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Figure 4.6 Glycosylation of the IgE at Asn 21 from a PGM3 patient  
The ions are in the form of M+nHn+. Glycopeptides were detected in 3 fractions. 
Fraction A was eluted from 30.5 min to 31.5 min (panel A), fraction B was eluted 
from 32.5 min to 33.5 min (panel B), and fraction C was from 35 min to 37 min 
(panel C). The glycan structures were deduced according to the molecular weight 
and N-glycosylation pathway of human B cells. Non-sialylated glycans were 
observed in fraction A, mono-sialylated glycans were detected in fraction B, and 
bi-sialylated glycans were in fraction C. All glycans are fucosylated.  
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Figure 4.7 XIC of IgE glycopeptides at m/z 1198.13+, m/z 1265.83+, m/z 1295.23+ 
and m/z 1362.93+ 
XIC data of the atopic IgE (A) and the IgE from a PGM3 patient (B) are shown. The 
non-glycosylated glycopeptides in Figure 4.5 B and Figure 4.6 B were co-eluted 
with their mono-sialylated counterparts from the nanoLC system.     
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Figure 4.8 XIC of mono-sialylated and bi-sialylated IgE glycopeptides 
The peptides were chosen from Figure 4.5 C and Figure 4.6 C and the XIC is 
shown in panel A and panel B respectively. The mono-sialylated peptides were 
co-eluted with their bi-sialylated counterparts from the nanoLC system.   
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Figure 4.9 XIC of IgE glycopeptides at m/z 1198.13+, m/z 1533.12+ and m/z 1614.12+ 
Peaks at m/z 1198.13+, m/z 1533.12+ and m/z 1614.12+ of the atopic IgE (A) and the 
IgE from the patient with PGM3 mutation (B). The incompletely processed glycans 
at m/z 1533.12+ and m/z 1614.12+ were most probably the in-source fragments of 
their completely processed counterpart (for example m/z 1198.13+ shown in this 
figure).  
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4.2.3.2 Glycosylation at Asn49 
Glycosylation at Asn49 of the atopic IgE and the IgE from a patient with PGM3 
mutation is shown in Figure 4.10 and Figure 4.11 respectively. No significant 
differences were observed between the two IgE samples at this site.  
 
The elution pattern of glycopeptides with Asn49 were similar to that of 
glycopeptides with Asn 21; non-sialylated, mono-sialylated and bi-sialylated 
glycopeptides were eluted in fraction A, B, and C respectively (Figure 4.10, Figure 
4.11). The glycan structures at Asn49 were similar to those at Asn21; all glycans are 
fucosylated, with bi-antennary structures.  
 
The mono-sialylated glycan in fraction C (m/z 12573+ in Figure 4.10 C and Figure 
4.11 C) was probably from their bi-sialylated counterparts (m/z 1354.23+ and m/z 
1015.94+ in Figure 4.10 C and Figure 4.11 C respectively) according to the XIC data 
(not shown here). The XIC data (not shown here) also suggest the incompletely 
processed glycans like m/z 1702.62+ and m/z 1804.12+ were from their completely 
processed counterparts.   
 
ESI-CID-MS/MS data of m/z 12573+ and 10664+ are shown in Figure 4.12 and 
Figure 4.13. Simiar to the previous study using the same instrument (Figure 1.33) 
(Harrison, Hitchen et al. 2012), the two spectra were dominated by glycan 
fragments, such as a GlcNAc at m/z 204.1+, a sialic acid at m/z 292.1+, and a 
LacNAc unit at m/z 366.1+. In addition, GlcNAc with losses of water molecules (m/z 
186.1+ and m/z 168.1+) and sialic acid with losses of water molecules (m/z 274.1+ 
and m/z 256.1+) were observed. These peaks provide diagnostic ions for the 
presence of glycopeptides. No fucosylation was observed on LacNAc substructures, 
which indicates the glycan had a core Fuc structure.  
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Figure 4.10 Glycosylation of the atopic IgE at Asn 49 
The ions are in the form of M+nHn+. Glycopeptides were detected in 3 fractions. 
Fraction A was eluted from 47.2 min to 48.2 min (panel A), fraction B was eluted 
from 51.4 min to 52.4 min (panel B), and fraction C was from 57 min to 59 min 
(panel C). The glycan structures were deduced according to the molecular weight 
and N-glycosylation pathway of human B cells. Non-sialylated glycans were 
observed in fraction A, mono-sialylated glycans were detected in fraction B, and 
bi-sialylated glycans were in fraction C. All glycans are fucosylated.  
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Figure 4.11 Glycosylation of the IgE at Asn49 from a PGM3 patient 
The ions are in the form of M+nHn+. Glycopeptides were detected in 3 fractions. 
Fraction A was eluted from 37 min to 38 min (panel A), fraction B was eluted from 
40 min to 42 min (panel B), and fraction C was from 46 min to 47.5 min (panel C). 
The glycan structures were deduced according to the molecular weight and 
N-glycosylation pathway of human B cells. Non-sialylated glycans were observed in 
fraction A, mono-sialylated glycans were detected in fraction B, and bi-sialylated 
glycans were in fraction C. All glycans are fucosylated.  
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Figure 4.12 ESI-CID-MS/MS of an atopic IgE glycopeptide at m/z 12573+ 
The ions are in the form of M+H+. The spectrum is dominated by glycan fragments, 
such as GlcNAc at m/z 204.1+, sialic acid at m/z 274.1+ and LacNAc unit at m/z 
366.1+. Losses of water molecules from GlcNAc and sialic acid were also detected. 
Fucosylated LacNAc unit was not observed. A few fragments of peptide backbone 
were observed at m/z 502.2+ and 615.3+.  
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Figure 4.13 ESI-CID-MS/MS of an atopic IgE glycopeptide at m/z 10664+ 
The ions are in the form of M+H+. The spectrum is dominated by glycan fragments, 
such as GlcNAc at m/z 204.1+, sialic acid at m/z 274.1+ and LacNAc unit at m/z 
366.1+. Losses of water molecules from GlcNAc and sialic acid were also detected. 
A few fragments of peptide backbone were observed at m/z 502.2+ and 615.3+.  
4.2.3.3 Glycosylation at Asn99 
Glycosylation at Asn99 was detected on a tryptic peptide. The glycopeptides of the 
atopic IgE were eluted between 24 min and 26 min (Figure 4.14), and the 
glycopeptides of the IgE from a patient with PGM3 mutation were eluted between 
21 min and 23 min (Figure 4.15). No significant differences of glycosylation were 
observed at this site between the two IgE samples.  
 
A non-fucosylated glycan at m/z 1157.43+ was detected in both samples with low 
intensity. All the other gycans were fucosylated. The majore glycans had 
bi-antennary structures with sialic acid, like m/z 1206.13+ and 1303.23+. 
183 
 
Tri-antennary glycans were observed at m/z 996.24+, m/z 1327.93+, and 1424.93+. 
The tri-antennary glycan at 1424.93+ with two sialic acids was not detected in the 
glycomic data (Figure 4.3, Figure 4.4), probably because it was below the detection 
limit. A small amount of non-sialylated glycans were detected, such as the peaks at 
m/z 1109.13+ and m/z 1163.22+.  
 
ESI-CID-MS/MS of the glycopeptide at m/z 1206.13+ is shown in Figure 4.16. 
Similar to the fragment patterns observed in Figure 4.12 and Figure 4.13, glycan 
fragments at low m/z range dominated the spectrum. The peptide containing a 
GlcNAc residue (m/z 880.42+ and m/z 1759.9+) and the peptide with a GlcNAc and a 
Fuc residue (m/z 1905.8+) were detected, which provides strong evidence for the 
presence of core Fuc structure. Fragmentation on the peptide backbone is 
observed in the form of b and y ions, which provide information for the peptide 
sequence (Figure 4.16). Peptide fragments in the form of y ions with glycan 
fragments were also detected, which provides additional information on both 
peptide sequence and glycan core structures (Figure 4.16).  
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Figure 4.14 Glycosylation at Asn99 of the atopic IgE 
The ions are in the form of M+nHn+. The glycopeptides were eluted from 24 min to 
26 min. The glycan structures on the peptides were deduced according to the 
molecular weight and N-glycosylation pathway of human B cells.   
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Figure 4.15 Glycosylation at Asn99 of the IgE from a PGM3 patient  
The ions are in the form of M+nHn+. The glycopeptides were eluted from 21 min to 
23 min. The glycan structures on the peptides were deduced according to the 
molecular weight and N-glycosylation pathway of human B cells.  
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Figure 4.16 ESI-CID-MS/MS of an atopic IgE glycopeptide at m/z 1206.13+ 
The ions are in the form of M+nHn+. The major peaks are glycan fragments at low 
m/z range, such as the peaks at m/z 204.1+ (GlcNAc), m/z 292.1+ (sialic acid) and 
m/z 366.1+ (LacNAc unit). Losses of water molecules from the GlcNAc and sialic 
acid were observed. Peptide with glycan fragments were detected at m/z 880.42+ 
(peptide+GlcNAc+2H+), m/z 1759.9+ (peptide+GlcNAc+H+) and m/z 1905.8+ 
(peptide+GlcNAc+Fuc+H+). Fragmentation on both peptide backbone and glycans 
were detected at m/z 982.12+, 1063.02+, 1144.02+ and m/z 1351.6+. The IgE 
glycopeptide from the PGM3 patient showed similar fragmentation and therefore is 
not shown here.   
4.2.3.4 Glycosylation at Asn252 and Asn275 
Glycosylation at Asn252 of the atopic IgE is shown in Figure 4.17 (the first fraction) 
and Figure 4.18 (the second fraction). The first fraction was eluted from 29.5 min to 
34 min and contained mainly mono-sialylated glycans, such as m/z 1099.43+ and 
m/z 1031.73+. A tri-antennary glycan with a single sialic acid was detected at m/z 
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1153.53+. The second fraction was eluted between 37 min and 39 min, containing 
mainly bi-sialyated glycans. A tri-antennary glycan with two sialic acid residues was 
observed with low intensity at m/z 1250.53+, which was not detected in the glycomic 
data.   
 
Asn275 of the atopic IgE only contained high mannose glycans (Figure 4.17). 
Surprisingly, a glycopeptide with a single GlcNAc was observed at m/z 860.42+. 
According to the XIC data (Figure 4.19), the glycopeptide with a smaller high 
mannose glycan tended to be eluted later, but the glycopeptide with a single 
GlcNAc was co-eluted with other glycopeptides with high mannose glycans, which 
suggests the peak at m/z 860.42+ was most probably the in-source fragments of 
high mannose glycans. The other IgE sample exhibited similar glycosylation at this 
site (Figure 4.20 and Figure 4.21) compared to the atopic IgE.  
 
ESI-CID-MS/MS of m/z 1002.43+ of the PGM3 patient is shown in Figure 4.22. The 
major peaks were GlcNAc at m/z 204.1 and LacNAc unit at m/z 366.1. Sialic acid 
was not observed, which is consistent with the MS annotation that this glycopeptide 
was not sialylated.  Peptide+GlcNAcFuc+H+ and peptide+GlcNAc2Fuc+H+ were 
detected at m/z 1382.6+ and m/z 1585.6+ respectively, which confirmed that the 
location of the Fuc residue was at the core structure.  
 
 
 
 
 
 
 
 
188 
 
 
 
 
    
 
 
 
Figure 4.17 Glycosylation at Asn252 (the first fraction) and Asn275 of the atopic IgE 
The ions are in the form of M+nHn+. Glycopeptides were eluted between 29.5 min 
and 34 min. Glycans attached to Asn252 were mainly fucocylated, mono-sialylated 
structures with two antennae (peptide backbone is in yellow). All glycans attached 
to Asn275 had high mannose structures (peptide backbone is in purple). The glycan 
structures on the peptides were deduced according to the molecular weight and 
N-glycosylation pathway of human B cells.  
 
 
 
189 
 
 
 
Figure 4.18 Glycosylation at Asn252 (the second fraction) of the atopic IgE 
The ions are in the form of M+nHn+. The glycopeptides were eluted from 37 min to 
39 min. Bi-sialylated structures were mainly observed. The glycan structures on the 
peptides were deduced according to the molecular weight and N-glycosylation 
pathway of human B cells. 
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Figure 4.19 XIC of IgE glycopeptides with high mannose glycans and the one with a 
single GlcNAc 
The glycopeptides at m/z 860.42+ was co-eluted with other glycoepeptides with high 
mannose glycans, which provides strong evidence that the single GlcNAc was the 
result of in-source fragmentation of other high mannose glycans.  
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Figure 4.20 Glycosylation at Asn252 (the first fraction) and Asn275 of the IgE from a 
PGM3 patient  
The ions are in the form of M+nHn+. Glycopeptides were eluted between 27.5 min 
and 32 min. Glycans attached to Asn252 were mainly fucocylated, mono-sialylated 
structures with two antennae. All glycans attached to Asn275 had high mannose 
structures. The glycan structures on the peptides were deduced according to the 
molecular weight and N-glycosylation pathway of human B cells. 
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Figure 4.21 Glycosylation at Asn252 (the second fraction) of the IgE from a PGM3 
patient 
The ions are in the form of M+nHn+. The glycopeptides were eluted from 34.5 min to 
36.5 min. Bi-sialylated structures were mainly observed. The glycan structures on 
the peptides were deduced according to the molecular weight and N-glycosylation 
pathway of human B cells. 
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Figure 4.22 ESI-CID-MS/MS of an IgE peptide at m/z 1002.43+ from PGM3 patient  
The ions are in the form of M+H+. The spectrum is dominated by glycan fragments, 
such as GlcNAc at m/z 204 and LacNAc unit at m/z 366. Peptide backbone was 
detected at 1033.5+. Peptide + GlcNAc + H+, peptide + GlcNAcFuc + H+, peptide + 
GlcNAc2 + H+, peptide +  GlcNAc2Fuc + H+, and peptide+GlcNAc2+Man+H+ were 
observed.    
4.2.3.5 Glycosylation at Asn264 
No glycosylation was observed at Asn264 and the unglycosylated tryptic peptide 
was detected in both IgE samples (Figure 4.23, Figure 4.24) at m/z 385.23+ and m/z 
577.32+. The MS/MS of m/z 385.23+ peptide of the atopic IgE is shown in Figure 4.25, 
which confirmed the presence of the non-glycosylated peptide. The peptide at m/z 
385.23+ from the other IgE was not selected by the instrument for MS/MS analysis.  
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Figure 4.23 Asn 264 detected in a tryptic peptide of the atopic IgE 
The peptide was eluted from 38 min to 42 min. No glycosylation was observed on 
this peptide.    
 
 
  
 
Figure 4.24 Asn 264 detected in a tryptic peptide of the IgE from a PGM3 patient.  
The peptide was eluted from 36 min to 40 min. No glycosylation was observed on 
this peptide. 
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Figure 4.25 MS/MS analysis of m/z 385.23+ from the atopic IgE peptide 
The masses of fragments provide strong evidence for the peptide sequence shown 
in the spectrum.   
  
4.3 Discussion  
During the course of this thesis work, the glycan structures at each IgE 
glycosylation site had not been reported. The glycoproteomic strategy here mapped 
6 of 7 potential glycosylation sites. In spite of the fact that the two IgE samples 
belong to two types of diseases, the glycosylation on each site was similar. This is 
consistent with the glycomic results, which also showed the overall glycan profile 
was similar. These observations indicate IgE glycosylation is similarly regulated 
between atopic dermatitis and PGM3 related hyper IgE syndrome.  
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Table 4.6 Distribution of glycan structures among the IgE glycosylation sites 
mapped using glycoproteomic strategy 
Glycosylation site Glycan structures 
Asn 21 
      
Asn 49 
       
Asn 99 
         
Asn 252 
        
Asn 275 
    
 
The glycans shown in the glycomic data were distributed differently among IgE 
glycosylation sites (Table 4.6). Among the 6 mapped glycosylation sites, no 
glycosylation was found at Asn 264, high mannose glycans were only found at Asn 
275, tri-antennary glycans were only observed at Asn 99 and Asn 252, and 
non-fucosylated complex glycans were only detected at Asn99. The ratio of the 
bisecting glycan with two sialic acids to its non-bisecting counterpart was low in the 
glycomic data (m/z 3212 relative to m/z 2967) (Figure 4.3, Figure 4.4). However, 
this ratio varied at different glycosylation sites; the highest ratio was found at Asn 
252 (m/z 1196.43+ relative to m/z 1128.83+) (Figure 4.18, Figure 4.21), while the 
lowest was at Asn 99 (m/z 1370.83+ relative to m/z 1303.23+) (Figure 4.14, Figure 
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4.15). For an individual glycoprotein, the glycosylation environment provided by the 
Endoplastic Reticulum and the Golgi complex are the same. However, 
macro-heterogeneity is commonly found on glycoproteins, possibly because the 
surrounding sequences near glycosylation sites and the 3-D structure of a 
glycoprotein can affect the access of glycosyltransferases or glycosidases, resulting 
in varied glycosylation. The 3-D structure of IgE may be the reason for the presence 
of high mannose glycans at Asn275 (Table 4.6). Molecular modeling shows that 
these high mannose glycans are not on the surface of this antibody (Figure 4.26). 
This model coincides with the observation that mannose binding lectin showed a 
higher binding affinity for unfolded IgE (Arnold, Radcliffe et al. 2004). It is possible 
that IgE folds during the glycosylation pathway, so that the enzymes involved in the 
trimming and elongating processes cannot have access to the high mannose 
glycans.  
 
 
Figure 4.26 A molecular model of IgE based on crystal structures  
The complex glycans, which are highted in red, are on the surface of the protein, 
while the high mannose glycans, which are in green, are within the protein. The light 
chain is in purple, and the heavy chain is in blue. This figure is taken from Arnold, 
Wormald et al (Arnold, Wormald et al. 2007).  
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Previous studies (Baenziger, Kornfeld et al. 1974, Baenziger, Kornfeld et al. 1974, 
Dorrington and Bennich 1978) measured the monosaccharide composition of each 
glycosylation site on a myeloma IgE (Table 4.1) and showed that Asn264 was not 
occupied by glycans and Asn275 contained only high mannose glycans, which is 
consistent with our glycoproteomic data. Although the monosaccchride composition 
of a glycosylation site cannot tell the exact profile of glycan structures, it reveals the 
status of fucosylation. As each complex glycan has 3 mannoses, the ratio of Fuc 
residues to Man 1/3 residues indicates the number of Fuc per glycan. In the 
myeloma IgE the ratios at Asn 21 and Asn 49 were 1.2 (Table 4.1), which means the 
majority of glycans at the two sites had a Fuc residue. This is consistent with our 
glycoproteomic data, which showed all glycans at Asn 21 and Asn 49 were core 
fucosylated (Figure 4.5, Figure 4.6). However, the myeloma IgE had different 
fucosylation at Asn 99 and Asn 252. The ratio of Fuc to 1/3 Man at Asn 252 was 
0.61 in the myeloma IgE (Table 4.1), which means around 40% of glycans did not 
have Fuc, but in the atopic IgE and the IgE from a donor with PGM3 mutation, all 
glycans were fucosylated at this site (Figure 4.17, Figure 4.18, Figure 4.20 and 
Figure 4.21). A trace amount of Fuc was detected in the myeloma IgE at Asn 99 
(Table 4.1), while the glycans were highly fucosylated at this site in the two IgE 
samples we analyzed (Figure 4.14, Figure 4.15). Moreover, our glycomic and 
glycoproteomic data showed the complex glycans were highly sialylated, but the 
myeloma IgE had low sialylation at Asn 21 and Asn 49. These observations suggest 
IgE glycosylation was differently regulated in the myeloma disease. 
 
A previous report (Arnold, Radcliffe et al. 2004) using HPLC based glycomic 
analysis of an atopic IgE did not detect any tri-antennary glyan, Man9 glycan or 
bi-sialylated bisecting glycans, but these structures were observed in our glycomic 
and glycoproteomic data, probably due to the fact that mass spectrometry is more 
sensitive than HPLC. In addition, this report indicated all the seven sites were 
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occupied by N-glycans. However, our results together with previous studies 
(Baenziger, Kornfeld et al. 1974, Baenziger, Kornfeld et al. 1974, Dorrington and 
Bennich 1978) and a most recent report (Plomp, Hensbergen et al. 2014) show Asn 
264 is not glycosylated.  
 
Asn146 was not mapped in this study, although several efforts were tried. Mass 
spectrometry has bias against some (glyco) peptides, probably because they are 
difficult to ionize (Mallick, Schirle et al. 2007). This phenomenon occurs commonly 
in the field of proteomics and it is not usual for proteomic analysis to have a 100% 
sequence coverage (Cox and Mann 2011). Compared to peptides, glycopeptides 
are more difficult to be detected by mass spectrometers, so it is not surprising to 
miss some glycosylation sites during glycoproteomic analysis.  
4.4 Summary  
IgE is the most heavily glycosylated antibody, but the glycosylation is not well 
studied, due to its low level in the serum. During the couse of this thesis work, no 
studies had provided the glycan profile of each glycosylation site on IgE. In this 
study, two IgE samples were prepared from an atopic patient and a PGM3 patient. 
The glycosylation was investigated by mass spectrometry. Six of seven potential 
glycosylation sites were mapped. Both glycomic and glycoproteomic approaches 
found similar glycosylation between the two samples. Glycoproteomic data 
revealed macro- and micro-heterogeneity of glycosylation. No glycosylation was 
found at Asn 264, high mannose glycans were only found at Asn275, tri-antennary 
glycans were only observed at Asn 99 and Asn 252, and non-fucosylated complex 
glycans were only detected at Asn99. Most of the complex glycans were highly 
sialylated with core fucosylation. Bisecting GlcNAc was commonly found. 
Compared to the analysis of a myeloma IgE, the two IgE samples had higher levels 
of fucosylation at Asn 99 and Asn 252 and enhanced sialylation at Asn 21 and  
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Asn 49. These observations indicate that the glycosylation is differently regulated in 
the myeloma IgE.     
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Chapter 5 
 
Glycomic analysis of a novel congenital 
disorder of glycosylation 
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5 Glycomic analysis of a novel congenital 
disorder of glycosylation 
5.1 Background 
Congenital disorders of glycosylation (CDG) are a group of diseases caused by 
deficiencies in N-glycosylation (Freeze 2006). Nineteen types of CDGs have been 
idenfied in around 600 patients with a wide range of symptoms (Freeze 2006), 
including immune disorders. The death rate in the first five years of life is about 20% 
(Freeze 2006). CDGs can be divided into two groups: CDG-I and CDG-II. CDG-I is 
caused by defects of genes involved in the synthesis of the N-glycan precursor or in 
the transfer of the precursor to a glycosylation site, while CDG-II is caused by 
genetic defects involved in the modification of a protein bound N-glycan. Therefore, 
CDG-I results in the loss of an entire N-glycan at a glycosylation site, whereas 
CDG-II results in abnormal trimming and elongation of an N-glycan. Each group has 
subgroups which are indicated by lower case letters according to the chronological 
order of identification of the defective gene. For example, CDG-Ia was identified 
earlier than CDG-Ib.  
Although CDGs affect a wide range of glycoproteins, the most popular indicator for 
this type of disease is transferrin. The glycosylation on transferrin is quite 
homogeneous, making it a sensitive marker for CDG diagnostics (Freeze 2006). 
Transferrin has two glycosylation sites at Asn413 and Asn611, each of which is 
mainly occupied by bi-antennary glycans with two sialic acid residues. Sialylation is 
usually at the end of the glycosylation pathway, so defects in the previous 
glycosylation steps could change the number of sialic acid residues on transferrin 
and result in a different isoelectric point. One of the methods to diagnose CDG is 
isoelectric focusing (IEF). IEF is able to separate transferrin molecules with different 
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numbers of sialic acid residues (Marklova and Albahri 2007). For CDG type I, an 
increase in disialo- and asialo-transferrin band could be detected in IEF analysis, 
which reflects the loss of one and two entire glycans respectively. For CDG type II, 
an enhanced mono- and tri-sialo transferrin could be observed besides disialo- and 
asialo-transferrin band (Marklova and Albahri 2007).  
Mass spectrometry is another method which can provide more informative data for 
CDG diagnostics than IEF analysis. Defects of glycosylation can change the 
molecular weights of glycans, which can be detected by mass spectrometry with 
high accuracy. For example, ESI-MS analysis of intact transferrin can easily detect 
the loss of an entire glycan for the CDG-I test. For the CDG-II test, ESI-MS is able 
to identify the changes of monosaccharides on an intact transferrin. However, in 
some cases, ESI-MS analysis of a CDG transferrin could reveal a shift of molecular 
weight which can neither be explained as a loss of an entire glycan nor be 
considered as a change of monosaccharide. For example, a CDG has been 
discovered recently with immune abnormalities; the patient exhibits a high number 
of neutrophils in the blood. ESI-MS analysis of transferrin detected a very major 
peak at 183 +/- 5 Da (avg) below the normal transferrin peak. This peak does not 
represent a loss of an entire glycan, nor does it correspond to the loss of 
monosaccharides.  
The aim of the study in this chapter was to define the exact change of glycosylation 
in the patient and to suggest the most possible genetic defect which is involved in 
this CDG. A serum sample was collected from the patient for glycomic, proteomic 
and glycoproteomic analysis.  
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5.2 Results 
5.2.1 Glycomic anlaysis of the serum sample 
Figure 5.1 shows the results of glycomic analysis of the serum sample from the 
CDG patient. Highly sialylated complex glycans were observed in the high m/z 
range (m/z 2792, m/z 3603 and m/z 3777), which is like the glycan profile of a 
normal serum. Surprisingly, in the low m/z range, glycans at m/z 1836, m/z 2040 
and m/z 2244 were almost undetected. As discussed in Section 3.3.2, the three 
glycans are mainly from serum IgG. The result suggests a dramatic decrease in 
serum IgG or a significant change of IgG glycosylation. Moreover, an atypical peak 
was observed at m/z 2600. According to the normal N-glycan biosynthesis pathway, 
this peak should be GlcNAc2Man9Glc, which is a glycan produced by the removal of 
two Glc residues from the N-glycan precursor (Section 1.2.1). However, 
unexpectedly it was identified as the unusual GlcNAc2Man7Glc3 structure shown in 
the figure by the MS/MS and enzymatic digestion analyses described below.  
 
MS/MS analysis of m/z 2600 is shown in Figure 5.2. Fragments at m/z 1262 and 
m/z 1362 were observed in the MS/MS data. The peak at m/z 1262 revealed a 
fragment with six hexose residues and the peak at m/z 1362 represents a loss of six 
hexose residues from the precursor glycan. MS/MS of GlcNAc2Man9Glc can 
produce neither of the two fragments. By contrast, the two fragments can be 
produced by fragmentation of GlcNAc2Man7Glc3. In addition, the fragment at m/z 
1085 suggests there were only two Man residues attached to the 1-6 arm, which 
again proves the presence of the structure GlcNAc2Man7Glc3.   
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Figure 5.1 Glycomic analysis of the serum sample from a novel CDG patient 
Glycans were permethylated and data were acquired in the form of [M+Na]+ ions. 
Peaks representing complex glycans were annotated with putative structures 
according to the molecular weight and the glycan biosynthetic pathway. Peaks 
representing high mannose glycans were annotated according to the molecular 
weight and MS/MS analysis as well as enzymatic digestion analysis described in 
the following sections. Glycans at m/z 1836, m/z 2040 and m/z 2244 disappeared. 
Abnormal high mannose glycans with 3 terminal Glc residues were observed, 
especially the one at m/z 2600.  
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Figure 5.2 MS/MS of m/z 2600 of a novel CDG patient 
The glycan from the serum at m/z 2600 was selected for analysis. The fragments at 
m/z 1085, m/z 1262 and m/z 1362 (highlighted in red) provide strong evidence for 
the presence of the structure shown above the spectrum.  
5.2.2 α-mannosidase digestion  
In order to further confirm the presence of the structure GlcNAc2Man7Glc3, the 
serum N-glycans were digested by α-mannosidase for 24 hours. The result is 
shown in Figure 5.3. The glycan at m/z 2600 significantly decreased relative to the 
glycan at m/z 2792, which cannot be digested by α-mannosidase. New glycans 
were detected at m/z 2396 and 2192, which had the loss of one and two Man 
residues respectively from the glycan at m/z 2600. No glycans with further losses of 
Man residues were detected, which is evidence for the presence of the 3 Glc 
residues.  
 
MS/MS of m/z 2396 is shown in Figure 5.4. In the normal glycosylation pathway, 
m/z 2396 is the high mannose glycan GlcNAc2Man9 with two Man residues on the 
1-3 arm and four Man residues on the 1-6 arm (Figure 1.6). However, the 
fragmentation pattern provides strong evidence for the presence of the structure 
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GlcNAc2Man6Glc3. The peaks at m/z 1058 and m/z 1361 revealed the loss of five 
hexose residues, which cannot be produced from the GlcNAc2Man9 structure. In 
addition, the peaks at m/z 1262 and m/z 1157 revealed the loss of six hexose 
residues, which cannot be produced from the GlcNAc2Man9 structure either. 
Moreover, the peak at m/z 880 suggests the presence of a single Man residue on 
the 1-6 arm, but the structure GlcNAc2Man9 has four Man residues on this arm. All 
these observations do not support the structure GlcNAc2Man9 but were consistent 
with GlcNAc2Man6Glc3. Similarly, the fragmentation pattern of MS/MS of m/z 2192 
(Figure 5.5) provides strong evidence for the structure GlcNAc2Man5Glc3, because 
the fragments at m/z 676, 953, 1058, 1157, and 1262 were detected.     
 
 
Figure 5.3 Glycomic analysis of α-mannosidase digested N-glycans from a novel 
CDG patient. 
The peak at m/z 2600 decreased relative to the peak at m/z 2792. Two significant 
peaks were observed at m/z 2396 and m/z 2192. No glycans with further losses of 
Man were detected.     
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Figure 5.4 MS/MS of m/z 2396 from α-mannosidase digested N-glycans from a 
novel CDG patient 
The peaks indicated by red numbers (m/z 880, m/z 1058, m/z 1157, m/z 1262 and 
m/z 1361) strongly support the existence of the structure shown in the figure.   
 
 
 
Figure 5.5 MS/MS of m/z 2192 from α-mannosidase digested N-glycans from a 
novel CDG patient 
The peaks indicated by red numbers (m/z 676, m/z 953, m/z 1058, m/z 1157 and 
m/z 1262) strongly support the existence of the structure shown in the figure. 
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5.2.3 Glycomic anlaysis of IgG and transferrin 
The disappearance of normal IgG glycans and the appearance of novel glycans 
with three Glc residues were observed in the patient’s serum, which indicates 
abnormal glycosylation on the IgG. In addition, as discussed in the background 
section of this chapter, ESI-MS analysis of transferrin detected a very major peak at 
183 +/- 5 masses (avg) below the normal transferrin peak, which indicates atypical 
glycosylation on transferrin. Therefore, glycomic analysis was then focused on the 
two glycoproteins. The serum sample was first analysed by reduced SDS-PAGE 
(Figure 5.6). The major bands were cut for protein identification by in-gel proteomic 
analysis. The protein identification results are shown in Table 5.1-Table 5.8. Both 
the IgG heavy chain and light chain significantly decreased in the CDG patient. This 
observation is consistent with the serum glycomic anlaysis, which showed IgG 
specific glycans were almost undetected. However, the level of transferrin in the 
CDG patient did not change significantly (Figure 5.6).  
 
N-glycans were removed from the IgG heavy chain and the transferrin of the CDG 
patient, and were analyzed by mass spectrometry. Glycomic results are shown in 
Figure 5.7 and Figure 5.8. A single glycan at m/z 2600 was observed on IgG (Figure 
5.7). This peak was also detected on the transferrin (Figure 5.8). Two major 
complex glycans at m/z 2431 and m/z 2792 were also observed on the transferrin, 
which are commonly found on normal transferrin molecules. The results are 
consistent with the serum glycomic data, which showed the presence of a major 
glycan at m/z 2600.    
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Figure 5.6 Reduced SDS-PAGE analysis of the serum sample from a novel CDG 
patient 
1 ul serum was diluted to 150 ul with SDS-sample buffer and 20 ul was loaded. 
Samples were analyzed using 4-12% Bis-Tris gel with MOPS running buffer.  * : 
proteins of these gel bands were confirmed by in-gel proteomic identification. IgG 
level significantly decreased in the CDG patient.  
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Table 5.1 Proteomic identification of alfa-2-macroglobulin of a novel CDG patient 
 
Proteins on the gel bands were digested by trypsin. The peptides were extracted for 
MALDI MS and MS/MS analysis.  
  
Table 5.2 Proteomic identification of transferrin of a novel CDG patient 
 
Proteins on the gel bands were digested by trypsin. The peptides were extracted for 
MALDI MS and MS/MS analysis  
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Table 5.3 Proteomic identification of alfa-1-antitrypsin of the CDG patient 
 
Proteins on the gel bands were digested by trypsin. The peptides were extracted for 
MALDI MS and MS/MS analysis  
 
Table 5.4 Proteomic confirmation of IgG heavy chain of a novel CDG patient 
 
Proteins on the gel bands were digested by trypsin. The peptides were extracted for 
MALDI MS and MS/MS analysis  
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Table 5.5 Proteomic identification of alfa-2-macroglobulin of a control serum 
 
Proteins on the gel bands were digested by trypsin. The peptides were extracted for 
MALDI MS and MS/MS analysis  
 
Table 5.6 Proteomic identification of transferrin of a control serum 
 
Proteins on the gel bands were digested by trypsin. The peptides were extracted for 
MALDI MS and MS/MS analysis  
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Table 5.7 Proteomic identification of alfa-1-antitrypsin of a control serum 
 
Proteins on the gel bands were digested by trypsin. The peptides were extracted for 
MALDI MS and MS/MS analysis  
 
Table 5.8 Proteomic confirmation of IgG heavy chain of a control serum 
 
Proteins on the gel bands were digested by trypsin. The peptides were extracted for 
MALDI MS and MS/MS analysis  
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Figure 5.7 Glycomic analysis of IgG of a novel CDG patient 
A single glycan at m/z 2600 was detected. The other peaks are background signals.  
 
 
 
Figure 5.8 Glycomic analysis of transferrin of a novel CDG patient 
The glycan at m/z 2600 was detected together with normal complex glycans. Peaks 
not annotated are background signals. 
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5.3 Discussion 
Glycosylation changes on transferrin are the most widely used indicator for CDG 
identification (Freeze 2006). Transferrin has two glycosylation sites mainly occupied 
with bi-antennary, bi-sialylated glycans. A change of glycosylation results in a 
variation of transferrin molecular weight, which can be detected by mass 
spectrometry. In this study, ESI-MS analysis of serum transferrin from a CDG 
patient detected an atypical peak which is 183 +/- 5 masses (avg) below the normal 
transferrin peak, which cannot be explained by a loss of an entire glycan or a loss of 
monosaccharides from normal transferrin glycans. We used a glycomic strategy to 
solve this problem. Glycomic results of transferrin detected sialylated complex 
glycans and an abnormal glycan GlcNAc2Man7Glc3 (Figure 5.8). The results 
suggest one of the bisialo-glycans on transferrin was substituted with the atypical 
glycan GlcNAc2Man7Glc3. This substitution reduces the molecular weight of 
transferrin by 178 Da when one site carries the abnormal glycan, which can explain 
the ESI-MS data. 
 
Only an abnormal high mannose glycan with three Glc residues was observed on 
the IgG (Figure 5.7). This could explain the decreased serum IgG level in the 
patient (Figure 5.6), as a previous study showed IgG with high mannose glycans 
had shorter halflife in the serum (Goetze, Liu et al. 2011). Normally, serum proteins 
do not have high mannose glycans. Although a small portion of high mannose 
structures are found on antibodies like IgE and IgM, they are masked by peptide 
backbone (Arnold, Wormald et al. 2007) or possibly by other complex glycans and, 
therefore, cannot be recognized by lectins. Pathogens express a large number of 
high mannose glycans on the cell surface, which can be recognized and then 
cleared from the serum by mannose receptors expressed by the innate immune 
system. It is important to note that mannose receptors do not only recognize 
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mannose residues. The orientation of the hydroxyl groups at C3 and C4 of terminal 
mannose residues is the key structure for the identification by mannose receptors 
(Weis, Taylor et al. 1998). Terminal GlcNAc residues have the same orientation of 
the hydroxyl groups at C3 and C4, so they can interact with mannose receptors 
(Weis, Taylor et al. 1998). Also, terminal Glc residues have the same orientation of 
the two hydroxyl groups, so they can probably be recognized by mannose receptors. 
As a result, the terminal Man residues and Glc residues on the patient’s IgG could 
have been recognized by mannose receptors, which then caused reduced IgG level 
in the serum.   
 
It is interesting that no significant decrease in the transferrin was observed in the 
patient (Figure 5.6). It is possible that the transferrin glycans were not completely 
substituted with the abnormal high mannose glycan (Figure 5.8). Indeed, both the 
glycomic data and the ESI-MS data suggest only one of the two glycosylation sites 
on transferrin was substituted with the abnormal glycan. Structural studies have 
shown that the two N-glycosylation sites are closed to each other (Figure 5.9) (Yang, 
Zhang et al. 2012), so the abnormal glycan could probably have been masked by 
the complex glycan on the other site, so that the binding of mannose receptors was 
prevented. It is also interesting that the abnormal glycan did not occupy both 
glycosylation sites on transferrin, as a peak which is 2 X (183 +/- 5) masses (avg) 
below the normal transferrin peak was not observed. One of the possible reasons is 
that a small amount of transferrin that was fully occupied by the abnormal glycan 
was removed by mannose receptors, like the case of IgG.  
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Figure 5.9 The 3-D structure of human serum transferrin 
PDB: 4H0W, method: X-ray diffraction, resolution: 2.4 Å. The N1 sub-domain is in 
blue, N2 in green, C1 in yellow, C2 in red, and peptide linker in purple. Fe ions are 
in brown. NAG' and NAG on C1 sub-domain indicate two GlcNAcs attached to the 
two glycosylation sites.  
 
In order to provide further evidences for the presence of the abnormal glycan, 
α-mannosidase digestion was used. N-glycans were digested by Jack bean 
α-mannosidase, which is able to remove all α-linked mannoses. Although the 
glycans were digested for 24 hours, the digestion was incomplete (Figure 5.3). This 
result is consistent with the digestion pathway of Jack bean α-mannosidase (Figure 
5.10) (Dohi, Isoyama-Tanaka et al. 2011). The digestion pathway shows that the 
α1-3 and α1-6 linked Man residues on the 1-6 arm are removed only after the 
removal of the α1-3 linked mannose on the 1-3 arm (Figure 5.10, B→D), which 
indicates the presence of Man residues on the 1-3 arm could hinder the removal of 
the α1-3 and α1-6 linked Man residues on the 1-6 arm. This is consistent with our 
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results that the glyan at m/z 2600 was not completely digested (Figure 5.3). In 
addition, the pathway shows that the α1-3 and α1-6 linked Man residues on the 1-6 
arm are removed separately (Figure 5.10, C→E), which explains the presence of 
the glycan at m/z 2396 (Figure 5.3). Jack bean alfa-mannosidase digestion of a 
hybrid glycan showed that the α1-6 linked mannose residue on the 1-6 arm was the 
most difficult to remove; it needs more than 128-hour digestion to remove this 
residue (Dohi, Isoyama-Tanaka et al. 2011). This observation is consistent with our 
results that the glycan at m/z 2192 was detected and no further significant removal 
of Man was observed at 24-hour digestion (Figure 5.3).  
  
 
Figure 5.10 The digestion pathway of Jack bean α-mannosidase 
The α1-2 linked mannose residues are first removed to generate Man5 (A→B). 
The α1-3 linked mannose residues on the 1-3 arm is then removed (B→C). After 
that, the terminal α1-6 linked mannose residues on the 1-6 arm is removed (C→D), 
followed by the removal of the terminal α1-3 linked mannose residue (D→E). 
Finally, the last α1-6 mannose residue on the Man2 glycan is removed (E→F) The 
pathway is according to a previous study (Dohi, Isoyama-Tanaka et al. 2011).  
 
An important goal of the study in this chapter was to provide the most likely genetic 
defect involved in this CDG. Glycomic analysis of serum, transferrin and IgG 
suggests that the first glucose on the N-glycan precursor could not be removed in 
the patient, which stongly supports that the mutation is in ER glucosidase I (GCS1) 
(Figure 1.6).  
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A case of congenital disorder of glycosylation (CDG IIb, OMIM #606056) with 
mutations in GCS1 was reported in 2000. The patient was a compound 
heterozygote for two mutations in the glucosidase I gene. One allele had a G→C 
transition at nt 1587, resulting in the substitution of R with T at 486. The other allele 
harboured a T→C transition at nt 2085, resulting in F652L mutation in the protein. 
Enzymatic studies in cultured fibroblasts showed that the glucosidase I activity in 
the patient was less than 1% of that in the healthy control. The patient had 
occurrence of hepatomagaly, hypoventilation, feeding problems, seizures and 
passed away at the age of 74 d. Glycosylation studies of the patient found the same 
abnormal glycan GlcNAc2Man7Glc3. In addition, the activity of endo-α1,2 
mannosidase increased by 2 to 3 fold in the patient. This enzyme removes the 
Glc3-Man structure from the N-glycan precursor, so that further trimming and 
processing steps on the precursor can be possible. This observation can be one of 
the reasons why our glycomic analysis detected complex glycans in the recently 
discovered CDG patient.   
 
Parallel experients has been done by our collaborator, which confirmed that the 
mutation is in GCS1 in our patient, but at a novel site.  
5.4 Summary 
ESI-MS analysis of a CDG patient detected a major peak at 183 +/- 5 masses (avg) 
below the normal transferrin peak. It is difficult to macth this mass shift with either 
CDG-I or CDG-II. A glycomic, proteomic and glycoproteomic strategy were used to 
find the abnormal glcosylation. An atypical glycan GlcNAc2Man7Glc3 was detected 
with in the serum, IgG and transferrin. The presence of this glycan strongly 
suggests the CDG was caused by a mutation in glucosidase I, which was confirmed 
by subsequent DNA sequencing. The abnormal glycan observed in the patient also 
provides possible reasons for the reduced IgG level in the serum.  
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Glycomic analysis of engineered IgG 
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6 Glycomic analysis of engineered IgG 
6.1 Background 
IgG is the most abundant serum antibody which serves as an important mediator of 
inflammation against pathogens. It has a long serum half-life and is well tolerated by 
patients. As a result, intravenous immunoglobulin (IVIG), which mainly consists of 
pooled IgG from sera of thousands of donors, was intuitively used as an IgG 
replacement therapy for patients with immunodeficiency. Surprisingly, follow-up 
studies found that high doses of IVIG could also effectively induce anti-inflammatory 
activity (Imbach, Barandun et al. 1981, Fehr, Hofmann et al. 1982). This leads to a 
paradox that the same antibody can induce both pro-inflammatory and 
anti-inflammatory reactions (Nimmerjahn and Ravetch 2007). Although the 
mechanism of the paradox is not fully understood, various recent studies suggest 
the interactions between IgG and its Fc receptors are involved (Schwab and 
Nimmerjahn 2013).  
 
Seven IgG Fc receptors have been identified in human, which induce different 
effector functions. FcγRIA, FcγRIIA, FcγRIIC, FcγRIIIA and FcγRIIIB are activating 
receptors which induce cell activation and inflammatory processes (Schwab and 
Nimmerjahn 2013). By contrast, FcγRIIB is an inhibitory receptor and works as a 
counterbalance for cell activation (Samuelsson, Towers et al. 2001). FcRn is a 
receptor which can extend IgG half-life (Junghans and Anderson 1996). DC-SIGN 
has also been reported as an IgG Fc receptor involved in anti-inflammatory 
reactions (Anthony, Wermeling et al. 2008). Current studies suggest that IVIG 
exhibits anti-inflammatory activity by attenuating pro-inflammatory pathways and 
favouring anti-inflammatory pathways (Anthony, Wermeling et al. 2012, Schwab 
and Nimmerjahn 2013). For example, infusion of IVIG is able to downregulate the 
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expression of activating Fc receptors and upregulate the expression of FcγRIIB. 
Glycans on IgG play novel anti-inflammatory roles. Deglycosylated IVIG loses its 
anti-inflammatory activity (Kaneko, Nimmerjahn et al. 2006). In addition, sialylation 
of IgG reduces the binding to activating receptors (Section 1.4.4). Consistent with 
this observation, the anti-inflammation is abrogated by sialidase treatment, whereas 
the enrichment of sialylated IVIG resulted in a tenfold increase in anti-inflammatory 
activity (Kaneko, Nimmerjahn et al. 2006, Anthony, Wermeling et al. 2008). Also, it 
is reported that DC-SIGN binds to sialylated IgG and induces anti-inflammatory 
pathways (Anthony, Wermeling et al. 2008), possibly by enhancing the expression 
of FcγRIIB (Nikolova, Tchorbanov et al. 2009, Anthony, Wermeling et al. 2012).  
 
Nowadays, most of the global supply of IVIG is used to treat a wide range of 
inflammatory and autoimmune diseases, such as rheumatoid arthritis, systemic 
lupus erythematosus (SLE), immunothrombocytopenia (ITP), autoimmune 
haemolytic anaemia (AIHA) and chronic inflammatory demyelinating 
polyneuropathy (CIDP) (!!! INVALID CITATION !!!). Global supplies of IVIG are 
critically limited, due to the dependence on human donors for manufacture. In 
addition, less than 5% of injected IVIG is therapeutically active, as most IVIG does 
not have the glycosylation required for autoimmune therapy (Schwab and 
Nimmerjahn 2013), which means large amounts of IVIG should be given for a 
treatment. One of the ways to solve the problem is to produce engineered IgG with 
correct glycosylation by cell culture.  
 
Recently, two novel types of engineered IgG1 have been developed, which show 
promising potential for autoimmune therapy. The first type has three candidates 
which were developed by introducing point mutations to the heavy chain constant 
region (Figure 6.1). One of the candidates (IgG1 C) showed an obvious increase in 
molecular weight and exhibited a significant decrease in Fc receptor binding. The 
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second type is a hexameric IgG1-Fc (Figure 6.2), which binds to DC-SIGN with high 
avidity.  
 
The aim of the study in this chapter was to characterize the glycosylation of the two 
novel pharmaceutical antibodies.  
 
Figure 6.1 Mutations of the three candidates of engineered IgG1 in the Fc region 
The N-glycosylation site (Asn297) is also shown. The Figure is based on data 
provided by Dr. Mike Clark of the Department of Pathology, University of 
Cambridge.   
 
 
Figure 6.2 Top view of a molecular model of the engineered IgG1 Fc hexamer 
Cys residues are in yellow, the tailpieces are in red, the Fc in blue, and the sugars in 
white (terminal sialic acid is presented as white spheres). The Figure was kindly 
provided by Prof. Richard J. Pleass from Liverpool School of Tropical Medicine. 
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6.2 Results 
The glycomic analysis of IgG1 wild type, IgG1 A, IgG1 B and IgG1 C is shown in 
Figure 6.3. IgG1 and IgG1 A were dominated by non-sialylated, bi-antennary 
glycans. Most of the glycans had terminal GlcNAc. Core Fuc and bisecting GlcNAc 
were commonly found. Sialylated glycans started to be detected in IgG1 B at m/z 
2431, m/z 2792 and m/z 2966. A substantial increase in sialylation was detected in 
IgG1 C, exemplified by the peaks at m/z 2431, 2605, 2646, 2676, 2792, 2850, 2966 
and 3212. A small portion of NeuGc was detected in IgG1 C at m/z 2635, 2676, 
2880 and 3242. The presence of NeuGc was confirmed by MS/MS analysis (Figure 
6.4). The presence of m/z 877 (NeuGc-Gal-GlcNAc-) strongly supports the 
presence of NeuGc in these glycans. For bi-sialylated glycans (m/z 2966 and 3242), 
both m/z 847 (NeuAc-Gal-GlcNAc-) and m/z 877 (NeuGc-Gal-GlcNAc-) were 
detected, which means one antenna of an individual glycan was terminated by 
NeuGc while the other one was capped with NeuAc.      
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Figure 6.3 Glycomic analysis of a wild type IgG1 and three samples of engineered 
IgG1 (IgG1 A, IgG1 B and IgG1 C) 
Increased sialylation was detected in IgG1 B and particularly in IgG1 C. Peaks are 
annotated with putative structures according to the molecular weight and the glycan 
biosynthetic pathway.   
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Figure 6.4 MS/MS analysis of glycans at m/z 2676 (A), 2880 (B), 2966 (C) and 3242 
(D) of engineered IgG1 
The peak at m/z 2676 was identified as a mixture of two glycans, one of which did 
not have NeuGc. The fragment at m/z 877 strongly supports the presence of NeuGc 
in all other glycans.  
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The NeuGc sialylated glycans might have come from other glycoproteins. In order 
to rule out this possibility, the same quantities of the IgG samples were subjected to 
a proteomic study (Table 6.1 – Table 6.4). The results showed IgG1 was identified 
with high peptide count and total ion score and the presence of other glycoproteins 
can be ruled out. The peptide count and total ion score of IgG1 B and IgG1 C were 
not as high as IgG1 wild type and IgG1 A, because more mutations were introduced 
in IgG1 B and IgG1 C, resulting in fewer peptide matches during the database 
search. The main contaminant was bovine albumin (ALBU-BOVIN) which showed a 
high peptide count (16) and total ion score (778) in IgG1 B. The albumin was 
probably from the cell culture medium, to which bovine serum is usually added. 
Nevertheless, albumin is not a glycoprotein and cannot contaminate the glycomic 
data. Porcine trypsin (TRYP-PIG) was identified in all the four samples, as 1/50 
(w/w) of this trypsin was used during the digestion step.   
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Table 6.1 Off-line LC-MS/MS analysis of IgG1 wild type sample 
 
Proteins were digested by trypsin. The peptides were separated by nano-LC and 
analyzed by MALDI MS and MS/MS.  
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Table 6.2 Off-line LC-MS/MS analysis of IgG1 A sample 
 
Proteins were digested by trypsin. The peptides were separated by nano-LC and 
analyzed by MALDI MS and MS/MS. 
 
231 
 
Table 6.3 Off-line LC-MS/MS analysis of IgG1 B sample 
 
Proteins were digested by trypsin. The peptides were separated by nano-LC and 
analyzed by MALDI MS and MS/MS. 
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Table 6.4 Off-line LC-MS/MS analysis of IgG1 C sample 
 
Proteins were digested by trypsin. The peptides were separated by nano-LC and 
analyzed by MALDI MS and MS/MS. 
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Figure 6.5 Glycomic analysis of a IgG1 dimer and a hexamer 
The hexamer exhibited higher levels of high mannose glycans and sialylated 
glycans. 
   
The N-glycan profiles of a dimeric IgG1 Fc a hexameric IgG1 Fc are shown in 
Figure 6.5. The hexamer had two more sialylated glycans at m/z 3055 and m/z 
3504 compared to the dimer. In addition, the hexameric Fc contained higher levels 
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of high mannose glycans as shown at m/z 1580 and m/z 1784, which might be 
involved in the high affinity for DC-SIGN.  
6.3 Discussion 
The glycomic results showed increased sialylation in IgG1 B and IgG1 C (Figure 
6.3), which means mutations in the Fc region can affect glycosylation. The IgG 
N-glycans are located in a cavity formed by two heavy chains (Figure 6.6). Each 
N-glycan is positioned towards the center of the IgG molecule, with the 1-6 arm 
extending along the CH2 backbone and the 1-3 arm protruding into the cavity 
(Arnold, Wormald et al. 2007, Anthony, Wermeling et al. 2012). Due to the limited 
space provided by the cavity, most IgG glycans are not fully processed. 
Non-galactosylated and single-galactosylated structures are commonly found, and 
a small portion of glycans can be sialylated (Wuhrer, Stam et al. 2007). It is 
estimated that each IgG N-glycan has about 70 non-covalent interactions with the 
peptide backbone (Arnold, Wormald et al. 2007), which could restrict the movement 
and elongation of the glycan. The 3-D structure and/or the orientation of glycans 
could be altered to facilitate glycan elongation by introducing mutations at the 
glycan-protein interaction sites. For example, a previous study replaced residues at 
F241, F243, V264, D265, or R301 with A and found increased sialylation (Table 6.5) 
(Lund, Takahashi et al. 1996). As a result, the mutations in IgG1 B and IgG1 C 
(Figure 6.1) may have changed the 3-D structure of the cavity and allowed the 
incorporation of sialic acid residues.        
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Figure 6.6 A molecuclar model showing the N-glycans on IgG 
The N-glycans (highlighted in red) are located in a cavity of the Fc region. The light 
chain is in purple, and the heavy chain is in blue. This figure is taken from Arnold, 
Wormald et al (Arnold, Wormald et al. 2007). 
 
  
Table 6.5 The ratio of sialylated glycans in IgG mutants 
  Mutation   WT F241A F243A V264A D265A R301A 
Monosialylated glycans 3.5% 25.8% 41.8% 24.0% 12.1% 28.2% 
Disialylated glycans 0% 14.1% 31.2% 12.0% 3.7% 0% 
Data of this table are from (Lund, Takahashi et al. 1996). 
   
A dramatic increase in both mono and disialylated glycans were detected in IgG1 C 
(Figure 6.3). Compared to IgG1 B, IgG1 C has an exclusive mutation at R301H. 
This might be a key mutation responsible for the high levels of sialylation. An R301A 
mutation has been reported by a previous study (Lund, Takahashi et al. 1996). 
However, it is interesting that the increase in sialylation in this report was not so 
dramatic and no disialylated structures were observed (Table 6.5). It is possible that 
replacement R301 with H and A has different effects on the 3-D structure of the 
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cavity. It is also possible that the combination of R301H and the other mutations 
resulted in the dramatic increase in sialylation, as IgG1 C contains more than one 
mutation. The analysis of IgG1 with a single R301H mutation could be a useful 
future study if samples are available.   
 
IgG1 C contained a small amount of NeuGc (Figure 6.3, Figure 6.4), which was 
probably incorporated during cell culture. NeuGc is a sialic acid widely distributed in 
most mammalian tissues, but is a very rare sugar in humans (Varki 2001). 
CMP-N-acetylneuraminic acid hydroxylase is a rate-limiting enzyme responsible for 
producing NeuGc in mammals. In humans, this enzyme was inactivated sometime 
after the ape-human common ancestor. Incorporation of NeuGc into the human 
glycome has been shown to be diet-dependent (Tangvoranuntakul, Gagneux et al. 
2003). It has been reported that all humans express NeuGc specific antibodies 
(Padler-Karavani, Yu et al. 2008). NeuGc containing therapeutic glycoproteins can 
induce immune responses as well as reduced half-life and afficacy (Ghaderi, Taylor 
et al. 2010). Therefore, the NeuGc found in IgG1 C may affect its anti-inflammatory 
activity when used in humans. The NeuGc content could be reduced by adding a 
human sialic acid (NeuAc) to the culture medium (Ghaderi, Taylor et al. 2010).    
 
DC-SIGN is a C-type lectin which is known to bind high mannose glycans and 
Lewis type antigens (Section 1.4.1) but not sialylated glycans. Unexpectedly, this 
lectin has been identified as an IgG Fc receptor which is claimed to bind to 
sialylated Fc (Anthony, Wermeling et al. 2008). DC-SIGN-related protein 1 (SIGNR1) 
is a mouse homologue of human DC-SIGN (Park, Takahara et al. 2001). In a mouse 
model, deletion of SIGNR1 or blocking the CRD of SIGNR1 disabled IVIG induced 
anti-inflammatory activity (Anthony, Wermeling et al. 2008). In addition, the 
expression of human DC-SIGN in the SIGNR1 deleted mice restored the IVIG 
activity (Anthony, Kobayashi et al. 2011). How DC-SIGN binds sialylated Fc 
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remains an open question. A recent model suggests sialic acid is not directly 
involved. Instead, sialylation could alter the conformation of the Fc region and 
trigger DC-SIGN binding (Sondermann, Pincetic et al. 2013). However, a crystal 
structure of IgG Fc did not show conformational changes upon sialylation (Crispin, 
Yu et al. 2013). A current report even suggests the interaction between serum IgG 
and DC-SIGN is independent of antibody glycoform or Fc domain (!!! INVALID 
CITATION !!!). Here, we detected high mannose glycans in an anti-inflammatory 
hexameric IgG Fc which binds to DC-SIGN with high avidity and specificity. Thus 
the glycomic data is consistent with the hypothesis that a direct contact between 
IgG Fc and DC-SIGN is required for anti-inflammation.  
6.4 Summary 
Two types of engineered IgG1 were developed recently for treating auto-immune 
diseases. The first type was constructed by introducing mutations in the Fc region 
while the second type is a Fc hexamer. Glycomic analysis showed a dramatic 
increase in sialylation in IgG1 C of the first type, which indicates a desirable 
anti-inflammatory activity. Whether the mutation R301H alone or a combination of 
multiple mutations facilitated the sialylation cannot be confirmed. A substantial 
amount of high mannose glycans were observed in the Fc hexamer, which might be 
the reason for the DC-SIGN binding activity.  
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Conclusion  
Glycosylation plays multiple important roles in regulating the immune system. The 
main focus of this thesis is to investigate abnormal glycosylation in immune 
disorders, which is presented Chapter 3, Chapter 4 and Chapter 5. The focus 
moves forward in Chapter 6 to cover the glycosylation of engineered antibodies 
designed to treat immune disorders. Mass spectrometry was used to study the 
complexity of glycosylation.  
 
Two newly discovered immune disorders were investigated: a hyper IgE syndrome 
and a congenital disorder of glycosylation. The results well reflect the genetic 
findings. The hyper IgE syndrome is linked to mutations in PGM3. Impairment of 
this gene is expected to reduce the level of UDP-GlcNAc and preferentially hinder 
the synthesis of the third and the fourth antenna of N-glycans. Indeed, the glycomic 
data showed reduced tri- and tetra-antennary glycans. For the congenital disorder 
of glycosylation, glycomic analysis and genetic analysis were investigated in 
parallel by separate groups and the two studies gave consistent results. The 
glycomic study detected high mannose glycans terminated by three glucoses and 
the genetic study identified a mutation in GCS1, which is a gene encoding ER 
glucosidase I.  
 
In addition, the glycomic studies provided data beyond genetic based predictions. 
For the hyper IgE syndrome, both reduced branching and fucosylation were 
observed on neutrophils. The later cannot be directly linked to the PGM3 mutation. 
In spite of the fact that PGM3 is ubiquitously expressed, no significant branching 
changes were observed in sera/plasma (tri-/tetra-glycans mainly synthesized by the 
liver) or Tamm-Horsfall glycoprotein (secreted by the kidney). For the congenital 
disorder of glycosylation, the genetic study cannot tell how GCS1 mutation affects 
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different glycoproteins. In contrast, the glycomic study was able to show that both 
complex and abnormal tri-glucosylated high mannose glycans occur on transferrin, 
whereas only the abnormal glycan is found on IgG.   
 
Moreover, the glycomic results correlate with clinical findings. For the hyper IgE 
syndrome, reduced tri- and tetra-antennary glycans occurred on leukocytes but 
neither was affected on Tamm-Horsfall glycoprotein or in sera/plasma. Consistently, 
clinical studies found the symptoms were mainly confined to the immune system, 
and not in the kidney or liver. Besides the reduction in tri- and tetra-antennary 
glycans, decreased bi-antennary glycans and a substantial increase in hybrid 
glycans were detected in a patient with a deletion mutation in PGM3. Accordingly, 
patients with this mutation had dramatically reduced PGM3 protein expression and 
exhibited more severe clinical symptoms. For the congenital disorder of 
glycosylation, serum glycomic data lacked glycans characteristic of normal IgG, 
whilst glycomic analysis of IgG itself confirmed abnormal glycosylation. These 
findings coincide with the decreased serum IgG level.  
 
Finally, the glycomic data may explain some symptoms of the hyper IgE syndrome. 
Reduced branching and fucosylation on neutrophils indicates fewer galectin and 
selectin ligands, which could disable neutrophil migration and activation in response 
to infections. This may be one of the reasons for recurrent infections found in the 
patients. Neither glycomic nor glycoproteomic studies of IgE found significant 
changes of glycosylation, which means the elevated IgE in the patients is not 
caused by glycans attached to the antibody itself but on other proteins such as 
those on neutrophils. Fewer neutrophils at sites of infection could result in weak 
neutrophil-DC interaction, favour TH2 polarization, and increase IgE production.  
 
Glycans regulate antibody activities. The glycosylation of two types of novel 
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engineered IgG1 molecules were studied, both of which are designed to treat 
autoimmune diseases. Point mutations were introduced into the first type of 
antibody with the aim of achieving a high level of sialylation, which is known to 
inhibit autoimmune responses. Mass spectrometry was used to screen the 
candidates and identified a highly sialylated antibody. The second type is a hexa-Fc, 
which shows high avidity and specificity for DC-SIGN, which has been identified as 
a Fc receptor involved in anti-inflammation. The glycomic analysis may explain this 
observation, as a considerable amount of high mannose glycans were detected.     
  
The mass spectrometric data provide useful glycan structural information for future 
functional studies. For example, the abnormal glycosylation detected in the two 
immune disorders suggest atypical glycan-lectin interactions in the immune system. 
Therefore, lectin blot or flow cytometry can be used to study the hyper IgE 
syndrome and the congenital disorder of glycosylation in the future. The 
downstream signaling pathways upon glycan-lectin binding probably changed in the 
patients, so investigation of the altered pathways could provide a picture inside cells. 
In addition, O-GlcNAcylation is known to be hypersensitive to UDP-GlcNAc 
concentration. This special glycosylation occurs in the cytoplasm and regulates 
signal transduction and gene expression. As a result, studying the variation of 
O-GlcNAcylation in the hyper IgE syndrome could be an important component of 
future work. For the engineered antibodies, the candidate selected by mass 
spectrometry can be further evaluated by testing its binding affinity to different types 
of Fc receptors and its anti-inflammatory activities in mouse models. As the contact 
between Fc and DC-SIGN remains an open question at present, the glycomic data 
might provide some insights into this question if consistent results are obtained from 
other experiments such as mannosidase digestion or mannose inhibition. 
241 
 
References:  
Afonso, A. M. M., Charlwood, P. A. and Marshall, R. D. (1981). Isolation and characterization of 
glycopeptides from digests of human Tamm-Horsfall glycoprotein. Carbohyd Res, 89(2), 309-319. 
Ahlf, D. R., Thomas, P. M. and Kelleher, N. L. (2013). Developing top down proteomics to maximize 
proteome and sequence coverage from cells and tissues. Curr Opin Chem Biol, 17(5), 787-794. 
Aigner, S., Sthoeger, Z. M., Fogel, M., Weber, E., Zarn, J., Ruppert, M., Zeller, Y., Vestweber, D., Stahel, R., 
Sammar, M., et al. (1997). CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. 
Blood, 89(9), 3385-3395. 
Almkvist, J., Dahlgren, C., Leffler, H. and Karlsson, A. (2002). Activation of the neutrophil nicotinamide 
adenine dinucleotide phosphate oxidase by galectin-1. J Immunol, 168(8), 4034-4041. 
Altermann, E. and Klaenhammer, T. R. (2005). PathwayVoyager: pathway mapping using the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) database. BMC genomics, 6, 60. 
Alvarez-Manilla, G., Warren, N. L., Abney, T., Atwood, J., Azadi, P., York, W. S., Pierce, M. and Orlando, R. 
(2007). Tools for glycomics: relative quantitation of glycans by isotopic permethylation using (CH3I)-C-13. 
Glycobiology, 17(7), 677-687. 
Amano, M., Galvan, M., He, J. and Baum, L. G. (2003). The ST6Gal I sialyltransferase selectively modifies 
N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and 
T cell death. J Biol Chem, 278(9), 7469-7475. 
Anderson, N. L. and Anderson, N. G. (2002). The human plasma proteome: history, character, and diagnostic 
prospects. Mol Cell Proteomics, 1(11), 845-867. 
Anthony, R. M., Kobayashi, T., Wermeling, F. and Ravetch, J. V. (2011). Intravenous gammaglobulin 
suppresses inflammation through a novel T(H)2 pathway. Nature, 475(7354), 110-U133. 
Anthony, R. M., Nimmerjahn, F., Ashline, D. J., Reinhold, V. N., Paulson, J. C. and Ravetch, J. V. (2008). 
Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science, 320(5874), 373-376. 
Anthony, R. M., Wermeling, F., Karlsson, M. C. and Ravetch, J. V. (2008). Identification of a receptor 
required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A, 105(50), 19571-19578. 
Anthony, R. M., Wermeling, F. and Ravetch, J. V. (2012). Novel roles for the IgG Fc glycan. Ann N Y Acad 
Sci, 1253, 170-180. 
Armour, K. L., Clark, M. R., Hadley, A. G. and Williamson, L. M. (1999). Recombinant human IgG 
molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol, 29(8), 
2613-2624. 
242 
 
Arnold, J. N., Radcliffe, C. M., Wormald, M. R., Royle, L., Harvey, D. J., Crispin, M., Dwek, R. A., Sim, R. 
B. and Rudd, P. M. (2004). The glycosylation of human serum IgD and IgE and the accessibility of identified 
oligomannose structures for interaction with mannan-binding lectin. J Immunol, 173(11), 6831-6840. 
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M. and Dwek, R. A. (2007). The impact of glycosylation 
on the biological function and structure of human immunoglobulins. Annu Rev Immunol, 25, 21-50. 
Aruffo, A., Kolanus, W., Walz, G., Fredman, P. and Seed, B. (1991). CD62/P-selectin recognition of myeloid 
and tumor cell sulfatides. Cell, 67(1), 35-44. 
Aubry, J. P., Pochon, S., Gauchat, J. F., Nueda-Marin, A., Holers, V. M., Graber, P., Siegfried, C. and 
Bonnefoy, J. Y. (1994). CD23 interacts with a new functional extracytoplasmic domain involving N-linked 
oligosaccharides on CD21. J Immunol, 152(12), 5806-5813. 
Axford, J. S., Mackenzie, L., Lydyard, P. M., Hay, F. C., Isenberg, D. A. and Roitt, I. M. (1987). Reduced 
B-cell galactosyltransferase activity in rheumatoid arthritis. Lancet, 2(8574), 1486-1488. 
Babu, P., North, S. J., Jang-Lee, J., Chalabi, S., Mackerness, K., Stowell, S. R., Cummings, R. D., Rankin, S., 
Dell, A. and Haslam, S. M. (2009). Structural characterisation of neutrophil glycans by ultra sensitive mass 
spectrometric glycomics methodology. Glycoconjugate J, 26(8), 975-986. 
Babu, P., North, S. J., Jang-Lee, J., Chalabi, S., Mackerness, K., Stowell, S. R., Cummings, R. D., Rankin, S., 
Dell, A. and Haslam, S. M. (2009). Structural characterisation of neutrophil glycans by ultra sensitive mass 
spectrometric glycomics methodology. Glycoconjugate J, 26(8), 975-986. 
Bae, J. S., Kim, S. H., Ye, Y. M., Yoon, H. J., Suh, C. H., Nahm, D. H. and Park, H. S. (2007). Significant 
association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria. J Allergy 
Clin Immunol, 119(2), 449-456. 
Baenziger, J., Kornfeld, S. and Kochwa, S. (1974). Structure of the carbohydrate units of IgE 
immunoglobulin. I. Over-all composition, glycopeptide isolation, and structure of the high mannose 
oligosaccharide unit. J Biol Chem, 249(6), 1889-1896. 
Baenziger, J., Kornfeld, S. and Kochwa, S. (1974). Structure of the carbohydrate units of IgE 
immunoglobulin. II. Sequence of the sialic acid-containing glycopeptides. J Biol Chem, 249(6), 1897-1903. 
Barber, M., Bordoli, R. S., Sedgwick, R. D. and Tyler, A. N. (1981). Fast atom bombardment of solids (Fab) - 
a new ion-source for mass-spectrometry. J Chem Soc Chem Comm,(7), 325-327. 
Barondes, S. H., Castronovo, V., Cooper, D. N., Cummings, R. D., Drickamer, K., Feizi, T., Gitt, M. A., 
Hirabayashi, J., Hughes, C., Kasai, K., et al. (1994). Galectins: a family of animal beta-galactoside-binding 
lectins. Cell, 76(4), 597-598. 
Basset, C., Devauchelle, V., Durand, V., Jamin, C., Pennec, Y. L., Youinou, P. and Dueymes, M. (1999). 
Glycosylation of immunoglobulin A influences its receptor binding. Scand J Immunol, 50(6), 572-579. 
243 
 
Basu, R., Hatton, R. D. and Weaver, C. T. (2013). The Th17 family: flexibility follows function. Immunol Rev, 
252(1), 89-103. 
Batley, K. E. and Morris, H. R. (1977). Dihydrofolate reductase: partial sequence of the Lactobacillus casei 
enzyme and homology with other dihydrofolate reductases. Biochem Soc Trans, 5(4), 1097-1099. 
Baum, L. G., Pang, M., Perillo, N. L., Wu, T., Delegeane, A., Uittenbogaart, C. H., Fukuda, M. and Seilhamer, 
J. J. (1995). Human thymic epithelial-cells express an endogenous lectin, galectin-1, which binds to Core-2 
O-Glycans on thymocytes and T-lymphoblastoid-cells. J Exp Med, 181(3), 877-887. 
Baumheter, S., Singer, M. S., Henzel, W., Hemmerich, S., Renz, M., Rosen, S. D. and Lasky, L. A. (1993). 
Binding of L-selectin to the vascular sialomucin CD34. Science, 262(5132), 436-438. 
Beckey, H. D. and Schulten, H. R. (1975). Field desorption mass-spectrometry .2. new analytical methods. 
Angew Chem Int Edit, 14(6), 403-415. 
Bennouna, S., Bliss, S. K., Curiel, T. J. and Denkers, E. Y. (2003). Cross-talk in the innate immune system: 
neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J Immunol, 
171(11), 6052-6058. 
Bennouna, S. and Denkers, E. Y. (2005). Microbial antigen triggers rapid mobilization of TNF-alpha to the 
surface of mouse neutrophils transforming them into inducers of high-level dendritic cell TNF-alpha 
production. J Immunol, 174(8), 4845-4851. 
Berg, E. L., McEvoy, L. M., Berlin, C., Bargatze, R. F. and Butcher, E. C. (1993). L-selectin-mediated 
lymphocyte rolling on MAdCAM-1. Nature, 366(6456), 695-698. 
Berg, E. L., Robinson, M. K., Mansson, O., Butcher, E. C. and Magnani, J. L. (1991). A carbohydrate domain 
common to both sialyl Le(a) and sialyl Le(X) is recognized by the endothelial-cell leukocyte adhesion 
molecule ELAM-1. J Biol Chem, 266(23), 14869-14872. 
Bettler, B., Maier, R., Ruegg, D. and Hofstetter, H. (1989). Binding site for IgE of the human lymphocyte 
low-affinity Fc epsilon receptor (Fc epsilon RII/CD23) is confined to the domain homologous with animal 
lectins. Proc Natl Acad Sci U S A, 86(18), 7118-7122. 
Bettler, B., Texido, G., Raggini, S., Ruegg, D. and Hofstetter, H. (1992). Immunoglobulin E-binding site in Fc 
epsilon receptor (Fc epsilon RII/CD23) identified by homolog-scanning mutagenesis. J Biol Chem, 267(1), 
185-191. 
Bhende, Y. M., Deshpande, C. K., Bhatia, H. M., Sanger, R., Race, R. R., Morgan, W. T. and Watkins, W. M. 
(1952). A "new" blood group character related to the ABO system. Lancet, 1(6714), 903-904. 
Bluestone, J. A., Herold, K. and Eisenbarth, G. (2010). Genetics, pathogenesis and clinical interventions in 
type 1 diabetes. Nature, 464(7293), 1293-1300. 
Bogdanov, B. and Smith, R. D. (2005). Proteomics by FTICR mass spectrometry: Top down and bottom up. 
244 
 
Mass Spectrom Rev, 24(2), 168-200. 
Bogoevska, V., Nollau, P., Lucka, L., Grunow, D., Klampe, B., Uotila, L. M., Samsen, A., Gahmberg, C. G. 
and Wagener, C. (2007). DC-SIGN binds ICAM-3 isolated from peripheral human leukocytes through Lewis 
x residues. Glycobiology, 17(3), 324-333. 
Bonner, A., Almogren, A., Furtado, P. B., Kerr, M. A. and Perkins, S. J. (2009). Location of secretory 
component on the Fc edge of dimeric IgA1 reveals insight into the role of secretory IgA1 in mucosal 
immunity. Mucosal Immunol, 2(1), 74-84. 
Bowman, M. J. and Zaia, J. (2007). Tags for the stable isotopic labeling of carbohydrates and quantitative 
analysis by mass spectrometry. Anal Chem, 79(15), 5777-5784. 
Buckley, R. H., Belmaker, E. Z. and Wray, B. B. (1972). Extreme hyperimmunoglobulinemia-E and undue 
susceptibility to infection. Pediatrics, 49(1), 59-70. 
Burda, P. and Aebi, M. (1999). The dolichol pathway of N-linked glycosylation. Biochim Biophys Acta, 
1426(2), 239-257. 
Canis, K., McKinnon, T. A. J., Nowak, A., Haslam, S. M., Panico, M., Morris, H. R., Laffan, M. A. and Dell, 
A. (2012). Mapping the N-glycome of human von Willebrand factor. Bichem J, 447, 217-228. 
Cariappa, A., Takematsu, H., Liu, H., Diaz, S., Haider, K., Boboila, C., Kalloo, G., Connole, M., Shi, H. N., 
Varki, N., et al. (2009). B cell antigen receptor signal strength and peripheral B cell development are 
regulated by a 9-O-acetyl sialic acid esterase. J Exp Med, 206(1), 125-138. 
Carr, S. A., Huddleston, M. J. and Bean, M. F. (1993). Selective identification and differentiation of N- and 
O-linked oligosaccharides in glycoproteins by liquid chromatography-mass spectrometry. Protein Sci, 2(2), 
183-196. 
Casabo, L. G., Mamalaki, C., Kioussis, D. and Zamoyska, R. (1994). T cell activation results in physical 
modification of the mouse CD8 beta chain. J Immunol, 152(2), 397-404. 
Cavalcante, P., Bernasconi, P. and Mantegazza, R. (2012). Autoimmune mechanisms in myasthenia gravis. 
Curr Opin Neurol, 25(5), 621-629. 
Ceroni, A., Maass, K., Geyer, H., Geyer, R., Dell, A. and Haslam, S. M. (2008). GlycoWorkbench: a tool for 
the computer-assisted annotation of mass spectra of glycans. J Proteome Res, 7(4), 1650-1659. 
Chalabi, S., Panico, M., Sutton-Smith, M., Haslam, S. M., Patankar, M. S., Lattanzio, F. A., Morris, H. R., 
Clark, G. F. and Dell, A. (2006). Differential O-glycosylation of a conserved domain expressed in murine and 
human ZP3. Biochemistry, 45(2), 637-647. 
Chen, Y., Hu, D., Yabe, R., Tateno, H., Qin, S. Y., Matsumoto, N., Hirabayashi, J. and Yamamoto, K. (2011). 
Role of malectin in Glc(2)Man(9)GlcNAc(2)-dependent quality control of alpha1-antitrypsin. Mol Biol Cell, 
22(19), 3559-3570. 
245 
 
Cheong, K. A., Chang, Y. S., Roh, J. Y., Kim, B. J., Kim, M. N., Park, Y. M., Park, H. J., Kim, N. D., Lee, C. 
H. and Lee, A. Y. (2011). A novel function of Siglec-9 A391C polymorphism on T cell receptor signaling. Int 
Arch Allergy Immunol, 154(2), 111-118. 
Christianson, J. C., Shaler, T. A., Tyler, R. E. and Kopito, R. R. (2008). OS-9 and GRP94 deliver mutant 
alpha1-antitrypsin to the Hrd1-SEL1L ubiquitin ligase complex for ERAD. Nat Cell Biol, 10(3), 272-282. 
Clark, M. C., Pang, M., Hsu, D. K., Liu, F. T., de Vos, S., Gascoyne, R. D., Said, J. and Baum, L. G. (2012). 
Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. 
Blood, 120(23), 4635-4644. 
Collins, T., Read, M. A., Neish, A. S., Whitley, M. Z., Thanos, D. and Maniatis, T. (1995). Transcriptional 
regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J, 
9(10), 899-909. 
Colnot, C., Ripoche, M. A., Milon, G., Montagutelli, X., Crocker, P. R. and Poirier, F. (1998). Maintenance of 
granulocyte numbers during acute peritonitis is defective in galectin-3-null mutant mice. Immunology, 94(3), 
290-296. 
Comelli, E. M., Sutton-Smith, M., Yan, Q., Amado, M., Panico, M., Gilmartin, T., Whisenant, T., Lanigan, C. 
M., Head, S. R., Goldberg, D., et al. (2006). Activation of murine CD4+ and CD8+ T lymphocytes leads to 
dramatic remodeling of N-linked glycans. J Immunol, 177(4), 2431-2440. 
Cooper, C. A., Gasteiger, E. and Packer, N. H. (2001). GlycoMod - A software tool for determining 
glycosylation compositions from mass spectrometric data. Proteomics, 1(2), 340-349. 
Cooper, D., Iqbal, A. J., Gittens, B. R., Cervone, C. and Perretti, M. (2012). The effect of galectins on 
leukocyte trafficking in inflammation: sweet or sour? Ann N Y Acad Sci, 1253(4), 181-192. 
Cox, J. and Mann, M. (2011). Quantitative, high-resolution proteomics for data-driven systems biology. Annu 
Rev Biochem, 80, 273-299. 
Crispin, M., Yu, X. and Bowden, T. A. (2013). Crystal structure of sialylated IgG Fc: implications for the 
mechanism of intravenous immunoglobulin therapy. Proc Natl Acad Sci U S A, 110(38), E3544-3546. 
Crocker, P. R., Clark, E. A., Filbin, M., Gordon, S., Jones, Y., Kehrl, J. H., Kelm, S., Le Douarin, N., Powell, 
L., Roder, J., et al. (1998). Siglecs: a family of sialic-acid binding lectins. Glycobiology, 8(2), v. 
Crocker, P. R. and Gordon, S. (1989). Mouse macrophage hemagglutinin (sheep erythrocyte receptor) with 
specificity for sialylated glycoconjugates characterized by a monoclonal antibody. J Exp Med, 169(4), 
1333-1346. 
Crocker, P. R., Mucklow, S., Bouckson, V., McWilliam, A., Willis, A. C., Gordon, S., Milon, G., Kelm, S. and 
Bradfield, P. (1994). Sialoadhesin, a macrophage sialic acid binding receptor for haemopoietic cells with 17 
immunoglobulin-like domains. EMBO J, 13(19), 4490-4503. 
246 
 
Curtis, B. M., Scharnowske, S. and Watson, A. J. (1992). Sequence and expression of a membrane-associated 
C-type lectin that exhibits CD4-independent binding of human-immunodeficiency-virus envelope 
glycoprotein-gp120. P Natl Acad Sci USA, 89(17), 8356-8360. 
Davis, S. D., Schaller, J. and Wedgwood, R. J. (1966). Job's Syndrome. Recurrent, "cold", staphylococcal 
abscesses. Lancet, 1(7445), 1013-1015. 
Dell, A. (1987). F.A.B.-mass spectrometry of carbohydrates. Adv Carbohydr Chem Biochem, 45, 19-72. 
Dell, A. and Morris, H. R. (2001). Glycoprotein structure determination by mass spectrometry. Science, 
291(5512), 2351-2356. 
Dell, A., Reason, A. J., Khoo, K. H., Panico, M., McDowell, R. A. and Morris, H. R. (1994). Mass 
spectrometry of carbohydrate-containing biopolymers. Methods Enzymol, 230, 108-132. 
Demetriou, M., Granovsky, M., Quaggin, S. and Dennis, J. W. (2001). Negative regulation of T-cell activation 
and autoimmunity by Mgat5 N-glycosylation. Nature, 409(6821), 733-739. 
Dennis, J. W., Nabi, I. R. and Demetriou, M. (2009). Metabolism, cell surface organization, and disease. Cell, 
139(7), 1229-1241. 
Dhaliwal, B., Yuan, D., Pang, M. O., Henry, A. J., Cain, K., Oxbrow, A., Fabiane, S. M., Beavil, A. J., 
McDonnell, J. M., Gould, H. J., et al. (2012). Crystal structure of IgE bound to its B-cell receptor CD23 
reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcepsilonRI. Proc Natl 
Acad Sci U S A, 109(31), 12686-12691. 
Dodd, R. B. and Drickamer, K. (2001). Lectin-like proteins in model organisms: implications for evolution of 
carbohydrate-binding activity. Glycobiology, 11(5), 71R-79R. 
Dohi, K., Isoyama-Tanaka, J., Misaki, R. and Fujiyama, K. (2011). Jack bean alpha-mannosidase digestion 
profile of hybrid-type N-glycans: effect of reaction pH on substrate preference. Biochimie, 93(4), 766-771. 
Domon, B. and Costello, C. E. (1988). A systematic nomenclature for carbohydrate fragmentations in 
FAB-MS/MS spectra of glycoconjugates. Glycoconjugate J, 5(4), 397-409. 
Dorrington, K. J. and Bennich, H. H. (1978). Structure-function relationships in human immunoglobulin E. 
Immunol Rev, 41, 3-25. 
Drickamer, K. (1988). Two distinct classes of carbohydrate-recognition domains in animal lectins. J Biol 
Chem, 263(20), 9557-9560. 
Drickamer, K. (1992). Engineering galactose-binding activity into a C-type mannose-binding protein. Nature, 
360(6400), 183-186. 
Drickamer, K. (1993). Evolution of Ca(2+)-dependent animal lectins. Prog Nucleic Acid Res Mol Biol, 45, 
207-232. 
247 
 
Drickamer, K. and Dodd, R. B. (1999). C-Type lectin-like domains in Caenorhabditis elegans: predictions 
from the complete genome sequence. Glycobiology, 9(12), 1357-1369. 
Drickamer, K. and Taylor, M. E. (1993). Biology of animal lectins. Annu Rev Cell Biol, 9, 237-264. 
Earl, L. A., Bi, S. and Baum, L. G. (2010). N- and O-glycans modulate galectin-1 binding, CD45 signaling, 
and T cell death. J Biol Chem, 285(4), 2232-2244. 
Ellies, L. G., Tsuboi, S., Petryniak, B., Lowe, J. B., Fukuda, M. and Marth, J. D. (1998). Core 2 
oligosaccharide biosynthesis distinguishes between selectin ligands essential for leukocyte homing and 
inflammation. Immunity, 9(6), 881-890. 
Engelhardt, K. R., McGhee, S., Winkler, S., Sassi, A., Woellner, C., Lopez-Herrera, G., Chen, A., Kim, H. S., 
Lloret, M. G., Schulze, I., et al. (2009). Large deletions and point mutations involving the dedicator of 
cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J Allergy Clin Immun, 
124(6), 1289-1302. 
Eppihimer, M. J., Russell, J., Anderson, D. C., Wolitzky, B. A. and Granger, D. N. (1997). Endothelial cell 
adhesion molecule expression in gene-targeted mice. Am J Physiol, 273(4 Pt 2), H1903-1908. 
Fehr, J., Hofmann, V. and Kappeler, U. (1982). Transient reversal of thrombocytopenia in idiopathic 
thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med, 306(21), 1254-1258. 
Fenaille, F., Le Mignon, M., Groseil, C., Ramon, C., Riande, S., Siret, L. and Bihoreau, N. (2007). 
Site-specific N-glycan characterization of human complement factor H. Glycobiology, 17(9), 932-944. 
Fornelli, L., Damoc, E., Thomas, P. M., Kelleher, N. L., Aizikov, K., Denisov, E., Makarov, A. and Tsybin, Y. 
O. (2012). Analysis of intact monoclonal antibody IgG1 by electron transfer dissociation Orbitrap FTMS. Mol 
Cell Proteomics, 11(12), 1758-1767. 
Fornelli, L., Parra, J., Hartmer, R., Stoermer, C., Lubeck, M. and Tsybin, Y. O. (2013). Top-down analysis of 
30-80 kDa proteins by electron transfer dissociation time-of-flight mass spectrometry. Anal Bioanal Chem, 
405(26), 8505-8514. 
Fouillit, M., Joubert-Caron, R., Poirier, F., Bourin, P., Monostori, E., Levi-Strauss, M., Raphael, M., Bladier, 
D. and Caron, M. (2000). Regulation of CD45-induced signaling by galectin-1 in Burkitt lymphoma B cells. 
Glycobiology, 10(4), 413-419. 
Freeman, S. D., Kelm, S., Barber, E. K. and Crocker, P. R. (1995). Characterization of CD33 as a new 
member of the sialoadhesin family of cellular interaction molecules. Blood, 85(8), 2005-2012. 
Freeze, H. H. (2006). Genetic defects in the human glycome. Nat Rev Genet, 7(7), 537-551. 
Freeze, H. H., Chong, J. X., Bamshad, M. J. and Ng, B. G. (2014). Solving glycosylation disorders: 
fundamental approaches reveal complicated pathways. Am J Hum Genet, 94(2), 161-175. 
248 
 
Frickel, E. M., Riek, R., Jelesarov, I., Helenius, A., Wuthrich, K. and Ellgaard, L. (2002). TROSY-NMR 
reveals interaction between ERp57 and the tip of the calreticulin P-domain. Proc Natl Acad Sci U S A, 99(4), 
1954-1959. 
Fukuda, M., Bothner, B., Ramsamooj, P., Dell, A., Tiller, P. R., Varki, A. and Klock, J. C. (1985). Structures 
of sialylated fucosyl polylactosaminoglycans isolated from chronic myelogenous leukemia cells. J Biol Chem, 
260(24), 12957-12967. 
Fukuda, M., Spooncer, E., Oates, J. E., Dell, A. and Klock, J. C. (1984). Structure of sialylated fucosyl 
lactosaminoglycan isolated from human granulocytes. J Biol Chem, 259(17), 10925-10935. 
Fukumori, T., Takenaka, Y., Yoshii, T., Kim, H. R., Hogan, V., Inohara, H., Kagawa, S. and Raz, A. (2003). 
CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res, 63(23), 8302-8311. 
Fukuta, K., Abe, R., Yokomatsu, T., Kono, N., Nagatomi, Y., Asanagi, M., Shimazaki, Y. and Makino, T. 
(2000). Comparative study of the N-glycans of human monoclonal immunoglobulins M produced by 
hybridoma and parental cells. Arch Biochem Biophys, 378(1), 142-150. 
Gala, F. A. and Morrison, S. L. (2002). The role of constant region carbohydrate in the assembly and secretion 
of human IgD and IgA1. J Biol Chem, 277(32), 29005-29011. 
Galli, C., Bernasconi, R., Solda, T., Calanca, V. and Molinari, M. (2011). Malectin participates in a backup 
glycoprotein quality control pathway in the mammalian ER. PLoS One, 6(1), e16304. 
Galvan, M., Tsuboi, S., Fukuda, M. and Baum, L. G. (2000). Expression of a specific glycosyltransferase 
enzyme regulates T cell death mediated by galectin-1. J Biol Chem, 275(22), 16730-16737. 
Garcia-Vallejo, J. J., van Liempt, E., da Costa Martins, P., Beckers, C., van het Hof, B., Gringhuis, S. I., 
Zwaginga, J. J., van Dijk, W., Geijtenbeek, T. B., van Kooyk, Y., et al. (2008). DC-SIGN mediates adhesion 
and rolling of dendritic cells on primary human umbilical vein endothelial cells through LewisY antigen 
expressed on ICAM-2. Mol Immunol, 45(8), 2359-2369. 
Garman, S. C., Sechi, S., Kinet, J. P. and Jardetzky, T. S. (2001). The analysis of the human high affinity IgE 
receptor Fc epsilon RI alpha from multiple crystal forms. J Mol Biol, 311(5), 1049-1062. 
Garner, O. B., Aguilar, H. C., Fulcher, J. A., Levroney, E. L., Harrison, R., Wright, L., Robinson, L. R., 
Aspericueta, V., Panico, M., Haslam, S. M., et al. (2010). Endothelial Galectin-1 Binds to Specific Glycans 
on Nipah Virus Fusion Protein and Inhibits Maturation, Mobility, and Function to Block Syncytia Formation. 
Plos Pathog, 6(7), e1000993. 
Gauthier, L., Rossi, B., Roux, F., Termine, E. and Schiff, C. (2002). Galectin-1 is a stromal cell ligand of the 
pre-B cell receptor (BCR) implicated in synapse formation between pre-B and stromal cells and in pre-BCR 
triggering. P Natl Acad Sci USA, 99(20), 13014-13019. 
Geijtenbeek, T. B. H. and Gringhuis, S. I. (2009). Signalling through C-type lectin receptors: shaping immune 
responses. Nat Rev Immunol, 9(7), 465-479. 
249 
 
Geijtenbeek, T. B. H., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C. F., Adema, G. J., van Kooyk, Y. 
and Figdor, C. G. (2000). Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that 
supports primary immune responses. Cell, 100(5), 575-585. 
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S. and Varki, A. (2010). Implications of the presence of 
N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol, 28(8), 863-867. 
Goetze, A. M., Liu, Y. D., Zhang, Z., Shah, B., Lee, E., Bondarenko, P. V. and Flynn, G. C. (2011). 
High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. 
Glycobiology, 21(7), 949-959. 
Goldberg, D., Sutton-Smith, M., Paulson, J. and Dell, A. (2005). Automatic annotation of matrix-assisted 
laser desorption/ionization N-glycan spectra. Proteomics, 5(4), 865-875. 
Goldsby, R. A., Kindt, T. J., Osborne, B. A. and Kuby, J. (2000). Kuby Immunology. New York, W.H. 
Freeman. 
Goodnow, C. C. (2007). Multistep pathogenesis of autoimmune disease. Cell, 130(1), 25-35. 
Gornik, I., Maravic, G., Dumic, J., Flogel, M. and Lauc, G. (1999). Fucosylation of IgG heavy chains is 
increased in rheumatoid arthritis. Clin Biochem, 32(8), 605-608. 
Gottschalk, A. (1952). Carbohydrate residue of a urine mucoprotein inhibiting influenza virus 
haemagglutination. Nature, 170(4329), 662-663. 
Gould, H. J. and Sutton, B. J. (2008). IgE in allergy and asthma today. Nat Rev Immunol, 8(3), 205-217. 
Green, P. J., Tamatani, T., Watanabe, T., Miyasaka, M., Hasegawa, A., Kiso, M., Yuen, C. T., Stoll, M. S. and 
Feizi, T. (1992). High affinity binding of the leucocyte adhesion molecule L-selectin to 3'-sulphated-Le(a) and 
-Le(x) oligosaccharides and the predominance of sulphate in this interaction demonstrated by binding studies 
with a series of lipid-linked oligosaccharides. Biochem Biophys Res Commun, 188(1), 244-251. 
Greig, K. T., Antonchuk, J., Metcalf, D., Morgan, P. O., Krebs, D. L., Zhang, J. G., Hacking, D. F., Bode, L., 
Robb, L., Kranz, C., et al. (2007). Agm1/Pgm3-mediated sugar nucleotide synthesis is essential for 
hematopoiesis and development. Mol Cell Biol, 27(16), 5849-5859. 
Grimbacher, B., Holland, S. M., Gallin, J. I., Greenberg, F., Hill, S. C., Malech, H. L., Miller, J. A., O'Connell, 
A. C. and Puck, J. M. (1999). Hyper-IgE syndrome with recurrent infections - An autosomal dominant 
multisystem disorder. New Engl J Med, 340(9), 692-702. 
Hamerman, J. A. and Lanier, L. L. (2006). Inhibition of immune responses by ITAM-bearing receptors. Sci 
STKE, 2006(320), re1. 
Hanisch, F. G. (2001). O-glycosylation of the mucin type. Biol Chem, 382(2), 143-149. 
Harazono, A., Kawasaki, N., Itoh, S., Hashii, N., Matsuishi-Nakajima, Y., Kawanishi, T. and Yamaguchi, T. 
250 
 
(2008). Simultaneous glycosylation analysis of human serum glycoproteins by high-performance liquid 
chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 869(1-2), 
20-30. 
Hard, K., Van Zadelhoff, G., Moonen, P., Kamerling, J. P. and Vliegenthart, F. G. (1992). The Asn-linked 
carbohydrate chains of human Tamm-Horsfall glycoprotein of one male. Novel sulfated and novel 
N-acetylgalactosamine-containing N-linked carbohydrate chains. Eur J Biochem, 209(3), 895-915. 
Harrison, R., Hitchen, P. G., Panico, M., Morris, H. R., Mekhaiel, D., Pleass, R. J., Dell, A., Hewitt, J. E. and 
Haslam, S. M. (2012). Glycoproteomic characterization of recombinant mouse alpha-dystroglycan. 
Glycobiology, 22(5), 662-675. 
Hart, G. W., Slawson, C., Ramirez-Correa, G. and Lagerlof, O. (2011). Cross talk between O-GlcNAcylation 
and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem,80, 825-858. 
Harvey, D. J. (1999). Matrix-assisted laser desorption/ionization mass spectrometry of carbohydrates. Mass 
Spectrom Rev, 18(6), 349-450. 
Haslam, S. M., Coles, G. C., Munn, E. A., Smith, T. S., Smith, H. F., Morris, H. R. and Dell, A. (1996). 
Haemonchus contortus glycoproteins contain N-linked oligosaccharides with novel highly fucosylated core 
structures. J Biol Chem, 271(48), 30561-30570. 
Haslam, S. M., Julien, S., Burchell, J. M., Monk, C. R., Ceroni, A., Garden, O. A. and Dell, A. (2008). 
Characterizing the glycome of the mammalian immune system. Immunol Cell Biol, 86(7), 564-573. 
Hayee, B., Antonopoulos, A., Murphy, E. J., Rahman, F. Z., Sewell, G., Smith, B. N., McCartney, S., Furman, 
M., Hall, G., Bloom, S. L., et al. (2011). G6PC3 mutations are associated with a major defect of glycosylation: 
a novel mechanism for neutrophil dysfunction. Glycobiology, 21(7), 914-924. 
Hemmerich, S., Bertozzi, C. R., Leffler, H. and Rosen, S. D. (1994). Identification of the sulfated 
monosaccharides of GlyCAM-1, an endothelial-derived ligand for L-selectin. Biochemistry, 33(16), 
4820-4829. 
Hemmerich, S., Leffler, H. and Rosen, S. D. (1995). Structure of the O-glycans in GlyCAM-1, an 
endothelial-derived ligand for L-selectin. J Biol Chem, 270(20), 12035-12047. 
Hemmerich, S. and Rosen, S. D. (1994). 6'-sulfated sialyl-Lewis-X is a major capping group of glycam-1. 
Biochemistry, 33(16), 4830-4835. 
Hernandez, J. D., Nguyen, J. T., He, J., Wang, W., Ardman, B., Green, J. M., Fukuda, M. and Baum, L. G. 
(2006). Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death. J Immunol, 
177(8), 5328-5336. 
Hibbs, M. L., Tarlinton, D. M., Armes, J., Grail, D., Hodgson, G., Maglitto, R., Stacker, S. A. and Dunn, A. R. 
R. (1995). Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. 
Cell, 83(2), 301-311. 
251 
 
Hidalgo, A., Peired, A. J., Wild, M. K., Vestweber, D. and Frenette, P. S. (2007). Complete identification of 
E-selectin ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD44. Immunity, 26(4), 
477-489. 
Higai, K., Azuma, Y., Aoki, Y. and Matsumoto, K. (2003). Altered glycosylation of alpha1-acid glycoprotein 
in patients with inflammation and diabetes mellitus. Clin Chim Acta, 329(1-2), 117-125. 
Hirabayashi, J. and Kasai, K. (1993). The family of metazoan metal-independent beta-galactoside-binding 
lectins: structure, function and molecular evolution. Glycobiology, 3(4), 297-304. 
Holland, S. M., DeLeo, F. R., Elloumi, H. Z., Hsu, A. P., Uzel, G., Brodsky, N., Freeman, A. F., Demidowich, 
A., Davis, J., Turner, M. L., et al. (2007). STAT3 mutations in the hyper-IgE syndrome. N Engl J Med, 
357(16), 1608-1619. 
Holmes, E. H. (1988). Characterization of a beta 1-3-N-acetylglucosaminyltransferase associated with 
synthesis of type 1 and type 2 lacto-series tumor-associated antigens from the human colonic adenocarcinoma 
cell line SW403. Arch Biochem Biophys, 260(1), 461-468. 
Homeister, J. W., Thall, A. D., Petryniak, B., Maly, P., Rogers, C. E., Smith, P. L., Kelly, R. J., Gersten, K. M., 
Askari, S. W., Cheng, G., et al. (2001). The alpha(1,3)fucosyltransferases FucT-IV and FucT-VII exert 
collaborative control over selectin-dependent leukocyte recruitment and lymphocyte homing. Immunity, 15(1), 
115-126. 
Hosokawa, N., Kamiya, Y. and Kato, K. (2010). The role of MRH domain-containing lectins in ERAD. 
Glycobiology, 20(6), 651-660. 
Hosokawa, N., Tremblay, L. O., You, Z., Herscovics, A., Wada, I. and Nagata, K. (2003). Enhancement of 
endoplasmic reticulum (ER) degradation of misfolded Null Hong Kong alpha1-antitrypsin by human ER 
mannosidase I. J Biol Chem, 278(28), 26287-26294. 
Huang, C., Bhaskaran, R. and Mohanty, S. (2012). Eukaryotic N-glycosylation occurs via the 
membrane-anchored C-terminal domain of the Stt3p subunit of oligosaccharyltransferase. J Biol Chem, 
287(39), 32450-32458. 
Huddleston, M. J., Bean, M. F. and Carr, S. A. (1993). Collisional fragmentation of glycopeptides by 
electrospray ionization LC/MS and LC/MS/MS: methods for selective detection of glycopeptides in protein 
digests. Anal Chem, 65(7), 877-884. 
Huhn, C., Selman, M. H. J., Ruhaak, L. R., Deelder, A. M. and Wuhrer, M. (2009). IgG glycosylation analysis. 
Proteomics, 9(4), 882-913. 
Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E. 
and Engelhard, V. H. (1992). Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by 
mass spectrometry. Science, 255(5049), 1261-1263. 
Hunt, D. F., Michel, H., Dickinson, T. A., Shabanowitz, J., Cox, A. L., Sakaguchi, K., Appella, E., Grey, H. M. 
252 
 
and Sette, A. (1992). Peptides presented to the immune system by the murine class-II major 
histocompatibility ccomplex molecule I-Ad. Science, 256(5065), 1817-1820. 
Igura, M., Maita, N., Kamishikiryo, J., Yamada, M., Obita, T., Maenaka, K. and Kohda, D. (2008). 
Structure-guided identification of a new catalytic motif of oligosaccharyltransferase. EMBO J, 27(1), 
234-243. 
Ikehara, Y., Ikehara, S. K. and Paulson, J. C. (2004). Negative regulation of T cell receptor signaling by 
Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem, 279(41), 43117-43125. 
Imai, Y., Lasky, L. A. and Rosen, S. D. (1993). Sulfation requirement for Glycam-1, an endothelial ligand for 
L-selectin. Nature, 361(6412), 555-557. 
Imai, Y., Singer, M. S., Fennie, C., Lasky, L. A. and Rosen, S. D. (1991). Identification of a 
carbohydrate-based endothelial ligand for a lymphocyte homing receptor. J Cell Biol, 113(5), 1213-1221. 
Imbach, P., Barandun, S., d'Apuzzo, V., Baumgartner, C., Hirt, A., Morell, A., Rossi, E., Schoni, M., Vest, M. 
and Wagner, H. P. (1981). High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in 
childhood. Lancet, 1(8232), 1228-1231. 
Imre, T., Kremmer, T., Heberger, K., Molnar-Szollosi, E., Ludanyi, K., Pocsfalvi, G., Malorni, A., Drahos, L. 
and Vekey, K. (2008). Mass spectrometric and linear discriminant analysis of N-glycans of human serum 
alpha-1-acid glycoprotein in cancer patients and healthy individuals. J proteomics, 71(2), 186-197. 
Jin, L., McLean, P. A., Neel, B. G. and Wortis, H. H. (2002). Sialic acid binding domains of CD22 are 
required for negative regulation of B cell receptor signaling. J Exp Med, 195(9), 1199-1205. 
Jonuleit, H., Schmitt, E., Schuler, G., Knop, J. and Enk, A. H. (2000). Induction of interleukin 10-producing, 
nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature 
human dendritic cells. J Exp Med, 192(9), 1213-1222. 
Julien, S., Grimshaw, M. J., Sutton-Smith, M., Coleman, J., Morris, H. R., Dell, A., Taylor-Papadimitriou, J. 
and Burche, J. M. (2007). Sialyl-lewis(x) on P-selectin glycoprotein ligand-1 is regulated during 
differentiation and maturation of dendritic cells: A mechanism involving the glycosyltransferases C2GnT1 
and ST3Gal I. J Immunol, 179(9), 5701-5710. 
Junghans, R. P. and Anderson, C. L. (1996). The protection receptor for IgG catabolism is the 
beta(2)-microglobulin-containing neonatal intestinal transport receptor. P Natl Acad Sci USA, 93(11), 
5512-5516. 
Kaneko, M., Alvarez-Manilla, G., Kamar, M., Lee, I., Lee, J. K., Troupe, K., Zhang, W., Osawa, M. and 
Pierce, M. (2003). A novel beta(1,6)-N-acetylglucosaminyltransferase V (GnT-VB)(1). FEBS Lett, 554(3), 
515-519. 
Kaneko, Y., Nimmerjahn, F. and Ravetch, J. V. (2006). Anti-inflammatory activity of immunoglobulin G 
resulting from Fc sialylation. Science, 313(5787), 670-673. 
253 
 
Kang, P., Mechref, Y., Kyselova, Z., Goetz, J. A. and Novotny, M. V. (2007). Comparative glycomic mapping 
through quantitative permethylation and stable-isotope labeling. Anal Chem, 79(16), 6064-6073. 
Kapron, J. T., Hilliard, G. M., Lakins, J. N., Tenniswood, M. P., West, K. A., Carr, S. A. and Crabb, J. W. 
(1997). Identification and characterization of glycosylation sites in human serum clusterin. Protein Sci, 6(10), 
2120-2133. 
Karas, M. (1997). Time-of-flight mass spectrometer with improved resolution. J Mass Spectrom, 32(1), 1-3. 
Karas, M., Bachmann, D. and Hillenkamp, F. (1985). Influence of the wavelength in high-irradiance 
ultraviolet-laser desorption mass spectrometry of organic molecules. Anal Chem, 57(14), 2935-2939. 
Karas, M., Bahr, U. and Dulcks, T. (2000). Nano-electrospray ionization mass spectrometry: addressing 
analytical problems beyond routine. Fresenius J Anal Chem, 366(6-7), 669-676. 
Karas, M., Bahr, U., Strupat, K., Hillenkamp, F., Tsarbopoulos, A. and Pramanik, B. N. (1995). Matrix 
dependence of metastable fragmentation of glycoproteins in MALDI TOF mass spectrometry. Anal Chem, 
67(3), 675-679. 
Karas, M. and Hillenkamp, F. (1988). Laser desorption ionization of proteins with molecular masses 
exceeding 10,000 daltons. Anal Chem, 60(20), 2299-2301. 
Karlsson, A., Dahlgren, C., Feuk-Lagerstedt, E., Jordan, E. T. and Leffler, H. (1998). Galectin-3 activates the 
NADPH-oxidase in human neutrophils but not in HL-60 cells due to differences in receptor repertoire. J 
Leukocyte Biol, 17-17. 
Katayama, Y., Hidalgo, A., Chang, J. S., Peired, A. and Frenette, P. S. (2005). CD44 is a physiological 
E-selectin ligand on neutrophils. J Exp Med, 201(8), 1183-1189. 
Kawai, T. and Akira, S. (2010). The role of pattern-recognition receptors in innate immunity: update on 
Toll-like receptors. Nat Immunol, 11(5), 373-384. 
Kawasaki, T., Nakao, H., Takahashi, E. and Tominaga, T. (2006). GlycoEpitope: the integrated database of 
carbohydrate antigens and antibodies. Trends Glycosci Glyc, 18(102), 267-272. 
Kelleher, D. J. and Gilmore, R. (2006). An evolving view of the eukaryotic oligosaccharyltransferase. 
Glycobiology, 16(4), 47R-62R. 
Kelm, S., Gerlach, J., Brossmer, R., Danzer, C. P. and Nitschke, L. (2002). The ligand-binding domain of 
CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific 
inhibitor compound. J Exp Med, 195(9), 1207-1213. 
Kelm, S., Pelz, A., Schauer, R., Filbin, M. T., Tang, S., de Bellard, M. E., Schnaar, R. L., Mahoney, J. A., 
Hartnell, A., Bradfield, P., et al. (1994). Sialoadhesin, myelin-associated glycoprotein and CD22 define a new 
family of sialic acid-dependent adhesion molecules of the immunoglobulin superfamily. Curr Biol, 4(11), 
965-972. 
254 
 
Khoo, K. H., Sarda, S., Xu, X., Caulfield, J. P., McNeil, M. R., Homans, S. W., Morris, H. R. and Dell, A. 
(1995). A unique multifucosylated -3GalNAc beta 1-->4GlcNAc beta 1-->3Gal alpha 1- motif constitutes the 
repeating unit of the complex O-glycans derived from the cercarial glycocalyx of Schistosoma mansoni. J 
Biol Chem, 270(29), 17114-17123. 
Kinet, J. P. (1999). The high-affinity IgE receptor (Fc epsilon RI): From physiology to pathology. Anu Rev 
Immunol, 17, 931-972. 
Klein, A., Michalski, J. C. and Morelle, W. (2010). Modifications of human total serum N-glycome during 
liver fibrosis-cirrhosis, is it all about immunoglobulins? Proteom Clin Appl, 4(4), 372-378. 
Knochenmuss, R. (2006). Ion formation mechanisms in UV-MALDI. Analyst, 131(9), 966-986. 
Kolarich, D., Weber, A., Turecek, P. L., Schwarz, H. P. and Altmann, F. (2006). Comprehensive 
glyco-proteomic analysis of human alpha1-antitrypsin and its charge isoforms. Proteomics, 6(11), 3369-3380. 
Kozlov, G., Bastos-Aristizabal, S., Maattanen, P., Rosenauer, A., Zheng, F., Killikelly, A., Trempe, J. F., 
Thomas, D. Y. and Gehring, K. (2010). Structural basis of cyclophilin B binding by the calnexin/calreticulin 
P-domain. J Biol Chem, 285(46), 35551-35557. 
Krysov, S., Potter, K. N., Mockridge, C. I., Coelho, V., Wheatley, I., Packham, G. and Stevenson, F. K. (2010). 
Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo. Blood, 
115(21), 4198-4205. 
Kubach, J., Lutter, P., Bopp, T., Stoll, S., Becker, C., Huter, E., Richter, C., Weingarten, P., Warger, T., Knop, 
J., et al. (2007). Human CD4(+)CD25(+) regulatory T cells: proteome analysis identifies galectin-10 as a 
novel marker essential for their anergy and suppressive function. Blood, 110(5), 1550-1558. 
Kukushkin N. V., Alonzi D. S., Dwek R. A., Butters T. D. (2011). Demonstration that endoplasmic 
reticulum-associated degradation of glycoproteins can occur downstream of processing by endomannosidase. 
Biochem J, 438 (1), 133-142 
Kuwabara, I. and Liu, F. T. (1996). Galectin-3 promotes adhesion of human neutrophils to laminin. J Immunol, 
156(10), 3939-3944. 
Labriola, C., Cazzulo, J. J. and Parodi, A. J. (1995). Retention of glucose units added by the 
UDP-GLC:glycoprotein glucosyltransferase delays exit of glycoproteins from the endoplasmic reticulum. J 
Cell Biol, 130(4), 771-779. 
Lau, K. S., Partridge, E. A., Grigorian, A., Silvescu, C. I., Reinhold, V. N., Demetriou, M. and Dennis, J. W. 
(2007). Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and 
differentiation. Cell, 129(1), 123-134. 
Lemieux, G. A., Blumenkron, F., Yeung, N., Zhou, P., Williams, J., Grammer, A. C., Petrovich, R., Lipsky, P. 
E., Moss, M. L. and Werb, Z. (2007). The low affinity IgE receptor (CD23) is cleaved by the 
metalloproteinase ADAM10. J Biol Chem, 282(20), 14836-14844. 
255 
 
Lenter, M., Levinovitz, A., Isenmann, S. and Vestweber, D. (1994). Monospecific and common glycoprotein 
ligands for E- and P-selectin on myeloid cells. J Cell Biol, 125(2), 471-481. 
Levinovitz, A., Muhlhoff, J., Isenmann, S. and Vestweber, D. (1993). Identification of a glycoprotein ligand 
for E-selectin on mouse myeloid cells. J Cell Biol, 121(2), 449-459. 
Linscheid, M., Dangona, J., Burlingame, A. L., Dell, A. and Ballou, C. E. (1981). Field desorption mass 
spectrometry of oligosaccharides. P Natl Acad Sci-Biol, 78(3), 1471-1475. 
Liu, F. T. (2005). Regulatory roles of galectins in the immune response. Int Arch Allergy Immunol, 136(4), 
385-400. 
Liu, F. T., Patterson, R. J. and Wang, J. L. (2002). Intracellular functions of galectins. Biochim Biophys Acta, 
1572(2-3), 263-273. 
Liu, W., Ramachandran, V., Kang, J., Kishimoto, T. K., Cummings, R. D. and McEver, R. P. (1998). 
Identification of N-terminal residues on P-selectin glycoprotein ligand-1 required for binding to P-selectin. J 
Biol Chem, 273(12), 7078-7087. 
Lizak, C., Gerber, S., Numao, S., Aebi, M. and Locher, K. P. (2011). X-ray structure of a bacterial 
oligosaccharyltransferase. Nature, 474(7351), 350-355. 
Lo, C. Y., Antonopoulos, A., Gupta, R., Qu, J., Dell, A., Haslam, S. M. and Neelamegham, S. (2013). 
Competition between Core-2 GlcNAc-transferase and ST6GalNAc-transferase regulates the synthesis of the 
leukocyte selectin ligand on human P-selectin glycoprotein ligand-1. J Biol Chem, 288(20), 13974-13987. 
Lowe, J. B. (2002). Glycosylation in the control of selectin counter-receptor structure and function. Immunol 
Rev, 186, 19-36. 
Ludin, C., Hofstetter, H., Sarfati, M., Levy, C. A., Suter, U., Alaimo, D., Kilchherr, E., Frost, H. and 
Delespesse, G. (1987). Cloning and expression of the cDNA coding for a human lymphocyte IgE receptor. 
EMBO J, 6(1), 109-114. 
Lund, J., Takahashi, N., Pound, J. D., Goodall, M. and Jefferis, R. (1996). Multiple interactions of IgG with 
its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and 
influence the synthesis of its oligosaccharide chains. J Immunol, 157(11), 4963-4969. 
Lutteke, T., Bohne-Lang, A., Loss, A., Goetz, T., Frank, M. and von der Lieth, C. W. (2006). 
GLYCOSCIENCES.de: an Internet portal to support glycomics and glycobiology research. Glycobiology, 
16(5), 71R-81R. 
Maass, K., Ranzingei, R., Geyer, H., von der Lieth, C. W. and Geyer, R. (2007). "Glyco-peakfinder" - de novo 
composition analysis of glycoconjugates. Proteomics, 7(24), 4435-4444. 
Maita, N., Nyirenda, J., Igura, M., Kamishikiryo, J. and Kohda, D. (2010). Comparative structural biology of 
eubacterial and archaeal oligosaccharyltransferases. J Biol Chem, 285(7), 4941-4950. 
256 
 
Makarov, A. (2000). Electrostatic axially harmonic orbital trapping: a high-performance technique of mass 
analysis. Anal Chem, 72(6), 1156-1162. 
Mallick, P., Schirle, M., Chen, S. S., Flory, M. R., Lee, H., Martin, D., Ranish, J., Raught, B., Schmitt, R., 
Werner, T., et al. (2007). Computational prediction of proteotypic peptides for quantitative proteomics. Nat 
Biotechnol, 25(1), 125-131. 
Marklova, E. and Albahri, Z. (2007). Screening and diagnosis of congenital disorders of glycosylation. Clin 
Chim Acta, 385(1-2), 6-20. 
McEver, R. P. and Cummings, R. D. (1997). Role of PSGL-1 binding to selectins in leukocyte recruitment. J 
Clin Invest, 100(11 Suppl), S97-103. 
McEver, R. P., Moore, K. L. and Cummings, R. D. (1995). Leukocyte trafficking mediated by 
selectin-carbohydrate interactions. J Biol Chem, 270(19), 11025-11028. 
Mekhaiel, D. N., Czajkowsky, D. M., Andersen, J. T., Shi, J., El-Faham, M., Doenhoff, M., McIntosh, R. S., 
Sandlie, I., He, J., Hu, J., et al. (2011). Polymeric human Fc-fusion proteins with modified effector functions. 
Sci Rep, 1, 124. 
Minegishi, Y., Saito, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pasic, S., 
Stojkovic, O., et al. (2007). Dominant-negative mutations in the DNA-binding domain of STAT3 cause 
hyper-IgE syndrome. Nature, 448(7157), 1058-1062. 
Mitra, N., Banda, K., Altheide, T. K., Schaffer, L., Johnson-Pais, T. L., Beuten, J., Leach, R. J., Angata, T., 
Varki, N. and Varki, A. (2011). SIGLEC12, a human-specific segregating (pseudo)gene, encodes a signaling 
molecule expressed in prostate carcinomas. J Biol Chem, 286(26), 23003-23011. 
Moody, A. M., Chui, D., Reche, P. A., Priatel, J. J., Marth, J. D. and Reinherz, E. L. (2001). Developmentally 
regulated glycosylation of the CD8alphabeta coreceptor stalk modulates ligand binding. Cell, 107(4), 
501-512. 
Moody, A. M., North, S. J., Reinhold, B., Van Dyken, S. J., Rogers, M. E., Panico, M., Dell, A., Morris, H. R., 
Marth, J. D. and Reinherz, E. L. (2003). Sialic acid capping of CD8beta core 1-O-glycans controls 
thymocyte-major histocompatibility complex class I interaction. J Biol Chem, 278(9), 7240-7246. 
Moore, K. L., Stults, N. L., Diaz, S., Smith, D. F., Cummings, R. D., Varki, A. and McEver, R. P. (1992). 
Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. J Cell Biol, 118(2), 
445-456. 
Morris, H. R. (1972). Studies towards the complete sequence determination of proteins by mass spectrometry; 
a rapid procedure for the successful permethylation of histidine containing peptides. FEBS Lett, 22(3), 
257-260. 
Morris, H. R., Batley, K. E., Harding, N. G. L., Bjur, R. A., Dann, J. G. and King, R. W. (1974). Dihydrofolate 
reductase: low resolution mass spectrometric analysis of an elastase digest as a sequencing tool. Biochem J, 
257 
 
137(2), 409-411. 
Morris, H. R., Paxton, T., Panico, M., McDowell, R. and Dell, A. (1997). A novel geometry mass 
spectrometer, the Q-TOF, for low-femtomole/attomole-range biopolymer sequencing. J Protein Chem, 16(5), 
469-479. 
Morris, H. R., Thompson, M. R. and Dell, A. (1975). Synthesis and proof of structure of the new amino acid 
in prothrombin. Biochem Biophys Res Commun, 62(4), 856-861. 
Morris, H. R., Thompson, M. R., Osuga, D. T., Ahmed, A. I., Chan, S. M., Vandenheede, J. R. and Feeney, R. 
E. (1978). Antifreeze glycoproteins from the blood of an antarctic fish. The structure of the proline-containing 
glycopeptides. J Biol Chem, 253(14), 5155-5162. 
Morris, H. R., Williams, D. H., Midwinter, G. G. and Hartley, B. S. (1974). A mass-spectrometric sequence 
study of the enzyme ribitol dehydrogenase from Klebsiella aerogenes. Biochem J, 141(3), 701-713. 
Naito, Y., Takematsu, H., Koyama, S., Miyake, S., Yamamoto, H., Fujinawa, R., Sugai, M., Okuno, Y., 
Tsujimoto, G., Yamaji, T., et al. (2007). Germinal center marker GL7 probes activation-dependent repression 
of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation. 
Mol Cell Biol, 27(8), 3008-3022. 
Nesvizhskii, A. I. and Aebersold, R. (2005). Interpretation of shotgun proteomic data: the protein inference 
problem. Mol Cell Proteomics, 4(10), 1419-1440. 
Nikolova, K. A., Tchorbanov, A. I., Djoumerska-Alexieva, I. K., Nikolova, M. and Vassilev, T. L. (2009). 
Intravenous immunoglobulin up-regulates the expression of the inhibitory Fc gamma IIB receptor on B cells. 
Immunol Cell Biol, 87(7), 529-533. 
Nimmerjahn, F. and Ravetch, J. V. (2007). The antiinflammatory activity of IgG: the intravenous IgG paradox. 
J Exp Med, 204(1), 11-15. 
Nishizumi, H., Taniuchi, I., Yamanashi, Y., Kitamura, D., Ilic, D., Mori, S., Watanabe, T. and Yamamoto, T. 
(1995). Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient 
mice. Immunity, 3(5), 549-560. 
Nitschke, L., Carsetti, R., Ocker, B., Kohler, G. and Lamers, M. C. (1997). CD22 is a negative regulator of 
B-cell receptor signalling. Curr Biol, 7(2), 133-143. 
Norambuena, A., Metz, C., Vicuna, L., Silva, A., Pardo, E., Oyanadel, C., Massardo, L., Gonzalez, A. and 
Soza, A. (2009). Galectin-8 induces apoptosis in Jurkat T cells by phosphatidic acid-mediated ERK1/2 
activation supported by protein kinase A down-regulation. J Biol Chem, 284(19), 12670-12679. 
Norgard, K. E., Moore, K. L., Diaz, S., Stults, N. L., Ushiyama, S., McEver, R. P., Cummings, R. D. and 
Varki, A. (1993). Characterization of a specific ligand for P-selectin on myeloid cells. A minor glycoprotein 
with sialylated O-linked oligosaccharides. J Biol Chem, 268(17), 12764-12774. 
258 
 
North, S. J., Jang-Lee, J., Harrison, R., Canis, K., Ismail, M. N., Trollope, A., Antonopoulos, A., Pang, P. C., 
Grassi, P., Al-Chalabi, S., et al. (2010). Mass spectrometric analysis of mutant mice. Methods Enzymol, 478, 
27-77. 
North, S. J., von Gunten, S., Antonopoulos, A., Trollope, A., MacGlashan, D. W., Jang-Lee, J., Dell, A., 
Metcalfe, D. D., Kirshenbaum, A. S., Bochner, B. S., et al. (2012). Glycomic analysis of human mast cells, 
eosinophils and basophils. Glycobiology, 22(1), 12-22. 
O'Keefe, T. L., Williams, G. T., Batista, F. D. and Neuberger, M. S. (1999). Deficiency in CD22, a B 
cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J 
Exp Med, 189(8), 1307-1313. 
O'Keefe, T. L., Williams, G. T., Davies, S. L. and Neuberger, M. S. (1996). Hyperresponsive B cells in 
CD22-deficient mice. Science, 274(5288), 798-801. 
Oda, Y., Herrmann, J., Gitt, M. A., Turck, C. W., Burlingame, A. L., Barondes, S. H. and Leffler, H. (1993). 
Soluble lactose-binding lectin from rat intestine with two different carbohydrate-binding domains in the same 
peptide chain. J Biol Chem, 268(8), 5929-5939. 
Olivari, S. and Molinari, M. (2007). Glycoprotein folding and the role of EDEM1, EDEM2 and EDEM3 in 
degradation of folding-defective glycoproteins. FEBS Lett, 581(19), 3658-3664. 
Orlando, R. (2010). Quantitative glycomics. Methods Mol Biol, 600, 31-49. 
Orlando, R., Lim, J. M., Atwood, J. A., 3rd, Angel, P. M., Fang, M., Aoki, K., Alvarez-Manilla, G., Moremen, 
K. W., York, W. S., Tiemeyer, M., et al. (2009). IDAWG: Metabolic incorporation of stable isotope labels for 
quantitative glycomics of cultured cells. J Proteome Res, 8(8), 3816-3823. 
Ozcan, S., Andrali, S. S. and Cantrell, J. E. L. (2010). Modulation of transcription factor function by 
O-GlcNAc modification. Bba-Gene Regul Mech, 1799(5-6), 353-364. 
Pace, K. E., Lee, C., Stewart, P. L. and Baum, L. G. (1999). Restricted receptor segregation into membrane 
microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol, 163(7), 
3801-3811. 
Paclik, D., Danese, S., Berndt, U., Wiedenmann, B., Dignass, A. and Sturm, A. (2008). Galectin-4 controls 
intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. 
PLoS One, 3(7), e2629. 
Padler-Karavani, V., Yu, H., Cao, H., Chokhawala, H., Karp, F., Varki, N., Chen, X. and Varki, A. (2008). 
Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential 
implications for disease. Glycobiology, 18(10), 818-830. 
Palikhe, N., Kim, S. H., Yang, E. M., Kang, Y. M., Ye, Y. M., Hur, G. Y. and Park, H. S. (2008). Analysis of 
high-affinity IgE receptor (FcepsilonR1) polymorphisms in patients with aspirin-intolerant chronic urticaria. 
Allergy Asthma Proc, 29(3), 250-257. 
259 
 
Pang, P. C., Chiu, P. C., Lee, C. L., Chang, L. Y., Panico, M., Morris, H. R., Haslam, S. M., Khoo, K. H., 
Clark, G. F., Yeung, W. S., et al. (2011). Human sperm binding is mediated by the sialyl-Lewis(x) 
oligosaccharide on the zona pellucida. Science, 333(6050), 1761-1764. 
Pao, L. I., Lam, K. P., Henderson, J. M., Kutok, J. L., Alimzhanov, M., Nitschke, L., Thomas, M. L., Neel, B. 
G. and Rajewsky, K. (2007). B cell-specific deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell 
development and causes systemic autoimmunity. Immunity, 27(1), 35-48. 
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., 
Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985). Association of rheumatoid arthritis and primary 
osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature, 316(6027), 452-457. 
Park, C. G., Takahara, K., Umemoto, E., Yashima, Y., Matsubara, K., Matsuda, Y., Clausen, B. E., Inaba, K. 
and Steinman, R. M. (2001). Five mouse homologues of the human dendritic cell C-type lectin, DC-SIGN. Int 
Immunol, 13(10), 1283-1290. 
Park, S. Y., Yoon, S. J., Jeong, Y. T., Kim, J. M., Kim, J. Y., Bernert, B., Ullman, T., Itzkowitz, S. H., Kim, J. 
H. and Hakomori, S. I. N-glycosylation status of beta-haptoglobin in sera of patients with colon cancer, 
chronic inflammatory diseases and normal subjects. Int J Cancer, 126(1), 142-155. 
Parsons, C. L., Stein, P., Zupkas, P., Chenoweth, M., Argade, S. P., Proctor, J. G., Datta, A. and Trotter, R. N. 
(2007). Defective Tamm-Horsfall protein in patients with interstitial cystitis. J Urology, 178(6), 2665-2670. 
Pastuszak, I., Drake, R. and Elbein, A. D. (1996). Kidney N-acetylgalactosamine (GalNAc)-1-phosphate 
kinase, a new pathway of GalNAc activation. J Biol Chem, 271(34), 20776-20782. 
Perillo, N. L., Marcus, M. E. and Baum, L. G. (1998). Galectins: versatile modulators of cell adhesion, cell 
proliferation, and cell death. J Mol Med (Berl), 76(6), 402-412. 
Perillo, N. L., Pace, K. E., Seilhamer, J. J. and Baum, L. G. (1995). Apoptosis of T cells mediated by 
galectin-1. Nature, 378(6558), 736-739. 
Perillo, N. L., Uittenbogaart, C. H., Nguyen, J. T. and Baum, L. G. (1997). Galectin-1, an endogenous lectin 
produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med, 185(10), 1851-1858. 
Perry, R. H., Cooks, R. G. and Noll, R. J. (2008). Orbitrap mass spectrometry: instrumentation, ion motion 
and applications. Mass Spectrom Rev, 27(6), 661-699. 
Pillai, S., Netravali, I. A., Cariappa, A. and Mattoo, H. (2012). Siglecs and immune regulation. Annu Rev 
Immunol, 30, 357-392. 
Plomp, R., Hensbergen, P. J., Rombouts, Y., Zauner, G., Dragan, I., Koeleman, C. A., Deelder, A. M. and 
Wuhrer, M. (2014). Site-specific N-glycosylation analysis of human immunoglobulin E. J Proteome Res, 
13(2), 536-546. 
Polley, M. J., Phillips, M. L., Wayner, E., Nudelman, E., Singhal, A. K., Hakomori, S. and Paulson, J. C. 
260 
 
(1991). CD62 and endothelial cell-leukocyte adhesion molecule 1 (ELAM-1) recognize the same 
carbohydrate ligand, sialyl-Lewis X. Proc Natl Acad Sci U S A, 88(14), 6224-6228. 
Potaczek, D. P. and Kabesch, M. (2012). Current concepts of IgE regulation and impact of genetic 
determinants. Clin Exp Allergy, 42(6), 852-871. 
Potaczek, D. P., Sanak, M., Mastalerz, L., Milewski, M., Gawlewicz-Mroczka, A. and Szczeklik, A. (2007). 
Genetic polymorphisms of the novel FCERIA gene region: relation to total serum IgE levels. Ann Allergy 
Asthma Immunol, 98(5), 500-501. 
Potaczek, D. P., Sanak, M., Mastalerz, L., Setkowicz, M., Kaczor, M., Nizankowska, E. and Szczeklik, A. 
(2006). The alpha-chain of high-affinity receptor for IgE (FcepsilonRIalpha) gene polymorphisms and serum 
IgE levels. Allergy, 61(10), 1230-1233. 
Qin, J. and Chait, B. T. (1997). Identification and characterization of posttranslational modifications of 
proteins by MALDI ion trap mass spectrometry. Anal Chem, 69(19), 4002-4009. 
Rabinovich, G. A., Liu, F. T., Hirashima, M. and Anderson, A. (2007). An emerging role for galectins in 
tuning the immune response: Lessons from experimental models of inflammatory disease, autoimmunity and 
cancer. Scand J Immunol, 66(2-3), 143-158. 
Rabinovich, G. A., Rubinstein, N. and Toscano, M. A. (2002). Role of galectins in inflammatory and 
immunomodulatory processes. Biochim Biophys Acta, 1572(2-3), 274-284. 
Rabinovich, G. A. and Toscano, M. A. (2009). Turning 'sweet' on immunity: galectin-glycan interactions in 
immune tolerance and inflammation. Nat Rev Immunol, 9(5), 338-352. 
Rabinovich, G. A., Toscano, M. A., Jackson, S. S. and Vasta, G. R. (2007). Functions of cell surface 
galectin-glycoprotein lattices. Curr Opin Struct Biol, 17(5), 513-520. 
Raman, R., Venkataraman, M., Ramakrishnan, S., Lang, W., Raguram, S. and Sasisekharan, R. (2006). 
Advancing glycomics: implementation strategies at the consortium for functional glycomics. Glycobiology, 
16(5), 82R-90R. 
Ranzinger, R., Maass, K., Geyer, H., Geyer, R. and von der Lieth, C. W. (2006). Webapplication 
"Glyco-Peakfinder" - Automated annotation for MS peaks of glycoconjugates combined with database 
searches. Glycobiology, 16(11), 1137-1137. 
Ravetch, J. V. and Lanier, L. L. (2000). Immune inhibitory receptors. Science, 290(5489), 84-89. 
Redelinghuys, P., Antonopoulos, A., Liu, Y., Campanero-Rhodes, M. A., McKenzie, E., Haslam, S. M., Dell, 
A., Feizi, T. and Crocker, P. R. (2011). Early Murine T-lymphocyte Activation Is Accompanied by a Switch 
from N-Glycolyl- to N-Acetyl-neuraminic Acid and Generation of Ligands for Siglec-E. J Biol Chem, 
286(40), 34522-34532. 
Renner, E. D., Puck, J. M., Holland, S. M., Schmitt, M., Weiss, M., Frosch, M., Bergmann, M., Davis, J., 
261 
 
Belohradsky, B. H. and Grimbacher, B. (2004). Autosomal recessive hyperimmunoglobulin E syndrome: a 
distinct disease entity. J Pediatr, 144(1), 93-99. 
Richards, M. L. and Katz, D. H. (1990). The binding of IgE to murine Fc epsilon RII is calcium-dependent 
but not inhibited by carbohydrate. J Immunol, 144(7), 2638-2646. 
Robinson, K. and Bradley, J. E. (2010). The allergy epidemic: can helminths supply the antidote? Clin Exp 
Allergy, 40(11), 1586-1589. 
Romagnani, S. (2004). Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol, 
113(3), 395-400. 
Rosen, S. D., Chi, S. I., True, D. D., Singer, M. S. and Yednock, T. A. (1989). Intravenously injected sialidase 
inactivates attachment sites for lymphocytes on high endothelial venules. J Immunol, 142(6), 1895-1902. 
Rosen, S. D., Singer, M. S., Yednock, T. A. and Stoolman, L. M. (1985). Involvement of sialic acid on 
endothelial cells in organ-specific lymphocyte recirculation. Science, 228(4702), 1005-1007. 
Royle, L., Roos, A., Harvey, D. J., Wormald, M. R., van Gijlswijk-Janssen, D., Redwan, E. M., Wilson, I. A., 
Daha, M. R., Dwek, R. A. and Rudd, P. M. (2003). Secretory IgA N- and O-glycans provide a link between 
the innate and adaptive immune systems. J Biol Chem, 278(22), 20140-20153. 
Rudd, P. M., Morgan, B. P., Wormald, M. R., Harvey, D. J., van den Berg, C. W., Davis, S. J., Ferguson, M. A. 
J. and Dwek, R. A. (1998). The glycosylation of the complement regulatory protein, human erythrocyte CD59. 
Adv Exp Med Biol, 435, 153-162. 
Ruhaak, L. R., Zauner, G., Huhn, C., Bruggink, C., Deelder, A. M. and Wuhrer, M. (2010). Glycan labeling 
strategies and their use in identification and quantification. Anal Bioanal Chem, 397(8), 3457-3481. 
Sako, D., Chang, X. J., Barone, K. M., Vachino, G., White, H. M., Shaw, G., Veldman, G. M., Bean, K. M., 
Ahern, T. J., Furie, B., et al. (1993). Expression cloning of a functional glycoprotein ligand for P-selectin. 
Cell, 75(6), 1179-1186. 
Samuelsson, A., Towers, T. L. and Ravetch, J. V. (2001). Anti-inflammatory activity of IVIG mediated 
through the inhibitory Fc receptor. Science, 291(5503), 484-486. 
Sancho, D. and Reis e Sousa, C. (2012). Signaling by myeloid C-type lectin receptors in immunity and 
homeostasis. Annu Rev Immunol, 30, 491-529. 
Sassetti, C., Tangemann, K., Singer, M. S., Kershaw, D. B. and Rosen, S. D. (1998). Identification of 
podocalyxin-like protein as a high endothelial venule ligand for L-selectin: Parallels to CD34. J Exp Med, 
187(12), 1965-1975. 
Sassi, A., Lazaroski, S., Wu, G., Haslam, S. M., Fliegauf, M., Mellouli, F., Patiroglu, T., Unal, E., Ozdemir, M. 
A., Jouhadi, Z., et al. (2014). Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair 
immunity and increase serum IgE levels. J Allergy Clin Immunol, 133(5), 1410-1419, 1419 e1411-1413. 
262 
 
Sato, S., Ouellet, N., Pelletier, I., Simard, M., Rancourt, A. and Bergeron, M. G. (2002). Role of galectin-3 as 
an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol, 168(4), 
1813-1822. 
Scallon, B. J., Tam, S. H., McCarthy, S. G., Cal, A. N. and Raju, T. S. (2007). Higher levels of sialylated Fc 
glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol, 44(7), 1524-1534. 
Schachter, H. (2000). The joys of HexNAc. The synthesis and function of N- and O-glycan branches. 
Glycocojugate J, 17(7-9), 465-483. 
Schachter, H., Brockhausen, I. and Hull, E. (1989). High-performance liquid chromatography assays for 
N-acetylglucosaminyltransferases involved in N- and O-glycan synthesis. Methods Enzymol, 179, 351-397. 
Schallus, T., Jaeckh, C., Feher, K., Palma, A. S., Liu, Y., Simpson, J. C., Mackeen, M., Stier, G., Gibson, T. J., 
Feizi, T., et al. (2008). Malectin: a novel carbohydrate-binding protein of the endoplasmic reticulum and a 
candidate player in the early steps of protein N-glycosylation. Mol Biol Cell, 19(8), 3404-3414. 
Schwab, I. and Nimmerjahn, F. (2013). Intravenous immunoglobulin therapy: how does IgG modulate the 
immune system? Nat Rev Immunol, 13(3), 176-189. 
Scott, D. L., Wolfe, F. and Huizinga, T. W. (2010). Rheumatoid arthritis. Lancet, 376(9746), 1094-1108. 
Serafini-Cessi, F., Malagolini, N. and Dall'Olio, F. (1984). A tetraantennary glycopeptide from human 
Tamm-Horsfall glycoprotein inhibits agglutination of desialylated erythrocytes induced by leucoagglutinin. 
Biosci Rep, 4(11), 973-978. 
Sgroi, D., Varki, A., Braeschandersen, S. and Stamenkovic, I. (1993). CD22, a B cell-specific 
immunoglobulin superfamily member, is a sialic acid-binding lectin. J Biol Chem, 268(10), 7011-7018. 
Shaw, W. V., Packman, L. C., Burleigh, B. D., Dell, A., Morris, H. R. and Hartley, B. S. (1979). Primary 
structure of a chloramphenicol acetyltransferase specified by R plasmids. Nature, 282(5741), 870-872. 
Shikanai, T., Silverman, E. S., Morse, B. W., Lilly, C. M., Inoue, H. and Drazen, J. M. (2002). Sequence 
variants in the Fc epsilon RI alpha chain gene. J Appl Physiol (1985), 93(1), 37-41. 
Sicherer, S. H. (2012). US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up 
(vol 125, pg 1322, 2010). J Allergy Clin Immun, 130(1), 282-282. 
Sjoberg, E. R., Powell, L. D., Klein, A. and Varki, A. (1994). Natural ligands of the B cell adhesion molecule 
CD22 beta can be masked by 9-O-acetylation of sialic acids. J Cell Biol, 126(2), 549-562. 
Sondermann, P., Pincetic, A., Maamary, J., Lammens, K. and Ravetch, J. V. (2013). General mechanism for 
modulating immunoglobulin effector function. Proc Natl Acad Sci U S A, 110(24), 9868-9872. 
Sousa, M. and Parodi, A. J. (1995). The molecular basis for the recognition of misfolded glycoproteins by the 
UDP-Glc:glycoprotein glucosyltransferase. EMBO J, 14(17), 4196-4203. 
263 
 
Sperandio, M., Gleissner, C. A. and Ley, K. (2009). Glycosylation in immune cell trafficking. Immunol Rev, 
230(1), 97-113. 
Stamenkovic, I., Sgroi, D., Aruffo, A., Sy, M. S. and Anderson, T. (1991). The B lymphocyte adhesion 
molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and alpha 2-6 sialyltransferase, 
CD75, on B cells.. Cell, 66(6), 1133-1144. 
Stamper, H. B., Jr. and Woodruff, J. J. (1977). An in vitro model of lymphocyte homing. I. Characterization of 
the interaction between thoracic duct lymphocytes and specialized high-endothelial venules of lymph nodes. J 
Immunol, 119(2), 772-780. 
Steinman, R. M. (2000). DC-SIGN: A guide to some mysteries of dendritic cells. Cell, 100(5), 491-494. 
Stillman, B. N., Hsu, D. K., Pang, M., Brewer, C. F., Johnson, P., Liu, F. T. and Baum, L. G. (2006). 
Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol, 
176(2), 778-789. 
Stoolman, L. M. and Rosen, S. D. (1983). Possible role for cell-surface carbohydrate-binding molecules in 
lymphocyte recirculation. J Cell Biol, 96(3), 722-729. 
Stoolman, L. M., Tenforde, T. S. and Rosen, S. D. (1984). Phosphomannosyl receptors may participate in the 
adhesive interaction between lymphocytes and high endothelial venules. J Cell Biol, 99(4), 1535-1540. 
Sturm, A., Lensch, M., Andre, S., Kaltner, H., Wiedenmann, B., Rosewicz, S., Dignass, A. U. and Gabius, H. 
J. (2004). Human galectin-2: novel inducer of T cell apoptosis with distinct profile of caspase activation. J 
Immunol, 173(6), 3825-3837. 
Sun, P. D. (2006). Human CD23: Is it a lectin in disguise? Structure, 14(6), 950-951. 
Surolia, I., Pirnie, S. P., Chellappa, V., Taylor, K. N., Cariappa, A., Moya, J., Liu, H., Bell, D. W., Driscoll, D. 
R., Diederichs, S., et al. (2010). Functionally defective germline variants of sialic acid acetylesterase in 
autoimmunity. Nature, 466(7303), 243-247. 
Syka, J. E., Coon, J. J., Schroeder, M. J., Shabanowitz, J. and Hunt, D. F. (2004). Peptide and protein 
sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad Sci U S A, 101(26), 
9528-9533. 
Taguchi, T., Kitajima, K., Muto, Y., Yokoyama, S., Inoue, S. and Inoue, Y. (1995). Proton NMR study of the 
trimannosyl unit in a pentaantennary N-linked decasaccharide structure. Complete assignment of the proton 
resonances and conformational characterization. Eur J Biochem, 228(3), 822-829. 
Takematsu, H., Diaz, S., Stoddart, A., Zhang, Y. and Varki, A. (1999). Lysosomal and cytosolic sialic acid 
9-O-acetylesterase activities can be encoded by one gene via differential usage of a signal peptide-encoding 
exon at the N terminus. J Biol Chem, 274(36), 25623-25631. 
Tamm, I. and Horsfall, F. L., Jr. (1952). A mucoprotein derived from human urine which reacts with influenza, 
264 
 
mumps, and Newcastle disease viruses. J Exp Med, 95(1), 71-97. 
Tanaka, K., Waki, H., Ido, Y., Akita, S., Yoshida, Y., Yoshida, T. and Matsuo, T. (1988). Protein and polymer 
analyses up to m/z 100 000 by laser ionization time-of-flight mass spectrometry. Rapid Commun Mass 
Spectrom, 2(8), 151-153. 
Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A. and Muchmore, E. (2003). 
Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A, 
100(21), 12045-12050. 
Tremblay, L. O. and Herscovics, A. (1999). Cloning and expression of a specific human alpha 
1,2-mannosidase that trims Man9GlcNAc2 to Man8GlcNAc2 isomer B during N-glycan biosynthesis. 
Glycobiology, 9(10), 1073-1078. 
Tribulatti, M. V., Cattaneo, V., Hellman, U., Mucci, J. and Campetella, O. (2009). Galectin-8 provides 
costimulatory and proliferative signals to T lymphocytes. J Leukoc Biol, 86(2), 371-380. 
Tribulatti, M. V., Mucci, J., Cattaneo, V., Aguero, F., Gilmartin, T., Head, S. R. and Campetella, O. (2007). 
Galectin-8 induces apoptosis in the CD4(high)CD8(high) thymocyte subpopulation. Glycobiology, 17(12), 
1404-1412. 
Van den Steen, P., Rudd, P. M., Dwek, R. A. and Opdenakker, G. (1998). Concepts and principles of O-linked 
glycosylation. Crit Rev Biochem Mol Biol, 33(3), 151-208. 
van Gisbergen, K. P., Geijtenbeek, T. B. and van Kooyk, Y. (2005). Close encounters of neutrophils and DCs. 
Trends Immunol, 26(12), 626-631. 
van Gisbergen, K. P. J. M., Sanchez-Hernandez, M., Geijtenbeek, T. B. H. and van Kooyk, Y. (2005). 
Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions 
between Mac-1 and DC-SIGN. J Exp Med, 201(8), 1281-1292. 
van Kooyk, Y. and Rabinovich, G. A. (2008). Protein-glycan interactions in the control of innate and adaptive 
immune responses. Nat Immunol, 9(6), 593-601. 
van Rooijen, J. J., Voskamp, A. F., Kamerling, J. P. and Vliegenthart, J. F. (1999). Glycosylation sites and 
site-specific glycosylation in human Tamm-Horsfall glycoprotein. Glycobiology, 9(1), 21-30. 
Varki, A. (1999). Essentials of glycobiology. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press. 
Varki, A. (2001). Loss of N-glycolylneuraminic acid in humans: Mechanisms, consequences, and implications 
for hominid evolution. Am J Phys Anthropol, Suppl 33, 54-69. 
Vercelli, D., Helm, B., Marsh, P., Padlan, E., Geha, R. S. and Gould, H. (1989). The B-cell binding-site on 
human immunoglobulin-E. Nature, 338(6217), 649-651. 
von der Lieth, C. W., Freire, A. A., Blank, D., Campbell, M. P., Ceroni, A., Damerell, D. R., Dell, A., Dwek, 
265 
 
R. A., Ernst, B., Fogh, R., et al. (2011). EUROCarbDB: An open-access platform for glycoinformatics. 
Glycobiology, 21(4), 493-502. 
Wada, Y., Azadi, P., Costello, C. E., Dell, A., Dwek, R. A., Geyer, H., Geyer, R., Kakehi, K., Karlsson, N. G., 
Kato, K., et al. (2007). Comparison of the methods for profiling glycoprotein glycans - HUPO Human 
Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology, 17(4), 411-422. 
Wang, F., Nakouzi, A., Angeletti, R. H. and Casadevall, A. (2003). Site-specific characterization of the 
N-linked oligosaccharides of a murine immunoglobulin M by high-performance liquid 
chromatography/electrospray mass spectrometry. Anal Biochem, 314(2), 266-280. 
Weetman, A. P. (2000). Graves' disease. N Engl J Med, 343(17), 1236-1248. 
Weis, W. I. and Drickamer, K. (1996). Structural basis of lectin-carbohydrate recognition. Annu Rev Biochem, 
65, 441-473. 
Weis, W. I., Taylor, M. E. and Drickamer, K. (1998). The C-type lectin superfamily in the immune system. 
Immunol Rev, 163, 19-34. 
Weskamp, G., Ford, J. W., Sturgill, J., Martin, S., Docherty, A. J. P., Swendeman, S., Broadway, N., Hartmann, 
D., Saftig, P., Umland, S., et al. (2006). ADAM10 is a principal 'sheddase' of the low-affinity 
immunoglobulin E receptor CD23. Nat Immunol, 7(12), 1293-1298. 
Wilkins, P. P., Moore, K. L., McEver, R. P. and Cummings, R. D. (1995). Tyrosine sulfation of P-selectin 
glycoprotein ligand-1 is required for high affinity binding to P-selectin. J Biol Chem, 270(39), 22677-22680. 
Wilson, G. L., Fox, C. H., Fauci, A. S. and Kehrl, J. H. (1991). cDNA cloning of the B cell membrane protein 
CD22: a mediator of B-B cell interactions. J Exp Med, 173(1), 137-146. 
Wopereis, S., Lefeber, D. J., Morava, E. and Wevers, R. A. (2006). Mechanisms in protein O-glycan 
biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis defects: a review. Clin Chem, 
52(4), 574-600. 
Wuhrer, M., Balog, C. I., Koeleman, C. A., Deelder, A. M. and Hokke, C. H. (2005). New features of 
site-specific horseradish peroxidase (HRP) glycosylation uncovered by nano-LC-MS with repeated 
ion-isolation/fragmentation cycles. Biochim Biophys Acta, 1723(1-3), 229-239. 
Wuhrer, M., Catalina, M. I., Deelder, A. M. and Hokke, C. H. (2007). Glycoproteomics based on tandem 
mass spectrometry of glycopeptides. J Chromatogr B Analyt Technol Biomed Life Sci, 849(1-2), 115-128. 
Wuhrer, M., Stam, J. C., van de Geijn, F. E., Koeleman, C. A., Verrips, C. T., Dolhain, R. J., Hokke, C. H. and 
Deelder, A. M. (2007). Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. 
Proteomics, 7(22), 4070-4081. 
Yamaguchi, T., Hiromasa, K., Kabashima-Kubo, R., Yoshioka, M. and Nakamura, M. (2013). Galectin-7, 
induced by cis-urocanic acid and ultraviolet B irradiation, down-modulates cytokine production by T 
266 
 
lymphocytes. Exp Dermatol, 22(12), 840-842. 
Yamaoka, A., Kuwabara, I., Frigeri, L. G. and Liu, F. T. (1995). A human lectin, galectin-3 (epsilon bp/Mac-2), 
stimulates superoxide production by neutrophils. J Immunol, 154(7), 3479-3487. 
Yamashita, K., Kamerling, J. P. and Kobata, A. (1982). Structural study of the carbohydrate moiety of hen 
ovomucoid. Occurrence of a series of pentaantennary complex-type asparagine-linked sugar chains. J Biol 
Chem, 257(21), 12809-12814. 
Yamashita, M. and Fenn, J. B. (1984). Electrospray ion source - another variation on the free-jet theme. J 
Phys Chem-Us, 88(20), 4451-4459. 
Yang, D., Chen, Q., Chertov, O. and Oppenheim, J. J. (2000). Human neutrophil defensins selectively 
chemoattract naive T and immature dendritic cells. J Leukoc Biol, 68(1), 9-14. 
Yang, N., Zhang, H., Wang, M., Hao, Q. and Sun, H. (2012). Iron and bismuth bound human serum 
transferrin reveals a partially-opened conformation in the N-lobe. Sci Rep, 2, 999. 
Yang, W. H., Park, S. Y., Nam, H. W., Kim, D. H., Kang, J. G., Kang, E. S., Kim, Y. S., Lee, H. C., Kim, K. S. 
and Cho, J. W. (2008). NF kappa B activation is associated with its O-GlcNAcylation state under 
hyperglycemic conditions. P Natl Acad Sci USA, 105(45), 17345-17350. 
Yang, X., Qin, W., Lehotay, M., Toki, D., Dennis, P., Schutzbach, J. S. and Brockhausen, I. (2003). Soluble 
human core 2 beta6-N-acetylglucosaminyltransferase C2GnT1 requires its conserved cysteine residues for 
full activity. Biochim Biophys Acta, 1648(1-2), 62-74. 
Yeh, J. C., Hiraoka, N., Petryniak, B., Nakayama, J., Ellies, L. G., Rabuka, D., Hindsgaul, O., Marth, J. D., 
Lowe, J. B. and Fukuda, M. (2001). Novel sulfated lymphocyte homing receptors and their control by a core1 
extension beta 1,3-N-acetylglucosaminyltransferase. Cell, 105(7), 957-969. 
Yong, P. F. K., Freeman, A. F., Engelhardt, K. R., Holland, S., Puck, J. M. and Grimbacher, B. (2012). An 
update on the hyper-IgE syndromes. Arthritis Res Ther, 14(6). 
Yoon, S. J., Park, S. Y., Pang, P. C., Gallagher, J., Gottesman, J. E., Dell, A., Kim, J. H. and Hakomori, S. I. 
N-glycosylation status of beta-haptoglobin in sera of patients with prostate cancer vs. benign prostate diseases. 
Int J Oncol, 36(1), 193-203. 
Yuseff, M. I., Pardo, E., Lennon-Dumenil, A. M., Gozalez, A. and Soza, A. (2012). Galectin-8 enhances B cell 
antigen presentation. FEBS J, 279, 245-245. 
Zelensky, A. N. and Gready, J. E. (2005). The C-type lectin-like domain superfamily. FEBS J, 272(24), 
6179-6217. 
Zenobi, R. and Knochenmuss, R. (1998). Ion formation in MALDI mass spectrometry. Mass Spectrom Rev, 
17(5), 337-366. 
267 
 
Zhang, Q. A., Davis, J. C., Dove, C. G. and Su, H. C. (2010). Genetic, clinical, and laboratory markers for 
DOCK8 immunodeficiency syndrome. Dis Markers, 29(3-4), 131-139. 
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B. and 
Kuchroo, V. K. (2005). The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat 
Immunol, 6(12), 1245-1252. 
Zollner, O., Lenter, M. C., Blanks, J. E., Borges, E., Steegmaier, M., Zerwes, H. G. and Vestweber, D. (1997). 
L-selectin from human, but not from mouse neutrophils binds directly to E-selectin. J Cell Biol, 136(3), 
707-716. 
Zubarev, R. A., Kelleher, N. L. and McLafferty, F. W. (1998). Electron capture dissociation of multiply 
charged protein cations. A nonergodic process. J Am Chem Soc, 120(13), 3265-3266. 
 
